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CHAPTER I 
 
INTRODUCTION 
 
The Challenges of Low-Resource Settings 
One of the greatest challenges facing our world today is the interdependent, detrimental 
effect that poverty and disease have on a large portion of the population. For example, in Sub-
Saharan Africa, 73% of the population lives on less that $2 a day.1 In this same region, disability-
adjusted life years (DALY), which are the sum of the years of life lost due to premature death 
and those lost to disability, is the highest in the world (Figure I.1).2 These two situations are 
linked, as high DALY places a huge burden on a population, keeping it in poverty, while poverty 
limits access to adequate healthcare that would minimize this loss of life. The lack of effective 
	  
	  
Figure I.1. The disability-adjusted life years (DALY) per 100,000 in 2015. It can be seen that 
the majority of years lost are in the region of Sub-Saharan Africa.2 
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healthcare is demonstrated by the fact that developing (low-resource) countries account for only 
12% of the world’s total healthcare spending, despite the fact that they carry 90% of the disease 
burden.3, 4  
 As a result, the healthcare systems in low-resource areas look much different than those 
in high-resource areas of the world. In general, facilities in developing countries can be broken 
into three major types: (1) major-city hospitals, (2) district-level clinics and (3) village-level 
health outposts. Hospitals in major cities have reliable electricity, clean water and many other 
resources commonly found in high-resource health facilities. In district-level clinics, electricity is 
intermittent and there may or may not be access to clean water. Additionally, the environment is 
often windy and dusty, and ambient temperatures can reach 40°C. Finally, in the village setting, 
electricity and clean water are not available and healthcare workers are minimally trained (Figure 
I.2).5 Consequently, providing adequate medical diagnosis or care to people is these areas is not 
possible. This situation is only made worse by the fact that access even to these inadequate 
facilities is limited, as many patients have to walk for hours to reach them.6 Additionally, there is 
often distrust in the efficacy of diagnostic tests or the government, which is often responsible for 
implementation of disease control efforts.7, 8 It is also common for non-prescribed and traditional 
medication to be used by populations in these areas.9 Despite these situations, there is hope for 
increasing the availability of effective healthcare in these regions and closing the gap in DALY 
between low and high-resource areas. This prospect is based upon the fact that many of the 
diseases that currently plague low-resource areas are treatable. Therefore, disease prevalence 
could be reduced through accurate disease diagnosis and accurate diagnosis could occur with the 
implementation of diagnostics that are effective in low-resource settings.10  
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 Considering the characteristics of the healthcare facilities in low-resource settings, it is 
evident that the diagnostic tests used in hospitals in the developed world will not be practical or 
useful. This has led to large push for the development of point-of-care or low-resource 
diagnostics that are designed to take into account the challenges associated with low-resource 
settings. One of the first point-of-care diagnostics was the home pregnancy test.11 These tests are 
simple and inexpensive and can be performed by the general population. To direct the 
development of other low-resource diagnostics, the World Health Organization (WHO) 
summarized necessary characteristics through the acronym, ASSURED (Affordable, Sensitive, 
Specific, User-Friendly, Rapid, Equipment-free, Deliverable). The need for affordable 
diagnostics is evidenced by the small healthcare budget in low-resource areas. Furthermore, 
	  
	  
Figure I.2. Testing of individuals for malaria with rapid diagnostic tests in a village-level 
healthcare setting in the Southern Province of Zambia. Photo provided by Westley Bauer. 
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sensitive and specific diagnostics are needed to produce accurate results. User-friendly is a 
necessary characteristic as the tests will likely be run by minimally trained individuals, as there is 
there is little incentive for trained healthcare workers to remain in rural areas.7 Rapid time to 
result allows for the patient to receive diagnosis and treatment in one visit. Finally, the ideal 
diagnostic would be equipment-free and deliverable as electricity is intermittent at best, meaning 
power sources and controlled environmental conditions are not available. The development of 
diagnostics with these characteristics is not an easy task. As a result, many low-resource 
diagnostics are unreliable and the challenge of providing patients with proper diagnosis and care 
still needs to be addressed. 
 
Malaria: Disease and Diagnosis 
The difficulty of diagnosing disease in low-resource settings can be highlighted through 
exploration of the biology and diagnosis of the common infectious disease, malaria. Malaria is a 
parasitic disease and the parasite life cycle alternates between two hosts: the female Anopheles 
mosquito and vertebrates. There were 212 million cases of malaria in 2015 and 90% occurred in 
the African region.12 Five Plasmodium species are known to be a threat to humans; the deadliest 
being P. falciparum. Significant illness is also caused by P. vivax. The other species,  P. ovale, 
P. malariae, and P. knowlesi are much less common.13 The life cycle of the plasmodium parasite 
is shown in Figure I.3.14 It can be seen that humans are infected by the bite of Anopheles 
mosquitos as sporozoites, in the mosquito salivary glands, enter the dermis and then infect liver 
cells. Following asexual reproduction, the liver cells rupture releasing merozoites that infect red 
blood cells. In the blood stage infection, the parasite again asexually reproduces, resulting in 
repeated rupture and infection of red blood cells. This cycle produces the symptoms normally 
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associated with malaria such as fever, nausea and muscle pains. The cycle is completed when 
some of the merozoites in the blood stage are reprogrammed to form gametocytes which infect 
mosquitoes and sexually reproduce in the mosquito gut.13 
 There are treatments available for malaria, though their efficacy has changed over time. 
Chloroquine, one of the first and most extensively used malaria drugs became ineffective in 
many areas of the world as the parasite developed resistance to this drug. This resistance came to 
a head in the 1980s and 90s, resulting in an increase in the global burden of malaria. 
Consequently, there was an increase in global spending towards malaria control, which 
emphasized artemisinin combination drug therapies.13 As a result, since 2000, death rates due to 
malaria have fallen 60% worldwide and 66% in Africa.15 In order to allow these drugs to remain 
	  
	  
Figure I.3. Lifecycle of the malaria parasite.14 
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effective, current treatment strategies need to be designed in order to minimize the development 
of drug resistance. 
 In the treatment of malaria, two things must be considered. First, diagnosis of malaria 
based on the generic, flu-like symptoms is not reliable. Second, to prevent the spread of disease, 
the parasite must be eliminated from all human hosts. Taking into account these facts, a couple 
different treatment and elimination strategies have been employed. One method, mass drug 
administration, treats an entire population in a specific location. As a result, treatment is received 
regardless of whether an individual has malaria. This strategy removes the need for diagnosis 
and should eliminate the parasite from all human hosts. Unfortunately, many people do not take 
the full treatment, resulting in an ineffective dose. Also, the excessive use of the drug can be 
expensive and result in quick development of drug resistance.16, 17 This loss of drug efficacy is 
extremely dangerous as there are only a limited number of drugs available for treatment of the 
disease.  
A second strategy looks to limit the development of drug resistance by only treating 
patients that have been diagnosed with malaria, thus reducing drug use. This method is often 
called mass screening and treatment (MSAT).16 MSAT should effectively eliminate the parasite 
from the human host, assuming patients are accurately diagnosed. At this point, the fact that 
malaria cannot be reliably diagnosed based upon symptoms becomes a problem. Furthermore, 
there are asymptomatic malaria infections that must be treated.18 Thus, in order for MSAT to be 
effective, malaria diagnostic tests must be available for a large portion of the population. 
Essentially, a diagnostic that is reliable in low-resource settings is required. or many years, 
microscopy was exclusively used for malaria diagnosis in low-resource settings but this was less 
than ideal as trained personnel and purchase of microscopes was required. Furthermore, 
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microscope slides are not easily read in dusty and windy environments.19 Recently, the face of 
low-resource malaria diagnostics completely changed with the implementation of rapid 
diagnostic tests (RDTs). RDTs are lateral flow immunoassays and to run these tests a small 
blood sample is added to one end of a nitrocellulose strip, followed by addition of buffer. 
Capillary action then pulls the sample down the strip toward an absorbent pad. Detection occurs 
through antibody-conjugated gold nanoparticles that bind to the biomarker and this complex is 
captured by a line of immobilized antibody called the test line. Therefore, a pink line is visible 
from the bound biomarker/gold nanoparticle complex, when a patient is infected with malaria 
(Figure I.4). RDTs have been widely distributed throughout the world as they detect malaria in a 
simple to use, cost effective and relatively stable format.20  
RDTs can successfully diagnose symptomatic malaria infections and inform malaria 
treatment but as malaria death rates have dropped an ever-growing percentage of infections are 
low-level and asymptomatic.16, 21 Unfortunately, RDTs lack the sensitivity required to detect 
these infections levels, which have been reported to average around 5 parasites/µL.22 The 
number of malaria infections that go undetected by RDTs is highlighted by the results of samples 
analyzed by both RDT and polymerase chain reaction (PCR), an extremely sensitive method for 
	  
Figure I.4. The workflow of a rapid diagnostic test. 1) Sample is added to initiate flow. 2) 
Gold nanoparticle conjugates bind to biomarker. 3) Biomarker is captured to form test line. 
Figure provided by Westley Bauer. 
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malaria detection that is not viable in low-resource settings (Figure I.5). Reports have shown that 
in some cases RDTs only detect 1/6 of all PCR positive infections.16, 19 Consequently, several 
MSAT campaigns based on RDT diagnosis have been ineffective as many patients are left 
untreated, leaving a reservoir of disease that undermines control and elimination efforts.23, 24 
Additionally, there is evidence that long-term infections, even if asymptomatic, have deleterious 
effects on patient health.18 As a result, it is essential for sensitive, low-resource diagnostics to be 
developed. Use of these tests will improve patient health and move control efforts toward 
elimination of the disease without the development of drug resistance.25  
 
 
 
	  
	  
Figure I.5. The proportion of detectable and undetectable malaria infections by RDT relative 
to PCR (indicated by the height of the bar). The proportion of the population in each age group 
is reflected by the width of the bars.16 
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Toward Sensitive Low-Resource Diagnostics 
Low-resource diagnostics that are sensitive are essential for accurate malaria diagnosis 
and elimination of the disease. One approach to the development of more sensitive diagnostics is 
the enhancement of currently used RDTs. A major strength of this method is that a completely 
new system is not required. As a result, use and interpretation of the tests is familiar to healthcare 
workers reducing confusion and the cost of implementation required with the use of a completely 
new test. Enhancement of commercially available RDTs has been achieved and is discussed in 
Chapter III of this work.26-29 There are disadvantages to this method, though, as the enhancement 
is limited by the manufacturing and design of the current tests. Thus common downfalls of 
RDTs, such as sample volume limitations, incomplete test clearance and inconsistent 
manufacturing, still remain.27  
 These disadvantages have motivated the design of entirely new diagnostics. In the 
development of a diagnostic, there are four major components that need to be considered: (1) 
sample preparation, (2) diagnostic workflow, (3) molecular recognition element and (4) detection 
method. By careful design of each component followed by implementation into a complete 
diagnostic, the result can be a sensitive test that avoids the pitfalls of currently used RDTs. Thus, 
the end product would be stable in extreme environmental conditions, simple, inexpensive, and 
sensitive. Several group have taken on the challenge of developing diagnostics with these 
characteristics and many different strategies have resulted. For sample preparation, methods 
comprise biomarker separation from whole blood and collection of plasma without 
centrifugation.26, 30 Diagnostic workflows have included lateral and vertical flow assays.31, 32 For 
molecular recognition elements, more stable alternatives to antibodies, such as aptamers, have 
been considered.33 Finally, a wide variety of detection strategies have been designed, especially 
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as the field of materials science has grown. Detection has been achieved with proteins, 
nanoparticles and polymers. Additionally, these methods have been designed to implement 
signal amplification strategies to further increase sensitivity.34-36 
This work explores each of the approaches addressed above. In Chapters II and III, 
currently used diagnostics are enhanced for use in low-resource settings. In Chapter II, an ELISA 
for the malarial biomarker Plasmodium falciparum histidine-rich protein II (pfHRPII), is 
modified for use with dried blood spot samples. Dried blood spots are an extensively employed 
sample collection method in low-resource settings. Furthermore, the collected data is used to 
gain new understanding of the characteristics of pfHRPII as a diagnostic biomarker. In Chapter 
III, a simple sample preparation step that purifies and concentrates pfHRPII using magnetic 
beads is shown to greatly increase the sensitivity of commercially available malaria RDTs. 
Unfortunately, it was observed that variations in RDT manufacturing limited the reliability of 
this method.  
Thus, Chapters IV-VI pursue the second approach to development of sensitive 
diagnostics by looking at individual diagnostic components and designing new methods 
specifically for low-resource settings. Chapters IV and V explore new detection methods through 
the development of unique nanoparticle-based signal amplification strategies. These methods 
utilize porphyrin nanoparticles that are broken into thousands of constituent porphyrin molecules 
in the detection step. These molecules produce either a fluorescent or absorbent assay signal. The 
use of nanoparticle-based signal amplification produced sensitive detection strategies that show 
increased stability over commonly used protein enzyme detection methods. In this work, they are 
used to detect common malarial biomarkers but they can be easily modified for detection of 
other diseases. In Chapter VI, a vertical flow assay is developed based upon cellulose 
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membranes functionalized with metal affinity ligands. This diagnostic setup concentrates the 
biomarker on the test and allows for the use of large sample volumes, increasing the amount of 
biomarker available for detection. Additionally, the use of metal affinity ligands for biomarker 
capture is an environmentally stable method. Finally, the porphyrin nanoparticle detection 
method in Chapter V was used for biomarker detection on these membranes. As a result, through 
combination of the individually developed diagnostic components, a new diagnostic test was 
produced that accounts for the specific challenges of a low-resource setting. The projects 
presented in this work look to solve the problem of inaccurate disease diagnosis in low-resource 
settings. From enhancement of current diagnostics to the design and optimization of new ones, 
the goal is to provide inexpensive, simple, stable and sensitive diagnostics to low-resource areas. 
These diagnostics have to potential to provide patients with accurate diagnoses and thus 
treatment, a contribution that can lead to a better quality of life and assist in disease elimination 
campaigns. 
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CHAPTER II 
 
DRIED BLOOD SPOT ELISA FOR DETECTION OF A MALARIAL BIOMARKER IN 
PATIENT SAMPLES FROM RURAL ZAMBIA 
 
Introduction 
Sample collection is a major challenge for disease diagnosis in low-resource settings. In 
these areas, the collection of venous blood is not always feasible, so a blood sample is often 
collected via finger prick and stored on filter paper cards. These samples, called dried blood 
spots (DBS), have increased sample stability compared to liquid samples, as they can be stored 
in ambient conditions. Additionally, DBS samples have a low biohazard risk and thus can be 
easily shipped.37, 38 These advantages have led to the availability of several types of DBS 
collection cards with different features including easy labeling and incorporated reagents for 
blood lysis or biomarker stability.39 
Dried blood spot samples have proven useful for the analysis of a variety of markers 
including proteins, nucleic acids, and drugs. Methods employing DBS require an extraction 
procedure followed by techniques such as enzyme-linked immunosorbent assay (ELISA) or 
polymerase chain reaction (PCR) to analyze the extracted samples.40 For example, detection 
methods for hepatitis C, a measles specific antibody, and Streptococcus pneumoniae from DBS 
samples have been developed and were reliable when validated against gold standards.41-43  
In this work, dried blood spots samples were analyzed for Plasmodium falciparum 
histidine-rich protein II (pfHRPII), a uniquely structured and highly stable protein biomarker of 
malaria.44 Malaria, a parasitic disease transmitted through mosquitos, is primarily found in 
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Africa where access to clinical laboratories is limited.12 Through optimization of a method for 
the extraction of pfHRPII from dried blood spots, an ELISA protocol could be modified for 
analysis of these samples commonly collected in low-resource settings. Additionally, through 
analysis of pfHRPII in patient samples, biomarker levels, clearance trends and reliability can be 
determined and the advantages and disadvantages of pfHRPII for malaria diagnosis assessed. 
This knowledge could then contribute to the development of more effective diagnostics. In this 
work, particular parameters explored in the development of the extraction method include 
extraction buffer, mixing method and extraction time. Additionally, the percent recovery of 
pfHRPII and the biomarker stability were studied. Following extraction, a pfHRPII ELISA was 
used for biomarker detection, as this technique can detect low-level or asymptomatic infections 
that may otherwise be undetectable, and its high-throughput nature is useful for epidemiological 
studies.45 The coupling of the developed extraction method with this ELISA allowed for 
detection of pfHRPII from DBS; a procedure that was then used to test patient samples in rural 
Zambia. This study allowed for determination of the method sensitivity, specificity, and 
reproducibility, as well as biomarker clearance characteristics, giving more clear understanding 
to the requirements of a pfHRPII diagnostic.  
 
Experimental 
Materials 
Human Whole Blood (K3 EDTA) was purchased from Bioreclamation IVT (catalog no. 
HMWBEDTA3). Plasmodium falciparum D6 parasite was cultured in house. Recombinant 
HRPII protein for traditional ELISA standard curve was purchased from Immunology 
Consultants Laboratory Inc. (catalog no. AGPF-55). ELISA capture and detection antibodies 
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were acquired from Abcam Inc. (catalog nos. ab9206 and ab30384). Immulon 2HB ELISA plates 
(catalog no. 14-245-61) and Promega 3,3’,5,5’-tetramethylbenzidine (TMB) One ELISA 
substrate (catalog no. PR-G7431) were purchased from Fisher Scientific. 903 Protein Saver 
Cards and Whatman 3 filter paper, were purchased from GE Healthcare Life Sciences (catalog 
nos. 10534612 and 1003-055). Biopunches, 6 mm, were acquired from Ted Pella Inc. (catalog 
no. 15111-60). All other reagents were purchased from either Fisher Scientific or Sigma Aldrich. 
DBS extraction was performed with a Fisher Scientific Analog Vortex Mixer (catalog no. 02-
215-365). Absorbance measurements were collected on Biotek microplate readers. 
pfHRPII ELISA Protocol 
The pfHRPII ELISA protocol has been reported previously.26 Briefly, 1 µg/mL of anti-
HRPII IgM (ab9206) in PBS was immobilized in a 96-well plate, which was then blocked with 
5% BSA in PBST (1X PBS, 0.1% Tween-20). Samples were then diluted in sample buffer 
(PBST, 0.1% BSA) and added to the plate. Finally, horseradish peroxidase conjugated detection 
antibody (ab30384) was added at 0.5 µg/mL in PBST with 0.5% BSA. Signal was visualized 
with TMB-One, a commercially available 3,3',5,5'-tetramethylbenzidine (TMB) substrate and 
stopped with 2M sulfuric acid. Absorbance was read at 450 nm.  
Dried Blood Spot Extraction 
DBS were prepared by spiking Plasmodium falciparum D6 parasite culture into whole 
blood and spotting 10 µL onto 903 Protein Saver cards (903 cards) or Whatman 3 filter paper 
(W3). Cards were allowed to dry overnight. Extraction was performed by cutting 6 mm spots 
with a biopunch and then placing two spots for each sample, in one, 2-mL microcentrifuge tube 
with 300 µL (unless otherwise specified) extraction buffer (PBST). The tubes were vortexed, 
with continuous shaking at maximum speed (3200 rpm) for 10 minutes. Afterwards, the tubes 
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were put in a mini-centrifuge to remove bubbles and spin down the DBS paper. The supernatant 
was then removed and analyzed by ELISA. 
Dried Blood Spot pfHRPII ELISA 
The previously reported pfHRPII ELISA was performed with the following modifications 
for analysis of dried blood spots. First, the standard curve was made from DBS standards to 
incorporate extraction conditions into the standard curve. Second, samples were directly added to 
the plate in the PBST extraction buffer instead of being diluted in sample buffer. 
Percent Recovery Calculation 
Percent recovery was determined by comparing ELISA signal from a blank (whole blood 
diluted 1:15 in PBST) and a positive control (whole blood spiked with parasite to 200 
parasites/µL, diluted 1:15 in PBST), to ELISA signal from an extracted DBS sample. For 
example, percent recovery for a 200 parasite/µL DBS sample was calculated by the following 
equation. 
% Recovery pfHRPII = !"#$%!&'()*!+,-./.01%	  !&'()* ×	  100 
Stability Study 
Dried blood spots were prepared on 903 cards and W3. The spots were stored in Ziploc 
bags containing desiccant at the following temperatures: room temperature (RT), 4ºC, -20ºC and 
-80ºC. Samples were stored for various lengths of time, extending up to 6 months, and analyzed 
for percent recovery of pfHRPII. 
Study Setting 
Patient samples were collected during a separate study carried out in the Nchelenge 
District of Zambia, an area where malaria transmission has been sustained at a high level despite 
interventions.46 The original study was designed to determine parasite clearance rates after 
	   16 
treatment with artemisinin combination therapy (ACT) in children under 5 years of age 
presenting with uncomplicated malaria to the local clinic. The anonymized samples were made 
available for the current study to determine if pfHRPII clearance could be used as a proxy for 
parasite clearance rates. 
Patient Recruitment and Ethics 
Children who arrived at the clinic and tested positive for malaria according to SD Bioline 
pfHRPII malaria RDTs were recruited for this study after the parent or guardian provided signed 
informed consent. The study and samples were collected under IRB approval TDRC/C4/09/2014 
as well as after approval was granted by the Zambian National Health Research Authority 
(MH/101/17/6). 
Patient Samples 
Patient finger-prick blood samples were collected on 903 cards between December 2014 
and August 2015. DBS pfHRPII ELISA analysis was done in July 2016. In the interim between 
collection and analysis, the DBS samples were stored at -20 °C. At the time of collection, finger-
prick samples were analyzed by thick smear microscopy to determine quantitative parasite levels 
by counting parasites per 200 white blood cells (WBC) and then using an estimate of 8,000 
WBC/µL to obtain the parasite count for that particular time point. This analysis was used as the 
gold standard in this study. After diagnosis by RDT and Plasmodium falciparum parasitemia 
confirmed by a malaria smear,  patients were enrolled and treated with artemether-lumefantrine 
(Coartem). Thick blood film malaria smears and DBS samples were collected at 15 time points: 
0, 6, 12, 18, 24, 30, 36, 42, and 48 hours and days 3, 7, 14, 21, 28, and 35. In the current study, 
samples from time points 0, 6, 12 and 18 hours as well as days 28 and/or 35 were made available 
and analyzed for 35 patients. Additionally, all 15 time points were studied for 10 patients.  
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Dried Blood Spot pfHRPII ELISA for Patient Samples 
Before analysis, patient samples were coded to ensure assays were performed blinded to 
microscopy results. To begin, one, 6-mm DBS spot was placed in a 2 mL microcentrifuge tube 
with 300 µL of PBST extraction buffer. After vortexing for 10 minutes, the supernatants were 
removed for analysis by pfHRPII ELISA with two modifications. First, the standard curve (0-20 
parasites/µL or 0-34 pM pfHRPII) was made from D6 parasite culture spiked into diluted whole 
blood (whole blood mixed 1:30 (v:v) with PBST). Second, after extraction, the samples were 
diluted 10-fold in PBST before addition to the plate. After completion of the assay, samples that 
did not produce a signal were analyzed a second time without dilution, and samples that 
exceeded the linear range were analyzed at a greater dilution. This second ELISA was performed 
on the same day, and samples were refrigerated between assays.  
Sample Size Calculation 
Appropriate sample size is essential for validation of diagnostic tests. Buderer reported an 
equation for calculation of sample size to ensure that a planned study would have sufficient 
power.47, 48 This number is dependent on sensitivity or specificity, so equations for each are 
shown below. To ensure sufficient sample size, the larger of the two was chosen.  
𝑛78 = 	   :;<<78(>%78)@<×AB8C               𝑛7D = 	   :;<<7D(>%7D)@<×(>%AB8C) 
Variables are defined as: n = number of samples, Se = sensitivity, Sp = specificity, Z = Z score 
(1.96 for this analysis), d = confidence interval, and Prev = prevalence of disease. For this study, 
we chose d = 0.1. Considering the samples that were available for analysis, the prevalence was 
approximated at 70%. Additionally the desired sensitivity of the test was 90% and specificity 
80%. When these values were incorporated nSe = 49 samples and nSp = 205 samples. In this 
study, a sufficient sample size of 238 DBS was analyzed. 
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Data Analysis 
For DBS samples, the concentration of pfHRPII extracted was determined via standard 
curves. For the standard D6 parasite culture, 1 parasite/µL = 1.7 pM pfHRPII. Intra-assay 
variability was calculated by finding the standard deviation of replicates run at a single 
concentration, in a single assay, and dividing by the mean of the replicates. Inter-assay 
variability was found by determining the standard deviation of a single concentration for assays 
run on different days and dividing by the mean value for that concentration.  The sensitivity and 
specificity of the DBS pfHRPII ELISA method was determined through a receiver operating 
characteristic (ROC) curve analysis using microscopy results as the gold standard. 
 
Results and Discussion 
Optimization of Extraction Parameters 
In order to analyze the pfHRPII in a DBS sample, the extraction method had to first be 
optimized. The technique used for mixing was chosen by extraction into PBST with mixing 
using a rotisserie, vortex, and sonicator and without mixing. It was found that recovery of 
pfHRPII increased as the energy imparted by mixing method increased (Figure II.1A). Vortex 
mixing was selected as it resulted in a high recovery and is also feasible in low resource 
settings.49 No difference in recovery was seen between 10 and 30 minutes of mixing (Figure SI 
II.1).  
Extraction buffer compositions with varying salt concentrations and lysis reagents were 
also explored. The composition of the buffers analyzed are listed in Table II.1. Three different 
surfactants were tested, non-ionic surfactants Tween-20 and Triton X-100 and the ionic 
surfactant sodium deoxycholate. A greater recovery of pfHRPII was observed with buffers which 
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contained nonionic surfactants, likely due to greater solubilization of the protein by the long 
polyethylene glycol chains. It was found that salt concentration did not affect recovery (Figure 
II.1B). Considering these results, PBST (Buffer 1) was chosen as the extraction buffer.  
The ratio of extraction buffer to 6 mm DBS was also examined for impact on pfHRPII 
recovery. Our study showed no significant difference in recovery for volumes of 150-250 µL per 
6 mm DBS (Figure SI II.2). Furthermore, an inherent challenge in DBS analysis is the sample 
dilution that occurs upon extraction of the protein from the card. For example, a 6 mm DBS 
punch contains approximately 10 µL of sample, so if 100 µL of extraction buffer is used then a 
10-fold dilution results.50 The DBS pfHRPII ELISA was designed to balance required sample 
volume and assay sensitivity. It was found that extracting two, 6 mm DBS in 300 µL of buffer 
compared to one, 6 mm DBS doubled the slope of the standard curve, increasing assay 
sensitivity while still providing sufficient sample (Figure SI II.3). 
Finally, the effect of heating was analyzed by placing DBS in extraction buffer and then 
in a heat block at 40ºC, 60ºC and 80ºC for 10 minutes. The samples were then vortexed for 10 
minutes before analysis by ELISA. Heating at 60ºC increased recovery of pfHRPII from 
approximately 70% to 90% (Figure II.1C). A decrease was observed at 80ºC, possibly due to 
	  
Table II.1. Composition of the various extraction buffers that were tested. 
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degradation of the protein. For this method, room temperature was chosen to reduce required 
instrumentation, but a heating step can be added if increased assay sensitivity is required.  
DBS Card Type and pfHRPII Recovery and Stability 
903 cards are designed for DBS collection with strict quality control in manufacturing to 
ensure reproducible absorbency and incorporated cover for storage and labeling. W3 is made for 
filtration but its thickness and pore size allow for retention and storage of dried blood samples. 
Because 903 cards cost up to 8 time more than W3, many field studies with limited budgets have 
	   	  
Figure II.1. Optimization of parameters for the extraction of pfHRPII from dried blood spot 
samples. A) mixing method, B) extraction buffer, C) temperature and D) dried blood spot card 
type. 
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employed W3 for sample collection. To determine if the paper type has an effect on pfHRPII 
recovery, DBS samples were prepared on each card type. It was found that recovery of pfHRPII 
from 903 cards was consistently 20% greater than recovery from samples on W3 (Figure II.1D).  
pfHRPII stability was also assessed with both card types. It was observed that pfHRPII was less 
stable in W3 samples with only 30% of the initial pfHRPII recovery observed after being stored 
at room temperature for 6 months. Samples on 903 cards retained 50% of the initial recovery 
after being stored for 6 months at room temperature. Additionally, samples on 903 cards retained 
100% of the original recovery after storage for 6 months at -20 and -80ºC (Figure II.2). 
Thus, though extraction of pfHRPII from DBS was achieved reproducibly, several factors 
affected its efficiency, most notably the type of paper on which the DBS was prepared. Since 903 
cards had up to a 20% greater recovery of pfHRPII, and pfHRPII did not degrade in these cards 
when stored frozen for 6 months (Figures II.1D, II.2), the extra cost is justifiable as it enhances 
method performance. We conclude that 903 cards most likely provide a more stable matrix for 
 
Figure II.2. The stability of pfHRPII in dried blood spots, over time, in different storage 
conditions. Stability on 903 Protein Saver Cards (left) and Whatman 3 filter paper (right). 
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protein storage, and their increased thickness allows for greater protein recovery from a specific 
DBS area.  
Comparison to Traditional pfHRPII ELISA 
Using the optimized protocol for extraction of two, 6 mm DBS in 300 µL of PBST, with 
vortex mixing for 10 minutes, standard curves were generated from parasite spiked DBS samples 
on 903 cards. The resulting curves were highly reproducible with an intra-assay variability of 7% 
and inter-assay variability of 10% (n=3) (Figure II.3). The limit of detection (LOD), defined as 
3sblank/slope, was 4 ± 5 parasites/µL (8 ± 8 pM pfHRPII). Samples were then analyzed 
simultaneously on the traditional pfHRPII ELISA and the DBS pfHRPII ELISA. A paired t-test 
showed no statistical difference between the pfHRPII levels found by the two methods (p = 
0.1746) (Figure II.3).  
Analysis of Patient Samples from Rural Zambia  
The standard curves used for analysis of DBS patient samples were made from parasite-
spiked diluted whole blood. These assays, performed at Macha Research Trust, had an intra-
 
Figure II.3. The reproducibility and accuracy of the developed DBS pfHRPII ELISA. DBS 
standard curves run on three different days (left) and comparison of pfHRPII values between 
the DBS ELISA and a traditional ELISA (right). 
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assay variability of 6% and an inter-assay variability of 18% (n=14). The LOD determined by 
3sblank/slope was 0.165 ± 0.003 pM pfHRPII (Figure SI II.4). 238 DBS patient samples collected 
within 24 hours or at least 28 days after malaria diagnosis and treatment were analyzed by DBS 
pfHRPII ELISA (Table SI II.1). Using microscopy as the gold standard, a ROC curve was used 
to determine the sensitivity and specificity of the assay. An ideal ROC curve forms an 
approximately 90º angle in the left corner of the graph, which corresponds to a test with 100% 
sensitivity and 100% specificity. In this analysis, the DBS pfHRPII ELISA was found to have a 
sensitivity of 94% (CI: 89-97%) and a specificity of 89% (CI: 79-95%), with a threshold of 3.5 
pM pfHRPII (Figure II.4). This demonstrates the developed DBS pfHRPII ELISA is a reliable 
diagnostic for malaria. Additionally, the area under the ROC curve was 0.96, indicating excellent 
accuracy of the method and the usefulness of pfHRPII as a diagnostic biomarker. Finally, using 
this threshold, the positive predictive value (PPV) for the assay was 95% and the negative 
predictive value (NPV) was 86%. 
 
Figure II.4. Receiver operating characteristics curve for DBS pfHRPII ELISA when 
compared to clinical microscopy values for patient samples from rural Zambia. Sensitivity of 
the assay was 94% (CI: 89-97%) and specificity was 89% (CI: 79-95%) when the threshold 
was set at 3.5 pM pfHRPII. 
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The reduced specificity compared to sensitivity that was observed can be attributed to the 
fact that the gold standard for malaria diagnosis (microscopy) detects the malaria parasite rather 
than the protein biomarker detected with the DBS pfHRPII ELISA. This discrepancy can result 
in false positives by DBS ELISA because pfHRPII can persist in the blood stream days to weeks 
after parasite clearance.51, 52 So, while a patient may not have an active malaria infection, the 
DBS pfHRPII ELISA may detect residual pfHRPII in the blood, not a non-specific signal. 
Furthermore, microscopy has shortcomings of its own, including a lack of sensitivity. In general, 
ELISA is more sensitive than microscopy.53 As a result, false positives could come from the 
ability of the DBS pfHRPII ELISA to detect malaria infections that are not seen by microscopy.  
While a lower threshold could allow for detection of more truly pfHRPII-positive 
samples, it will also result in detection of pfHRPII that is not the result of an active malaria 
infection. This observation points to a disadvantage of pfHRPII as a biomarker, as its persistence 
can result in misdiagnosis of patients and improper treatment.54 Consequently, there is a need for 
an alternative protein biomarker for malaria that quickly clears from the bloodstream. 
Plasmodium lactate dehydrogenase (pLDH) is one such biomarker that is being further explored 
in our lab.36, 52 Nonetheless, the importance of detection of pfHRPII remains, as it continues to be 
the most sensitive and prevalently used protein biomarker for detection of falciparum malaria 
infections.44 
pfHRPII Clearance  
For 10 patients, all 15 time points were analyzed and used to study the clearance of 
parasite and pfHRPII after treatment (Figure II.5). For these ten patients, the median clearance 
time was 1.38 days (33 hours) for the parasite and 3 days for pfHRPII. Various pfHRPII 
clearance trends were observed when looking at each patient individually, indicating many 
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difference response to the disease and treatment. Two patients with low initial parasitemias 
(Figures II.5A, II.5B), were negative for pfHRPII according to the threshold set by the ROC 
curve analysis. Patient 51 (Figure II.5C) had relatively low pfHRPII levels before a large spike at 
t=1 day. The level of pfHRPII in Patient 43 (Figure II.5D) spiked and fell throughout the study 
but was cleared by the last time point. Patients 25, 27 and 45 (Figures II.5E, II.5F, and II.5G 
respectively) all showed pfHRPII levels which corresponded with parasite load but with a lag in 
clearance time, demonstrating pfHRPII persistence. Patients 49 (Figure II.5H) and 50 (Figure 
II.5I) displayed the same trend except for a couple of spikes corresponding to a decrease in 
parasite levels, likely caused by the release of pfHRPII upon parasite death 55. Patient 44 (Figure 
II.5J) was also similar, but at the last three time points pfHRPII levels began to rise, while 
parasite levels remained negative, indicating reinfection or recrudescence may have occurred. 
Reinfection is when an individual is successfully treated for malaria but then becomes sick again 
with an entirely new malaria infection. This process is most common in high transmission 
areas.56 Recrudescence occurs when the same malaria infection is never fully eliminated by 
treatment and reappears.57 As sample genotyping was not performed on these samples, the cause 
of the spike in pfHRPII levels cannot be known for certain.58, 59  
As mentioned previously, the commonly observed trend in the patient samples of delayed 
pfHRPII clearance compared to parasite clearance, is an example of the persistence of pfHRPII.60 
The stability of pfHRPII allows it to remain in circulation for several days or even weeks after 
effective treatment, which can result in false positive diagnostic results. Using the ROC curve 
threshold, information can be gathered about infection levels and pfHRPII persistence in the 
blood. For the purposes of this study, infections levels were classified as follows: low (0-14,999 
parasites/µL), medium (15,000-75,000 parasites/µL) and high (≥75,000 parasites/µL).  
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Figure II.5. The pfHRPII clearance trends observed in patient samples collected at 15 time 
points, over a 35-day period. The concentration of pfHRPII extracted from the DBS samples 
and the parasitemia determined by microscopy are plotted against time. A) Patient 46, B) 
Patient 53, C) Patient 51 and D) Patient 43, E) Patient 25, F) Patient 27, G) Patient 45, H) 
Patient 49, I) Patient 50 and J) Patient 44.	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Besides the case of possible recrudescence, Patients 3 and 37 (Table SI II.1) had pfHRPII 
levels that were still positive at the end of the time study, meaning these samples contained 
pfHRPII as long as 30 days after the beginning of treatment. Furthermore, samples from Patients 
43 and 45 (Figures II.5D and II.5G), which were analyzed for the full time study, retained 
pfHRPII past the median time-to-clearance of 3 days. It was found that the initial parasite level 
for each of these patients was below 25,000 parasites/µL, suggesting that persistence of pfHRPII 
was a result of chronic infection not the level of infection. In chronic infections, low-level 
parasitemias can persist in a patient for years, with minimal symptoms, and then become 
symptomatic.61-63 The longevity of the infection can allow for build-up of pfHRPII over time, so 
even though the parasite load is low, a significant amount of pfHRPII persists in the blood.   
Association Between Parasite and Biomarker Levels 
To ascertain whether there was a correlation between parasite and pfHRPII levels, the 
DBS pfHRPII ELISA results for all 328 patient samples were compared to microscopy. A 
positive, linear correlation was observed, with a Spearman correlation coefficient (r) equal to 
 
Figure II.6. Correlation between parasite and pfHRPII levels that were observed in the 328 
patient samples from rural Zambia. Spearman correlation coefficient (r) = 0.70 (95% CI 0.63-
0.75, p<0.0001). 
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0.70 (95% CI 0.63-0.75, p<0.0001) (Figure II.6). Statistically, this result proves an association 
between these two variables and the strength of the association is considered to be moderate (r = 
0.5-0.7) to high (r = 0.7-0.9).64 As was demonstrated by the DBS standard curves made from 
samples spiked with parasite, there is a direct correlation between pfHRPII and parasite levels in 
parasite culture (Figure II.3). Several different factors could have contributed to the decrease in 
the strength of association observed with patient samples. For example, the lack of strictly 
controlled storage conditions for the DBS samples likely caused protein degradation and 
variability in extraction efficiency. As a result, in the analysis of the patient samples there were 
other influences on protein recovery besides the initial parasitemia of the sample. Additionally, 
the amount of pfHRPII produced by the parasite is dependent on the life stage and strain.55, 65 
Patient samples have much greater variety in these parameters than parasite culture, resulting in a 
weaker association between pfHRPII and parasite levels. Other literature reports have seen 
similar discrepancies in patient samples, as some report correlation between pfHRPII levels and 
disease severity, while others do not.66, 67 Nonetheless, in this work a positive association 
between pfHRPII and parasite levels was observed, indicating the usefulness of the pfHRPII 
biomarker in malaria diagnosis.   
Conclusion 
Dried blood spots represent a common and simple sample collection method in low-
resource areas. Samples stored in this way are stable and easily shipped. In order to analyze these 
samples, methods must be optimized for extraction of specific biomarkers and subsequent 
analysis. Here, we report a highly reproducible procedure for extraction of the malarial 
biomarker pfHRPII and subsequent analysis of the protein by ELISA. This assay was then used 
to analyze patient samples in rural Zambia and was found to have a 94% sensitivity and 89% 
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specificity. Examination of patient samples also revealed trends in biomarker clearance, showing 
sustained pfHRPII in the blood and an instance of possible recrudescence. Furthermore, the a 
positive association between parasite and pfHRPII levels was observed. Thus, a protocol was 
developed that allowed the ELISA technique to be used for analysis of samples from low-
resource setting. Additionally, the reported method is reliable and the results obtained give 
further insight into the both the strengths and drawbacks of pfHRPII as a diagnostic biomarker 
for malaria. 
 
Acknowledgements 
I would like to acknowledge Christine Markwalter, Danielle Kimmel, Lwiindi Mudenda, 
Saidon Mbambara, and Phil Thuma for their contributions to this work. Also, we thank the 
children and guardians who agreed to participate in the clinical aspect of this study, as well as 
Macha Research Trust for collection of the dried blood spot samples and for access to the 
samples and their on-site laboratories. This work was supported by the National Institute of 
Health/Fogarty International Center [D43 TW009348] and Vanderbilt University through 
Laboratories for Innovation in Global Health Technologies and the Mitchum E. Warren, Jr. 
Graduate Research Fellowship (L.E.G.). The clinical aspect of the study was supported by the 
National Institutes of Health as part of the International Centers of Excellence for Malaria 
Research (U19 AI089680). 
 
 
 
 
	   30 
CHAPTER III 
 
MALARIA RAPID DIAGNOSTIC TEST ENHANCEMENT 
 
Introduction 
The advent of point-of-care (POC) diagnostic tools has changed the face of healthcare in 
nations affected by the ongoing spread of infectious diseases, including malaria.7 These 
underdeveloped, remote areas are often characterized by poverty, absent or intermittent 
electricity, hot and humid environmental conditions as well as a lack of skilled clinicians. 
Molecular based diagnostic methods such as enzyme-linked immunosorbent assays (ELISA), 
used in Chapter II, and quantitative polymerase chain reaction (qPCR) are powerful tools for the 
detection of protein and nucleic acid biomarkers of infectious diseases. However, reagent 
instability and cost of these assays, in addition to time and expertise needed to perform the tests, 
limits their use in low-resource areas.68 For malaria, light microscopy is the gold standard for 
detection, but limited access to functional microscopes and trained microscopists prevents its 
widespread use at the point of care. Lateral flow immunochromatographic rapid diagnostic tests 
(RDTs), which operate much like commercial pregnancy tests, were developed to circumvent 
these challenges and bring affordable disease diagnosis to low-resource areas.69, 70 Several 
advantages of RDTs include low-cost, rapid time to result, and ease of use and interpretability.71 
Additionally, these tests have been widely used in public health programs to aid with patient 
management, disease surveillance and treatment campaigns.20 In 2010, 88 million RDTs were 
used in endemic countries for the detection of malaria alone.72  
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Malaria RDTs detect protein biomarkers of the malarial parasite. The predominant 
biomarker used in RDTs for detection of Plasmodium falciparum infection is histidine-rich 
protein II (pfHRPII).69 This biomarker was explored in Chapter II and was shown to be a reliable 
and accurate diagnostic biomarker for malaria. Detection of pfHRPII in an RDT format allows 
for a simple detection procedure opposed to ELISA. Unfortunately, despite the many advantages 
of RDTs, the need for these tests to have improved sensitivity and reliability has become 
apparent. The World Health Organization (WHO) periodically reviews all malaria RDTs 
manufactured for diagnostic use, and sets the limit of detection for these tests at 200 
parasites/µL.73 While this limit of detection is sufficient for the diagnosis of symptomatic 
malaria infections, many asymptomatic patients are not diagnosed and continue to be 
transmission reservoirs of the disease as current RDTs fail to identify these carriers. 
Additionally, poor manufacturing standards and storage conditions render many brands of 
malaria RDTs inoperable and unreliable.74 According to the WHO, in 2011, less than 10% of the 
60 brands and 200 types of tests manufactured were effective at detecting 200 parasites/µL 
parasite densities.73 Unfortunately, tests are often acquired based on government sanctions, 
history of use, and cost instead of acquisition based on reliability of the brand.75 This variability 
in test performance, sensitivity and reliability undermines the progress in malaria diagnosis and 
prevention.76  
We have recently reported the development of a low-resource extraction cassette that can 
extract, purify and concentrate Plasmodium falciparum histidine-rich protein II (pfHRPII) from a 
blood sample in less than 30 minutes.26 In this study, a series of aqueous buffer solutions 
separated by oil surface tension valves were preloaded into a single length of tubing. We were 
able to purify the protein biomarker from blood by processing biomarker bound magnetic 
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particles through the cassette using a handheld magnet. At least 50% extraction efficiency was 
demonstrated for samples with parasitemias as low as 12.5 parasites/µL. As a result of this 
technique, a commercial RDT brand was qualitatively improved over 8-fold. In this current 
study, we describe the utility of this extraction cassette for the improvement of a wide range of 
RDT brands of variable performance, providing a method to increase the sensitivity of 
commercially available tests for detection of pfHRPII. The use of commercial tests is a strength 
of this method, as it results in a diagnostic readout that healthcare workers are accustomed to 
analyzing. Furthermore, the improvement in RDT sensitivity was quantitated at parasitemias 
below the 200 parasites/µL regime, where many RDTs are ineffective. Finally, we describe the 
effect of individual donor samples on low, medium and high performing RDT brands at various 
parasite loads. 
 
Experimental 
Materials 
Both pooled and individual donor human whole blood in citrate phosphate dextrose 
(catalog no. HMWBCPD) were purchased from Bioreclamation LLC. For the enhancement 
study, pooled blood was used. For the individual donor effect study, individual donor blood was 
used. This study was blinded, as we did not know the identity of the donors. Plasmodium 
falciparum D6 strain was cultured in the lab. Tygon tubing was purchased from McMaster Carr 
(catalog no. ACF00002). Ni-NTA Magnetic Agarose Beads (catalog no. 36113) were purchased 
from Qiagen Inc. Donut magnet used in this study was purchased from Emovendo LCC. 
Paracheck (Pck), ParaHit Dipstick (PDip), ParaHit Total (PTot), ICT Pf (IPf), ICT Dual (IDual) 
and Blue Cross One Step Pf (OsPf) rapid diagnostic tests were acquired from their respective 
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manufacturers (Table III.1). Hewlett Packard Color LaserJet CM3530fs MFP scanner was used 
to image the RDTs. Image J software was downloaded from the National Institute of Health 
website (http://rsbweb.nih.gov/ij/). OriginPro 9.0 Software was employed for RDT analysis. The 
remaining products were purchased from either Fisher Scientific or Sigma Aldrich. 
Blood Sample Preparation 
 Human whole blood samples were combined in 1:1 (v:v) ratio with 2X lysis buffer (100 
mM potassium phosphate pH = 8.0, 600 mM NaCl, 250 mM imidazole, 2% Triton X-100). 
Subsequently, the blood sample was filtered through glass wool that was placed in the bottom of 
a plastic syringe. Following filtration, a 200 parasite/µL stock blood sample was made by adding 
	  
	  
Table III.1. Specifications of the RDTs used for this study.  
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a specific amount of D6 Plasmodium falciparum culture (at ~52000 parasites/µL) to the lysed 
and filtered sample. The remaining parasitemias were achieved by serial dilution of the 200 
parasite/µL stock. For the mimic patient study, this process was modified slightly in that the 
specific amount P. falciparum culture required for the desired parasitemia was spiked into the 
sample before filtration.  
Extraction and Analysis with RDTs 
 Extraction devices were constructed and prepared blood samples were purified and 
concentrated as described previously.26 Briefly, a 9-inch piece of Tygon tubing was injected with 
three 100 µL wash chambers (50 mM PB, pH 8.0, 300 mM NaCl, 125 mM imidazole, and 0.05% 
Tween-20) each separated by a 0.25 µL mineral oil valve. An elution chamber consisting of 10 
µL of elution buffer (50 mM potassium phosphate (PB), pH 8.0, 300 mM NaCl, 500 mM 
imidazole, 0.05% Tween-20) was injected at the end of the tube. One end of the Tygon tube was 
blocked with a capillary tube and a PCR tube was placed on the other end as the sample 
chamber. 200 µL of the blood sample were placed into this chamber with 10 µL of Ni-NTA 
magnetic agarose beads. After incubation in the chamber, the beads were pulled through the 
wash chambers into the elution chamber with a magnet. After incubating in the elution chamber 
the beads were pulled back into the adjacent oil valve. The elution chamber was then cut off with 
a razor and the contents were spotted onto an RDT. In the enhancement study, this process was 
done, in triplicate, on six types of RDTs, at six parasitemias (0, 12.5, 25, 50, 100 and 200 
parasites/µL). For the individual donor effect study, the process was done in triplicate for three 
parasitemias (0, 10 and 100 parasites/µL) with each donor sample, on three RDT brands, PTot, 
IPf and Pck, of low to high performance, respectively. For both studies, standard analysis of the 
blood samples that were not extracted consisted of spotting 5 µL of parasite spiked blood sample 
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directly onto the RDT and processing according to manufacturer’s specifications. These 
unextracted samples served as reference standards.   
Image Analysis 
 The process used for analysis of the RDTs is outlined in Figure III.1. To begin the image 
analysis portion of this workflow the lateral flow test strip, housed within the plastic cassette of 
the RDT, was removed. The absorption pad at the end of the strip was detached to aid in the 
drying of the strip. The strips were dried overnight prior to imaging with a Hewlett Packard 
Color LaserJet CM3530fs MFP scanner. This drying step did not affect peak signal over time 
(data not shown). Specific settings were used (darkness = 8, background = 1, sharpness = 4) and 
the highest image quality was selected. The image was then manipulated in Image J. First, the 
image was inverted. This is a processing step commonly performed in RDT reader algorithms to 
present the data in an intuitive manner.77 Secondly, the background was subtracted (rolling ball 
radius = 15 pixels, smoothing disabled). Once this was accomplished, a plot profile containing 
the test and control line was generated. This profile was imported into Origin® software, where 
Extract    
Develop RDT Invert 
Subtract Background Plot Profile Integrate 
Peaks 
Figure III.1. The workflow used to quantitate the RDT signals. 
 
	   36 
the peak in the plot profile associated with the test line was integrated using the Peak Analysis 
tool. When using this tool, the automatic background line was used. A test was considered 
positive if the height of the test line peak on the plot profile was at least 3% of the control peak. 
Peak width was determined manually by the user, and the result of the integration was generated 
by the software. This result was used to quantitate the intensity of the test line in the form of an 
integrated area. 
 
Results and Discussion 
Enhancement in RDT Performance 
 The advent and implementation of rapid diagnostic tests, which detect pfHRPII, have 
made an invaluable impact on the diagnosis and treatment of malaria in low-resource settings. 
The efficacy of these tests at high parasitemia was demonstrated in this study, as all RDT brands 
	  
 
Figure III.2. The integrated area of the RDT signal for unextracted samples at 2000 
parasites/µL. All brands, ICT Dual (IDual), ICT Pf (IPf), Paracheck (Pck), Parahit Dipstick 
(PDip), Parahit Total (PTot) and One Step Pf (OsPf) are able to detect pfHRPII at this level of 
parasitemia.  
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analyzed were found to produce detectable signal given unextracted samples at a parasite density 
of 2000 parasites/µL (Figure III.2). But as discussions about eradication strategies begin in 
earnest, the challenge becomes how to effectively identify the untreated asymptomatic patient 
reservoir. Management of submicroscopic malarial infections has become a challenge in the 
field, as current rapid diagnostics are unable to detect these patients.78-80 Thus, for this study we 
set our desired detection limit to less than 20 parasites/µL as this will allow for detection of 
parasite at submicroscopic levels and lead to the diagnosis of more asymptomatic infections.78  
 The RDT diagnostic process was modified by adding a simple sample preparation step 
which consists of a self-contained extraction device that purifies and concentrates the malaria 
biomarker pfHRPII, enhancing RDT performance. Improvement in test performance was 
benchmarked on changes in the signal intensity of the pfHRPII test line. The RDT brands 
evaluated in this study were chosen based on performance as indicated in the WHO report on all 
manufactured malaria RDTs. The brands used were representative of low, medium and high 
performing tests (Table III.1). 
The effect of sample preprocessing on RDT performance can be seen in Figure III.3. This 
analysis showed five of the six RDT brands tested were able to detect 200 parasites/µL from an 
unextracted sample. Four brands detected 100 parasites/µL, as compared to only two at 50 
parasites/µL. Only IDual detected unextracted samples at 25 and 12.5 parasites/µL. After 
extraction, all brands were improved to detect parasite concentrations of 12.5 parasites/µL and 
higher, with the exception of OsPf.  
To quantitate performance, the lateral flow strips within each cassette for all brands were 
scanned and the corresponding plot profiles analyzed using peak integration software. Analysis 
methods of this type are common in recently developed RDT readers.77 The degree of 
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enhancement in RDT signal that occurs with extraction of the sample (enhancement factor) was 
calculated for 200 parasites/µL by the following relationship: 𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑒𝑑	  𝐴𝑟𝑒𝑎MNOBPQO8@ 𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑒𝑑	  𝐴𝑟𝑒𝑎RS8NOBPQO8@ 
This enhancement factor ranged from 4 to 13 among the five brands that produced a detectable 
signal at 200 parasites/µL unextracted (Figure III.4). The greatest enhancement was observed for 
those tests that gave minimal or undetectable results when the samples were unextracted. For 
example, the enhancement of OsPf was practically infinite, as the unextracted sample was not 
detected at 200 parasites/µL (Figure III.4).  
	  
Figure III.3. Integrated area of the RDT signal as a function of parasitemia, extraction and RDT 
brand. Curves for extracted (black lines) and unextracted (dashed line) samples are shown and the 
signal increase gained from extraction can be seen. The diagnostic threshold for all tests analyzed 
was 200 parasites/µL, as set by the World Health Organization. 
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 Despite the observed enhancement, visual and pixel analysis of the tested brands revealed 
several brand-to-brand discrepancies. The most noted was in the case of OsPf, where smearing of 
the sample and RDT components on the test strip increased the background, preventing detection 
of low parasitemias in this brand. This failure of the test strip to clear the sample and reagents 
prevented proper development of the test line and peak identification. Other brand-to-brand 
differences were observed by comparing the shape of the titration curves. Pck reached saturation 
in signal intensity after 100 parasites/µL, whereas PTot and IPf remained linear through 200 
parasites/µL, where our analysis stopped (Figure III.3). These differing trends suggest a greater 
concentration of active antibody on the test line of IPf and PTot RDTs, thus providing a wider 
linear range for calculations made through our algorithm.  
Limit of Detection of Enhanced RDT Signal 
Given the nature of the algorithm used to detect the peaks on the scanned RDT image, the 
limit of detection was found as a percentage of the control peak (threshold height). For each 
	  
 
Figure III.4. The multiplicity of enhancement observed at 200 parasites/µL for each RDT 
brand, as a result of extraction. 
	  
	   40 
brand tested, the integrated area for all of the control lines analyzed were averaged and converted 
to the 3% threshold height maximum. Given this threshold height, the LOD was found for 
extracted and unextracted samples of each brand.  
According to the WHO, the limit of detection for malaria RDTs is required to be at least 
200 parasites/µL.73 We found five out of six of these brands to have limits of detection ranging 
from 15-150 parasites/µL given an unextracted sample. OsPf did not detect unextracted samples 
within the LOD recommended by the WHO. When samples were extracted, the limits of 
detection were found to be between 3-33 parasites/µL (Table III.2). Both Pck and IDual had 
LODs of 3 parasites/µL after extraction and of the six brands tested, five were enhanced to detect 
below the set detection limit of 20 parasites/µL, which is representative of asymptomatic and 
submicroscopic levels of malaria infection. IDual was the only brand tested that was able to 
detect at this level before extraction. To our knowledge, no previously developed method for 
RDT analysis has allowed for the detection of such low parasitemias. Furthermore, the desired 
	  
	  
Table III.2. Limit of detection (in parasites/µL) for all brands of RDTs tested with unextracted 
and extracted samples.	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detection limits were reached through modification of the current RDT diagnostic process, which 
has allowed our method to be simple, rapid and affordable. 
Effect of Individual Donor Samples on RDT Performance 
 After quantifying the LOD of these brands, we focused the study to three brands (Pck, 
PTot and IPf) analyzing individual donor blood samples to examine the influence of individual 
donor background. The three brands were selected by their WHO panel detection score (PDS), 
which is established by the RDT brand’s inter-test and inter-lot consistency.73 Pck fell in the high 
(>90%), IPf in the medium (50-90%) and PTot in the low (10-40%) range. These three brands 
were tested with unextracted and extracted samples at 0, 10 and 100 parasites/µL to demonstrate 
their utility at low parasitemias. As can be observed in Figure III.5, the extracted donor samples 
at 100 parasites/µL had average signal intensities that were statistically different among brands 
and trended with their respective PDS. The highest signal intensities for the extracted samples 
	  
 
Figure III.5. Quantitative performance of three RDT brands for 100 parasites/µL extracted 
samples. Five blood donor samples were analyzed. Donor 1 (red), Donor 2 (green), Donor 3 
(yellow), Donor 4 (black), Donor 5 (blue).   The WHO panel detection scores for Parahit 
Total (PTot), ICT Pf (IPf) and Paracheck (Pck) are 35.4%, 86.9% and 96.0%, respectively.	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were observed for Pck, which had a PDS of 96.0%. Signal intensity decreased for IPf followed 
by PTot, whose detection scores were 86.9% and 35.4%, respectively. Generally, all samples of 
the same parasitemia, analyzed by the same RDT brand, experienced similar enhancements 
(Figure III.6). Thus, the test performance at 10 and 100 parasites/µL was not affected by 
individual blood donors for the three brands evaluated. As a result, any variations in signal 
intensity of a given RDT observed for samples with the same preparation and parasitemia were 
attributed to manufacturing and brand differences. 
 It can also be seen in Figure III.6 that when unextracted donor samples were applied to 
Pck, 5/5 were detected at 100 parasites/µL, while 0/5 were detected at 10 parasites/µL. When 
extracted donor samples were applied to Pck, 5/5 were detected at 100 and 10 parasites/µL. 
When unextracted donor samples were applied to IPf, 3/5 were detected at 100 parasite/µL and 
0/5 were detected 10 parasites/µL. When extracted donor samples were applied to IPf, 5/5 were 
detected at 100 parasites/µL and 4/5 were detected at 10 parasites/µL. When unextracted donor 
samples were applied to PTot 0/5 were detected at 100 and 10 parasites/µL. When extracted 
donor samples were applied to PTot 5/5, were detected at 100 parasites/µL and 0/5 were detected 
at 10 parasites/µL. This data shows that sample extraction reduced the incidence of false 
Figure III.6. Plots of the average peak areas from the RDT test lines for each surrogate 
patient sample, extracted and unextracted, at all parasitemias. Donor 1 (red), Donor 2 (green), 
Donor 3 (yellow), Donor 4 (black), Donor 5 (blue). 
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negative test results as more donor samples produced detectable signal when extracted than when 
not extracted (Figure III.6). Thus, the inclusion of the extraction step makes seemingly bad 
RDTs work better, by increasing signal and thus reducing false negatives. This method be 
invaluable to malaria management programs to enhance the performance of brands available for 
use.  
 
Conclusion 
We have described a method of improving existing rapid diagnostic tests for the detection 
of malaria by adding a simple sample preparation step prior to performing the test. Thus, this 
method enhances tests familiar to healthcare workers. Regardless of the panel detection scores 
assigned to the selected brands by the World Health Organization, we found five of six brands 
were improved and detected parasitemia within submicroscopic levels of infection, a regime of 
diagnosis that RDTs have traditionally been unable to detect. Both the visual signal and limit of 
detection gained a 4-fold and in some cases 100-fold enhancement. Limits of detection, after 
extraction, were estimated to be as low as 3 parasites/µL for two brands. Several labs are 
currently developing cell phone RDT readers, which use an algorithm similar to that described 
here to convert the visual test signal to a quantitative one.77, 81, 82 By combining our extraction 
technology with these developing resources, the positive impact of pfHRPII RDTs for malaria 
control could become an important tool for diagnosing symptomatic and asymptomatic carriers 
in low-resource settings.  
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CHAPTER IV 
 
SIGNAL AMPLIFICATION WITH TETRA(4-CARBOXYPHENYL) PORPHYRIN 
NANOPARTICLES FOR SENSITIVE BIOMOLECULE DETECTION  
 
Introduction 
Methods for signal amplification improvements are driven by the fact that more sensitive 
diagnostics result from the detection of ever smaller quantities of biomarker. The problem of 
detecting minute amounts of nucleic acids was surmounted by the development of polymerase 
chain reaction (PCR) in 1980s.83 In this method, through the use of a DNA polymerase, a nucleic 
acid sequence of interest can be exponentially replicated producing a detectable amount of 
biomarker. Additionally, the sensitivity and ease with which detection of protein biomarkers was 
performed was greatly increased by the origination of the enzyme-linked immunosorbent assay 
(ELISA).84, 85 In this assay, a detection antibody is conjugated to an enzyme, typically 
horseradish peroxidase, and signal amplification is achieved through the enzymatic turnover of a 
colorimetric substrate in the presence of peroxide.  
Though the discoveries of these signal amplification methods were groundbreaking and 
the methods are prolifically employed, they do not solve the problems facing disease diagnosis in 
low-resource settings. As was seen in Chapter III, current malaria diagnostics suffer from a lack 
of sensitivity. While this shortcoming was surmounted by the introduction of a simple sample 
processing step, this method was still limited by variability in RDT manufacturing and the 
addition of extra user steps. So, the design of a completely new diagnostic was considered with 
implementation of a signal amplification detection strategy for increased sensitivity. 
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Unfortunately, the signal amplification methods mentioned earlier lack stability and are not cost 
effective, preventing their use in low-resource diagnostics. To address this problem, several 
signal amplification methods with increased stability have been developed. These methods 
include metal enhancement of gold nanoparticles by increasing the nanoparticle size,32 
polymerization-based signal amplification35 and nanocrystal-based signal amplification.34 In the 
nanocrystal-based signal amplification method, Tong et al. reported that metal-oxide 
nanoparticles attached to detection antibodies produced amplification by dissolution of the 
nanoparticles and visualization of the metal ions through addition of a chromogenic reagent.34 
The result was that for every biomolecule, there were thousands of signal producing metal ions. 
The assay was found to be more reliable and have comparable sensitivity to ELISA.34  
 We found nanocrystal-based signal amplification to be an intriguing method for further 
development and implementation into more sensitive low-resources diagnostics. So, in this work, 
we applied the principle of nanocrystal-based signal amplification to tetra(4-
carboxylphenyl)porphyrin nanoparticles (TCPP NPs). When TCPP is incorporated into the 
nanoparticle structure, its inherent fluorescence is quenched. However, when the nanoparticle 
structure is disrupted by the addition of base, the individual TCPP molecules are released into 
solution and fluorescence is activated. Thus, a “fluorescent on” nanoparticle amplification 
system results. In addition to the signal amplification component of this system, further 
advantages, relative to other nanoparticle-based detection methods, include simple synthesis and 
bioconjugation procedures, environmentally stable reagents, and readily available 
instrumentation for signal readout. These advantages make this particular nanoparticle 
amplification strategy uniquely suited for the low resource setting. Herein, we optimized the 
TCPP NP method for detection of rabbit-IgG (Rab-IgG) in a standard sandwich ELISA format. 
	   47 
The assay was then applied to the detection of the malarial biomarker, pfHRPII, from a complex 
matrix.  
 
Experimental 
Materials 
Meso-tetra(4-carboxyphenyl)porphyrin, 98% (catalog no. 07-1970), was purchased from 
STREM Chemicals. Tetraethyleneglycol monomethyl ether (catalog no. 4200350050), Pierce™ 
Sulfo-NHS-LC diazirine photoreactive crosslinker (catalog no. PI-26174), 10 kDa SnakeSkin™ 
dialysis tubing, 33 mm (pore size 0.45 µm) PVDF syringe filters, 0.5 mL Zeba™ Spin Desalting 
Columns (7K MWCO) were acquired from Fisher Scientific. Goat anti-rabbit IgG antibody 
(pAb) and rabbit IgG control (whole molecule) were purchased from Genscript Inc (catalog nos. 
A00131 and A01008 respectively). Anti-Plasmodium falciparum antibodies were acquired from 
Abcam (catalog nos. ab9206 and ab9203). Plasmodium falciparum D6 strain was cultured in 
house. Human Whole Blood (CPD) was purchased from Bioreclamation IVT (catalog no. 
HMWBCPD). 1000 kDa Spectra/Por® Float-A-Lyzer® G2 dialysis devices (catalog no. 
G235062) and Spectra/Gel® absorbent (catalog no. 292600) were purchased from Spectrum 
Laboratories Inc. All other reagents were obtained from either Sigma-Aldrich or Fisher 
Scientific. 
Instrumentation  
Dynamic light scattering measurements were performed using a Malvern Instruments 
Nano Zetasizer. TEM images were taken using an FEI Tecnai Osiris™ transmission electron 
microscope, on formvar coated copper grids, at 200 kV. Nanoparticle concentration 
measurements were made on a ZetaView PMX110. A Spectroline handheld UV light (Model 
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ENF-260C) with irradiation at 365 nm was used to initiate the photoreactive crosslinker. 
Absorbance and fluorescence measurements were collected on a Biotek Synergy™ H4 
microplate reader. 
Tetra(4-carboxyphenyl)porphyrin Nanoparticle Synthesis 
TCPP NPs were synthesized as previously reported.86 Briefly, 400 µL of a 1.56 mM 
solution of TCPP in THF was added to a glass vial and combined with 50 µL of 
tetraethyleneglycol monomethyl ether. After stirring with a magnetic stir bar for 30 seconds, 5 
mL of deionized water was quickly added. The solution was then mixed for 1 hour with a stir 
bar. The resulting particles were dialyzed overnight to remove excess reagents and filtered 
through a 0.45 µm syringe filter to eliminate large aggregates. For larger batches of TCPP NPs 
the synthesis was doubled and the result was nanoparticles of the same size as a single batch. 
Nanoparticle Concentration Measurements 
The number of TCPP molecules within one nanoparticle was determined using a 
ZetaView PMX110 analyzer. This instrument employs a laser scattering video microscope for 
nanoparticle tracking analysis. A 1 mL sample, in DI water, was injected into the ZetaView cell. 
It was analyzed at 11 positions within the cell, with two cycles of readings per position. 100 nm 
polystyrene particles were used to calibrate the instrument. The sample was a solution of 
dialyzed TCPP NPs, with a known TCPP concentration (determined by e415 = 170,000 
L/mol×cm). A 10,000-fold dilution was made to reach the particle concentration range required 
by the ZetaView instrument. After analysis, the nanoparticle concentration and TCPP 
concentration were known, so the number of TCPP molecules per nanoparticle could be 
determined. 
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Antibody Conjugation to TCPP Nanoparticles  
Goat anti-rabbit IgG antibodies were conjugated to TCPP NPs through a sulfo-NHS-LC-
diazirine photoreactive linker. The linker was attached to the antibodies according to 
manufacturer instructions. Then a spin column (7K MWCO) was used to exchange the modified 
antibodies into phosphate buffer pH 5.7. The concentration of antibody was determined by light 
absorption using a Take3 microvolume plate and the molar extinction coefficient of IgG at 280 
nm (ε280 = 13.7 L/gm×cm). For the conjugation reaction, 36 µg of modified antibody was added 
for every 1000 µg of TCPP (mole ratio approximately 100:1 IgG:TCPP NP). The concentration 
of TCPP NPs for conjugation was 130 µg TCPP/mL. This concentration was achieved through 
use of an absorbent. The concentration of TCPP in a nanoparticle solution was found by breaking 
the TCPP NPs apart into individual TCPP molecules with 0.1 M NaOH and measuring the 
absorbance at 415 nm (ε415 = 170,000 L/mol×cm). The modified antibody solution was added to 
the TCPP NPs and 150 µL of this solution was added to each well of a 96-well plate. A handheld 
UV light was then placed on top of the plate and the solutions were irradiated at 365 nm for 20 
minutes, promoting coupling of the antibody to the TCPP NPs. Excess antibody was removed 
through dialysis with a 1000 kDa dialysis device. Conjugation of the anti-Plasmodium 
falciparum antibody (ab9203) to the TCPP NPs was done by the same procedure except 180 µg 
of modified antibody was added for every 1000 µg of TCPP. 
Detection of Rabbit IgG and pfHRPII with TCPP Nanoparticles 
The detection of rabbit IgG control protein (Rab-IgG) with goat anti-rabbit antibody 
conjugated TCPP NPs (Ab-TCPP NPs) was carried out in a sandwich plate assay format. First, 
100 µL of 4 µg/mL goat anti-rabbit IgG in 1X PBS was incubated in an Immulon 96-well plate 
for 1 hour at room temperature. Next, the plate was washed five times with PBST (1X PBS, 
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0.1% Tween-20). The plate was then blocked by incubating 300 µL of 2% BSA in PBST on the 
plate for 2 hours. Afterward, the plate was again washed with PBST and then 100 µL samples of 
Rab-IgG in 2% BSA were added and incubated for 2 hours. The plate was then washed with 
PBST but the pH of the buffer was adjusted to 5.7 to prevent degradation of the Ab-TCPP NPs in 
the next step. Finally, 100 µL of Ab-TCPP NPs in 10% BSA, at a concentration of 100 µg 
TCPP/mL, were added to the plate and it was incubated on a shaker for 1 hour. Following five 
more washes with PBST (pH 5.7), 100 µL of 0.1 M NaOH was added to each well. After shaking 
the plate for 5 minutes, the solutions were transferred to a black plate and the fluorescence was 
read with an excitation wavelength of 415 nm and an emission wavelength of 648 nm (Figure 
IV.1).  
 Detection of pfHRPII was performed in a similar manner. In this assay, pfHRPII from 
Plasmodium falciparum culture was detected by anti-Plasmodium falciparum antibody 
conjugated TCPP NPs (pfAb-TCPP NPs). First, 100 µL of 2 µg/mL anti-Plasmodium falciparum 
	  
Figure IV.1. The workflow of porphyrin nanoparticle-based signal amplification sandwich 
assays for the detection of biomolecules. 
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capture antibody (ab9206) in 1X PBS was incubated on the plate for 1 hour. This step was 
followed by five washes with PBST and then the plate was blocked with 2% BSA. Next, the 
plate was washed and 100 µL diluted whole blood (whole blood mixed 1:1 (v:v) with 2% BSA in 
1X PBS) spiked with Plasmodium falciparum culture, were added and incubated for 2 hours. The 
plate was again washed with PBST pH 5.7, and pfAb-TCPP NPs in 10% BSA were added to the 
plate at a concentration of 75 µg TCPP/mL and incubated on a shaker for 1 hour. Finally, the 
plate was washed, 0.1 M NaOH was added and the fluorescence was read. The limit of detection 
was determined by the following equation: 3sblank/slope.   
Results and Discussion 
Characterization of TCPP Nanoparticles 
TCPP NPs were synthesized as reported by Drain et al.86, 87 The NP size was evaluated 
by DLS and a single peak centered around 100 nm was observed. The synthesis was very 
reproducible as the average hydrodynamic diameter over several batches (n=14) was found to be 
	  
Figure IV.2. DLS size distributions of filtered (blue), concentrated (red), antibody conjugated 
(green) TCPP NPs (left). TEM image of TCPP NPs (right). 
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110±9 nm with a polydispersity index of 0.11±0.01. Upon concentration of the TCPP NPs, the 
size distribution did not significantly change. When antibodies were coupled to TCPP NPs, an 
increase of approximately 75 nm in hydrodynamic diameter was seen, consistent with antibody 
conjugation (Figure IV.2). TEM images showed spherical nanoparticles with a background of 
TEGME from nanoparticles that collapsed when the sample was dried on the grid. The spherical 
nanoparticles have diameters within the range specified by DLS (Figure IV.2). TCPP NP size 
remained constant for over 60 days. After 90 days, large aggregates began to form (Figure IV.3). 
The number of TCPP molecules per NP was determined by finding the NP concentration with 
ZetaView instrumentation and the TCPP concentration by absorbance. It was determined that 
there was on the order of magnitude of 100,000 TCPP molecules/nanoparticle. This number 
highlights the advantage of this signal amplification strategy, because upon nanoparticle 
	  
Figure IV.3. The increase in diameter of the TCPP NPs over time. Aggregation of the 
TCPP NPs is observed after 90 days. 
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dissolution there are hundreds of thousands of signal-producing, fluorescent molecules that result 
from one nanoparticle. 
Dissolution conditions for TCPP NPs were examined as a function of pH. TCPP NPs 
were placed in buffers that covered a range of pH values (citrate/phosphate pH 3-5, phosphate 
pH 6-8, borate pH 9-12) and the absorption of the Soret band was observed. An increase in 
absorption of this band indicates more, free TCPP in solution. It was found that the TCPP NPs 
quickly broke apart at pH 6.5 as shown in the titration curve in Figure IV.4. We conclude that the 
inflection point at pH 6.75 corresponds to the pKa of the carboxylic acid groups on TCPP, as it is 
near the value previously reported.88 Thus, as the acid groups become deprotonated the non-
covalent forces holding the particles together are disrupted. Additionally, interaction of TCPP 
with the solvent is increased and the result is dissolution of the TCPP NPs. Thus, nanoparticle-
based signal amplification could be achieved through addition of sodium hydroxide (NaOH), for 
TCPP NPs.  
	  
Figure IV.4. Titration curve displaying the breakdown of TCPP NPs as a function of pH.  
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Optical characterization of porphyrin nanoparticles displays broadened and often split 
Soret bands.86 The TCPP NP absorption spectrum revealed both of these characteristics (Figure 
IV.5). The direction of the shift, either hypsochromic or bathochromic, indicates the type of 
interactions between porphyrins in the nanoparticles. Free TCPP has a maximum wavelength of 
the Soret band at 415 nm. The TCPP NP spectrum showed a Soret band with a bathochromic 
shift, indicative of J-type aggregates (edge-to-edge interactions) of the porphyrins in the 
nanoparticle.86, 87, 89, 90   
The formation of J-aggregates in the nanoparticle reduces the absorption intensity of the 
Soret band. Additionally, static quenching of the porphyrin fluorescence is observed.91 Upon the 
addition of NaOH, which results in free porphyrin in solution, the intensity of these properties 
was restored and a 3-fold rise in absorption and 240-fold increase in fluorescence were seen 
(Figure IV.5). The magnitude of the enhancement and intensity of the fluorescent signal, upon 
nanoparticle dissolution, made fluorescence the best signal readout for this assay. This signal 
was found to be stable on the benchtop for at least 4 hours (Figure IV.6). The longevity of the 
	  
Figure IV.5. The increase in absorbance (left) and fluorescence (right) that is seen with TCPP 
NP dissolution by NaOH. 
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fluorescent signal increases the assay stability relative to other colorimetric products that often 
degrade within an hour or are light sensitive.   
Conjugation of Antibodies to TCPP Nanoparticles 
To utilize TCPP NPs in an amplification strategy, an antibody was coupled to the 
nanoparticles to impart biomarker specificity. Studies began with the detection of a model 
biomarker, Rab-IgG. Anti-rabbit IgG antibody was coupled to the TCPP NPs through a 
photoreactive linker. The diazirine-based photoreactive linker was chosen because coupling 
could efficiently occur at pH 5.7, where the TCPP NPs are stable (Figure IV.4). Coupling was 
achieved by applying UV light to a mixture of TCPP NPs and antibodies modified with the 
photoreactive linker.  The UV light promotes the release of nitrogen from the diazirine producing 
a carbene that forms a covalent bond to the nanoparticle. Carbene groups quickly react with 
nucleophiles, and in certain circumstances, addition to hydrocarbons occurs.92 Considering that 
the reaction between TCPP NPs and the modified antibody takes place in aqueous conditions, the 
	  
Figure IV.6. TCPP NP fluorescence before and after dissolution with base. Fluorescence is 
quenched in the nanoparticle form but is very strong after the dissolution to TCPP molecules 
(left). Degradation of the fluorescent signal of TCPP molecules in 0.1 M NaOH after TCPP 
NP dissolution. The fluorescent signal did not decrease for 4.5 hours when left on the 
benchtop (right).  
 
	   56 
covalent bond is most likely formed between the carbene and the OH groups on the TEGME or 
TCPP components of the nanoparticles. Conjugation of the antibody was confirmed by detecting 
Rab-IgG on a plate. Fluorescent signal was observed when Rab-IgG was present, but when Rab-
IgG was not present a signal was not observed. Additionally, little non-specific signal was seen, 
as TCPP NPs without antibodies conjugated did not show signal in the presence of Rab-IgG. 
Similar results were observed for TCPP NPs conjugated to anti-Plasmodium falciparum 
antibodies. 
Optimization and Detection of Rabbit IgG 
The TCPP NP detection method was used to detect Rab-IgG in a sandwich assay format 
(Figure IV.1), where a capture antibody was immobilized onto the plate, followed by a blocking 
step. A sample containing Rab-IgG was then added and the Rab-IgG was captured by the 
antibody out of the sample matrix. After capture of the biomarker the Ab-TCPP NPs were added 
to the plate as the detection element. After several wash steps, NaOH was added to promote 
dissolution of the nanoparticles. The result was signal amplification as each nanoparticle broke 
into hundreds of thousands of signal-producing, porphyrin molecules for each Rab-IgG protein. 
Release of the porphyrins from the nanoparticle matrix eliminated fluorescence quenching, so 
the fluorescent signal of TCPP was read without the addition of any other chromogenic reagents.  
To begin the optimization of this assay, the capture antibody concentration that gave the 
best signal intensity while minimizing background signal was determined. Background signal 
can often increase with capture antibody concentration as a result of non-specific binding. 4 
µg/mL of capture antibody produced optimal signal-to-noise performance (Figure IV.7A).  
Additionally, a common blocking buffer containing 2% BSA was used for the assay to prevent 
nonspecific binding of proteins to the plate. The concentration of detection element, Ab-TCPP 
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NPs, needed to achieve maximum signal was also determined. As can be seen in Figure IV.7B, 
the signal against constant Rab-IgG saturates at a concentration of 75 µg TCPP/mL. At this point 
the signal is limited by the amount of Rab-IgG in the well, not by the amount of detection 
element. To ensure saturation was reached, 100 µg TCPP/mL of Ab-TCPP NPs were used in the 
assay.  Finally, blocking of the Ab-TCPP NPs was explored. It was found that increasing the 
amount of BSA used to block the Ab-TCPP NPs greatly improved the signal-to-noise of the 
assay. This observation is thought to be a result of the TCPP NPs having a weak attraction to the 
capture antibody but upon blocking with BSA, this nonspecific binding is eliminated.  A BSA 
blocking concentration of 10% was used for this assay (Figure IV.7C). The optimized sandwich 
assay produced a linear, concentration dependent response from 10 to 1000 pM. This linear 
range is greater than that observed for ELISAs because enzyme catalysis is not a linear process. 
In contrast, when TCPP NPs are used for signal amplification, signal is dictated by the number of 
porphyrin molecules in solution; this is linear with respect to the number of Rab-IgG proteins 
until saturation of the surface area of the well occurs.34 The limit of detection of the assay was 
found to be 2.05 ± 0.03 pM (Figure IV.8).  
	  
Figure IV.7. Optimization of assay conditions for the sandwich detection of Rab-IgG. 
Parameters analyzed include: A) capture antibody concentration, B) Ab-TCPP NP 
concentration and C) Ab-TCPP NP blocking. Concentrations chosen for the assay were 4 
µg/mL capture antibody, 100 µg TCPP/mL and 10% BSA. 
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Optimization and Detection of pfHRPII in Diluted Whole Blood 
pfHRPII is a standard protein biomarker of malaria, a common disease in low-resource 
areas of the world. In these areas, as malaria eradication campaigns have begun, it has become 
increasingly important to detect low-level, asymptomatic infections (<200 parasites/µL). 
Inaccurate detection and treatment of these infections results in a reservoir of the disease. As 
discussed in Chapter III, commonly used rapid diagnostic tests are not a viable solution to this 
problem as they do not have sufficient sensitivity.93 Additionally, microscopy, though it has a 
lower limit of detection, suffers from a high false positive rate and lack of reproducibility. Thus, 
the TCPP NP detection method was optimized for pfHRPII, as incorporation of this detection 
strategy into a diagnostic has the potential to produce the sensitive, stable and reproducible test 
needed for malaria in low-resource settings.  
For development of the pfHRPII TCPP NP detection strategy, the relevant parameters of 
the sandwich plate assay were re-optimized for the detection of pfHRPII from Plasmodium 
falciparum culture. It was found that the best signal-to-noise performance occurred with 2 µg/mL 
	  
Figure IV.8. Detection of Rab-IgG using Ab-TCPP NPs in sandwich assay format. Linear 
concentration dependent response observed from 10-1000 pM. Full titration (left) and 
enlargement of low concentrations (right). 
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of anti-Plasmodium falciparum capture antibody (Figure IV.9A). Furthermore, the signal was no 
longer limited by the pfAb-TCPP NPs at 50 µg TCPP/mL, so 75 µg TCPP/mL pfAb-TCPP NPs 
were used in the assay (Figure IV.9B). Additionally, as seen with the Ab-TCPP NPs, non-
specific binding of the pfAb-TCPP NPs was greatly reduced when the NPs were blocked with 
10% BSA (Figure IV.9C).  
Diluted whole blood spiked with clinically relevant amounts of Plasmodium falciparum 
culture was tested for pfHRPII. The assay workflow followed that of Figure IV.1. The result was 
an assay with a linear range of 16-250 parasites/µL and a limit of detection of 16.2 ± 0.5 
parasites/µL or the equivalent of 21 pM pfHRPII (Figure IV.10). The assay was repeated in 
triplicate on four different days and the intra-assay variability (defined as the standard deviation 
of the triplicate divided by the mean of the triplicate) was 9%. The inter-assay variability (the 
standard deviation of the concentrations from the four different days divided by the mean 
concentration) was 16%. This data shows that the TCPP NP detection method is reproducible 
and has a lower limit of detection and a similar linear range to commercially available ELISA 
kits for pfHRPII.94 Additionally, it is able to detect within the asymptomatic range of malaria 
	  
Figure IV.9. Optimization of assay conditions for the sandwich detection of pfHRPII. 
Parameters analyzed include: A) capture antibody concentration, B) pfAb-TCPP NP 
concentration, and C) pfAb-TCPP NP blocking. Concentrations chosen for the assay were 2 
µg/mL capture antibody, 75 µg TCPP/mL and 10% BSA.  
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infection. Thus, the TCPP NP detection method has the needed sensitivity as well as increased 
stability through replacement of the enzyme with a nanoparticle as the signal-generating moiety. 
These results show great potential for application of the TCPP NP detection method to low-
resource settings. Furthermore, this detection strategy is a platform technology and can be used 
to detect a wide variety of biomarkers through conjugation to other antibodies. As was discussed 
in Chapter II, pfHRPII is not an ideal biomarker as it can remain in circulation days to weeks 
after effective treatment. If detection of different biomarker, such a plasmodium lactate 
dehydrogenase was desired, the TCPP NP detection strategy could be easily modified for this 
biomarker.  
 
 
 
 
 
	  
Figure IV.10. Detection of pfHRPII from Plasmodium falciparum-spiked diluted whole blood 
using pfAb-TCPP NPs. Linear concentration dependent response observed from 16-250 
parasites/µL. Full titration (left) and enlargement of low concentrations (right). 
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Conclusion 
In this work, the principle of nanocrystal-based signal amplification reported by Tong et 
al. was employed to develop a new biomolecule detection method using TCPP NP signal 
amplification.34 Amplification was achieved through dissolution of the TCPP NPs into hundreds 
of thousands of fluorescent TCPP molecules. The product was a sensitive assay that did not 
require the use of a protein enzyme, which makes TCPP NP detection a more stable method 
relative to ELISAs. The use of a porphyrin nanoparticle eliminates the susceptibility of the 
detection method to environmental conditions and produces a more stable signal.  Furthermore, 
simplicity of the TCPP NP detection method relative to the original nanocrystal-based signal 
amplification method is increased by the inherent fluorescence of TCPP, which allows direct 
measurement of the assay signal without extra steps for neutralization and addition of a 
chromogenic reagent. Using the TCPP NP method, we were able to detect the Rab-IgG protein 
biomarker at low picomolar levels. Additionally, clinically relevant amounts of the malarial 
biomarker pfHRPII were detected out of diluted whole blood. This result also shows increased 
simplicity, as the original method was only able to detect low picomolar levels of biomolecule 
when multiple types of nanoparticles were added to the assay. The TCPP NP method only 
required one nanoparticle type.  The sensitivity of the TCPP NP method, accompanied by its 
increased stability and simplicity relative to other methods, makes it an intriguing option for 
further development as a detection method for low-resource areas.  
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CHAPTER V 
 
HEMIN NANOPARTICLE ENZYME MIMIC FOR BIOMOLECULE DETECTION IN LOW-
RESOURCE SETTINGS 
 
Introduction 
 Diagnostics for various applications are all plagued by one common problem: the most 
sensitive methods lack environmental stability. For example, the enzyme-linked immunosorbent 
assay (ELISA), a prevalently used protein detection assay, owes much of its sensitivity to the use 
of the horseradish peroxidase enzyme (HRPx) for signal generation.84 HRPx comes from the 
horseradish plant and is an extremely efficient catalyst for the oxidation of colorimetric 
substrates.95 As a result, signal amplification occurs in these assays because one HRPx molecule 
is associated with one disease molecule, but the signal results from the hundreds of thousands of 
colored, substrate molecules generated by HRPx. Thus, ELISAs are extensively used in disease 
diagnosis as they are able to detect the extremely small amounts of biomarker that are often 
indicative of a disease state.96 
 While there are many advantages to ELISAs, there are several properties associated with 
the HRPx enzyme that are less than ideal. The HRPx enzyme is expensive due to challenges in 
production and purification. Furthermore, the activity of HRPx is very susceptible to different 
environmental conditions which result in the degradation of the protein.97 While the requirement 
of HRPx to remain in a controlled climate is an inconvenience in modern laboratory settings, it 
prevents the use of the enzyme in low-resource settings, as electricity is intermittent in these 
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areas. Therefore, as mentioned previously, when designing more sensitive diagnostic for low-
resource settings, signal amplification with HRPx is not a viable detection strategy. 
 As a result, many different materials have been developed that mimic HRPx through 
signal amplification by catalytic turnover of a substrate that are more cost effective and stable. 
These methods include simple inorganic materials which rely on metals for catalytic activity.98-
103 Additionally, more complicated materials such as hybrid, shell or encapsulated nanoparticles 
have also been designed.104-107 Furthermore, supramolecular systems that aim to mimic the 
enzyme through incorporation of a hydrophobic environment and coordinating ligands have been 
developed.108-110 These approaches had varying degrees of success. While they essentially all 
show increased stability, most are far from reaching the catalytic efficiency of HRPx. Of these 
materials, those that that did shown comparable or improved efficiency required complicated 
synthesis schemes. Furthermore, complete development of these methods for protein detection 
from complex matrices has not been reported. 
 The porphyrin, hemin, is a tetrapyrrole with an iron center. This molecule serves a variety 
of biological functions. It is found in hemoglobin and serves as the molecular component 
responsible for oxygen binding.111 It also is found in the active site of HRPx and is responsible 
for binding the substrate, hydrogen peroxide, for the initiation of the catalytic turnover of a 
colorimetric substrate.95 It has been shown that hemin removed from the protein structure is still 
catalytically active.112 Thus, this molecule can be used as a mimic of HRPx. The removal of 
hemin from the protein structure results in greater stability but also reduces catalytic efficiency. 
In this chapter, we report a simple and fast synthesis for hemin nanoparticles (Hemin 
NP). By making nanoparticles out of hemin, we can exploit the catalytic properties of the 
molecule and combine thousands into one particle, compensating for the reduction in catalytic 
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efficiency that results from removal of the hemin from the protein structure. Thus, there are two 
types of signal amplification in this method. First, the nanoparticles are broken apart into their 
constituent hemin molecules. Consequently, one nanoparticle results in thousands of catalytic 
molecules. Second, each of these molecules then acts as an enzyme mimic to turnover a 
colorimetric substrate (Figure V.1). It is hypothesized that the combined activity of the hemin 
molecules in a nanoparticle would result in an enzyme mimic with comparable activity to HRPx 
but with increased environmental stability. Furthermore, in contrast to the fluorescent tetra(4-
carboxyphenyl) porphyrin nanoparticle strategy reported in Chapter IV, an easily visualized, 
absorbent signal would be produced, which is ideal for low-resource settings. Thus, upon 
synthesis of the Hemin NPs, their size, stability and catalytic properties were characterized. 
Furthermore, this detection strategy was incorporated into an assay for the detection of a model 
protein biomarker and a malarial biomarker from a complex matrix.  
 
 
	  
	  
Figure V.1. The signal amplification scheme for the Hemin NP detection method. Hemin 
nanoparticles break apart into constituent hemin molecules, which subsequently catalytically 
turn over a colorimetric substrate. 
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Experimental 
Materials 
Hemin was purchased from MP Biomedicals (catalog no. 198820).  Mn(III), Co(III), 
Cu(II), and Zn(II) protoporphyrin IX were acquired from Frontier Scientific (catalog nos.  
MnP562-9, Co654-9, P40769, Zn625-9).  Promega 3,3’,5,5’-tetramethylbenzidine (TMB) One 
ELISA substrate (catalog no. PR-G7431), horseradish peroxidase (HRPx) (catalog no. P131490), 
Pierce™ Sulfo-NHS-LC diazirine photoreactive crosslinker (catalog no. PI-26174), 10 kDa 
SnakeSkin™ dialysis tubing, and 0.5 mL Zeba™ Spin Desalting Columns (7K MWCO) were 
purchased from Fisher Scientific. 3,3’,5,5’-tetramethylbenzidine (TMB) tablets were purchased 
from Sigma Aldrich (catalog no. T55251000). 1000 kDa Spectra/Por® Float-A-Lyzer® G2 
dialysis devices (catalog no. G235062) and Spectra/Gel® absorbent (catalog no. 292600) were 
acquired from Spectrum Laboratories Inc. Goat anti-rabbit IgG antibody (pAb) (catalog no. 
A00131), and rabbit IgG control (whole molecule) (catalog no. A01008) were purchased from 
Genscript Inc. Pan-malaria anti-pLDH (capture) (catalog no. 19g7) and pan-malaria anti-pLDH 
(conjugate) (catalog no. 1201) were acquired from Vista Diagnostics International. Plasmodium 
falciparum D6 strain was cultured in house. Human Whole Blood (CPD) was purchased from 
Bioreclamation IVT (catalog no. HMWBCPD). All other reagents were obtained from either 
Sigma-Aldrich or Fisher Scientific. 
Instrumentation 
Sonication during nanoparticle synthesis was carried out with an Ace Glass GEX 600-5 
Ultrasonic Processor (600 Watts). Dynamic light scattering measurements were performed using 
a Malvern Instruments Nano Zetasizer. Nanoparticle concentration measurements were made on 
a ZetaView PMX110. Cyclic voltammetry measurements were made with a CH Instrument 
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Multichannel Analyzer with a glassy carbon working electrode, Ag/AgCl reference electrode, 
and a Pt wire/mesh counter electrode. A Spectroline handheld UV light (Model ENF-260C) with 
irradiation at 365 nm was used to initiate the photoreactive crosslinker. Absorbance 
measurements were collected on a Biotek Synergy™ H4 microplate reader.  
Hemin Nanoparticle Synthesis 
Hemin NPs were synthesized by combining 100 µL of 1.9 mM hemin in DMF with 80 
µL of hexaethylene glycol monomethyl ether (HEGME). 6 mL of DI water were then quickly 
added to this solution followed by sonication for 2 minutes. Sonication was performed in an ice 
water bath, using a probe sonicator with an amplitude setting of 3%. The concentration of hemin 
was determined by measuring the absorbance of the Soret band in a 5% pyridine solution (e405 = 
92,297 L/mol×cm). Optimization of each of these parameters is discussed in the results. 
Hemin Molecules per Nanoparticle 
 The number of hemin molecules within one nanoparticle was determined using a 
ZetaView PMX110 analyzer. This instrument employs a laser scattering video microscope for 
nanoparticle tracking analysis. For sample analysis, a 1 mL sample in DI water was injected into 
the ZetaView cell. It was analyzed at 11 positions within the cell, with two cycles of readings per 
position. The analysis was run at 26.6 °C. The remaining settings included: sensitivity of 85, 
frames per second of 30, shutter speed of 70 and laser pulse duration of 3 seconds. A standard of 
100 nm polystyrene particles was used to calibrate the instrument. The sample was a solution of 
dialyzed Hemin NPs, with a known hemin concentration (determined by e405 = 92,297 L/mol×cm 
in 5% pyridine). A 10,000-fold dilution was made to reach the particle concentration range 
required by the ZetaView instrument. After analysis, the nanoparticle concentration and the 
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concentration of hemin were known, so the number of hemin molecules per nanoparticle could 
be calculated. 
Hemin Nanoparticle Size Stability Study 
Three batches of Hemin NPs were synthesized and stored at room temperature. Dynamic 
light scattering measurements were taken at various time points to determine how long the size 
and polydispersity of the particles remained constant.  
Nanoparticle Synthesis Protocol for Additional Metal Protoporphyrin IX Derivatives 
Nanoparticles were synthesized from other metal protoporphyrin IX (Me PPIX) 
derivatives besides hemin (Fe(III) PPIX), to determine if the metal center had an effect on 
nanoparticle formation and stability. Me PPIX analyzed included Mn(III), Co(III), Cu(II), and 
Zn(II) PPIX.  These nanoparticles were synthesized by the same procedure used for Hemin NPs. 
Concentrations of each porphyrin were found under the following conditions: Mn(III) PPIX, e462 
= 25,000; Fe(III) PPIX, e385 = 58,400; Co(III) PPIX, e416 = 93,000; Cu(II) PPIX, e388 = 64,000; 
and Zn(II) PPIX, e412 = 87,400 (all molar extinction coefficients are in units of L/mol×cm). The 
solvent used for determination of concentration for Fe(III), Mn(III) and Zn(II) derivatives was 
0.1 M NaOH and 0.1 M Tris-Acetate buffer pH = 7.9 was used for Co(III) and Cu(II) 
derivatives. The concentration of each porphyrin solution in DMF, before addition to the 
nanoparticle synthesis reaction, was 1.7 mM. The resulting particles were analyzed by UV-Vis 
absorption spectroscopy and DLS (Table SI V.1).  
pH and Temperature Stability Studies 
The stability of the Hemin NPs from pH = 3-9 was analyzed by adding 30 µL of 
nanoparticles to 170 µL of the specified buffer. Solutions were then mixed for 5 minutes and the 
absorption spectrum taken. For pH = 3-5, citrate-phosphate buffer was used; pH = 6-8, phosphate 
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buffer; pH = 9-12, borate buffer. The pH dependent DLS samples were analyzed in buffers 
corresponding with the specified pH. The stability of the Hemin NPs at different temperatures 
was determined by DLS. The instrument was programmed to analyze the nanoparticles from 
20°C-80°C. The Hemin NP sample was kept at the specified temperature for 20 minutes before 
size analysis.  
Ligand Optimization for Catalytic Turnover 
Dialyzed Hemin NPs were combined with each ligand in 200 mM PB pH = 7. Final 
concentrations were 0.3 M ligand and 200 nM hemin. 100 µL of TMB-One was added and the 
absorbance was read at 650 nm every 30 seconds for 20 minutes. The same procedure was 
followed for the optimization of pyridine concentration, except pyridine solutions were made in 
10 mM borate buffer pH=8 and the final hemin concentration was 300 nM. Absorbance was read 
after 10 minutes. 
Cyclic Voltammetry of Hemin-Pyridine Complex 
For the analysis of the hemin-pyridine complex by cyclic voltammetry, the working, 
reference and counter electrodes were rinsed in DI water before each experiment. The counter 
electrode was also flame cleaned. Samples with less than 30% pyridine contained 0.5 M NaNO3, 
30% v/v 190 proof ethanol, 0.05 M Tris buffer pH 8.0, 0.5-1.0 mM hemin and the specified 
concentration of pyridine. These solutions were made in a 25 mL volumetric flask and additional 
volume was filled with DI water. If a solution contained greater than 30% pyridine, then the 
same procedure was used except the ethanol concentration was 10% v/v. Measurements were 
made after degassing the solution for 20 minutes. The solution was then immediately added to 
the test cell and the electrodes immersed. The experiment was run in the negative direction from 
0.4 V to -0.8 V to 0.4 V with a scan rate of 0.1 V/sec and a sensitivity of 1 x 10-5 A. 
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Kinetic Analysis 
The catalytic properties of HRPx and Hemin NPs were examined with respect to the 
substrates hydrogen peroxide (H2O2) and TMB and then compared. The solvent for all TMB 
solutions was 10% DMSO in citrate-phosphate buffer as specified by the manufacturer. When 
HRPx was analyzed with respect to H2O2, TMB was held constant at 0.4 mM and HRPx at 0.25 
mM. When HRPx was analyzed with respect to TMB, H2O2 was held constant at 1 mM (final 
concentrations). The following volumes of each component were combined for a total reaction 
volume of 200 µL: 190µL TMB, 8 µL H2O2 and 2 µL HRPx. The reaction was immediately 
analyzed by measuring the absorbance at 650 nm over time, with continuous plate shaking.  
 The catalytic properties of Hemin NPs were analyzed with pyridine in the same way 
except for the following modifications. Final concentration of pyridine was 0.3 M and that of 
hemin (from the Hemin NPs) was 42.8 nM. TMB was held constant at 0.4 mM when performing 
the analysis with respect to H2O2, and H2O2 was held constant at 20 mM when analyzing with 
respect to TMB. The total volume of 200 µL was divided in the following way: 190µL TMB, 2 
µL H2O2, 5 µL pyridine and 3 µL Hemin NPs.  
When Hemin NP catalytic properties were analyzed without pyridine, the final 
concentration of hemin was 3.9 µM. The concentration of TMB was held constant at 0.4 mM 
when analyzing with respect to H2O2 and the H2O2 concentration held constant at 500 mM when 
analyzing with respect to TMB. In this experiment, the component volumes for the 200 µL 
reaction were 145 µL TMB, 10.5 µL H2O2 and 44.5 µL Hemin NPs. The final concentration of 
DMSO in the wells was 9.5% to align with the other kinetic experiments.  
Kinetic data was acquired by measuring absorbance over time at different substrate 
concentrations. To determine kinetic properties, velocity curves were generated by first taking 
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these absorbance values and converting them to concentration of product through the molar 
absorptivity of TMB (e650 = 39,000 L/mol×cm). These concentration values were plotted versus 
time.113 The slope of the linear portion of these plots (the velocity) was then determined and 
plotted again the substrate concentration. The resulting plots were then fit to a Michaelis–Menten 
model using Prism software and kcat and KM were determined. Catalytic efficiency was defined as 
the ratio of the two. 
Stability of Hemin Nanoparticle Catalytic Properties 
Kinetic stability of the Hemin NPs was determined by storing the nanoparticles in the 
dark, at room temperature. At specified time points, portions of the nanoparticles were removed 
from the stock and analyzed for catalytic activity. Final concentrations of reactants were 42.8 nM 
hemin, 20 mM H2O2, 0.4 M TMB and 0.3 M pyridine. The absorbance was read after 1.5 
minutes at 650 nm. HRPx stability was analyzed by storing a 25 nM HRPx solution in a drawer. 
It was then analyzed at specific time points with reaction conditions of 2.27 nM HRPx combined 
with 100 µL of TMB-One. After 10 minutes the reaction was stopped with 2M H2SO4 and the 
absorbance read at 450 nm. 
Detection of Rabbit IgG  
Antibodies were conjugated to Hemin NPs for a protein detection assay. The conjugation 
of the antibody was carried out as previously reported.114 Briefly, a diazirine-based photoreactive 
linker was used for conjugation. The ratio of Hemin NPs to anti-rabbit IgG antibody (A00131) 
was 17 µg of anti-rabbit IgG antibody per 100 µg of hemin (mole ratio approximately 40:1 
IgG:Hemin NP). The amount of hemin was determined by adding 5 µL of Hemin NPs to 195 µL 
of 5% pyridine. The absorbance of the solution was read at 405 nm (e405 = 92,297 L/mol×cm). 
After conjugation, the particles were dialyzed at 4°C to remove any excess antibody or reagents.  
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 The plate assay for detection of the model biomarker, rabbit-IgG (Rab-IgG), was carried 
out according to the following procedure. In a 96-well Immulon plate, 100 µL of goat anti-rabbit 
IgG at 4 µg/mL was immobilized in each well and incubated for 1 hour. The plate was then 
blocked with 300 µL of 1% BSA in PBST (1X PBS, 0.1% Tween-20) and incubated for 2 hours. 
100 µL samples of Rab-IgG, in 1X PBS with 2% BSA, were then added and incubated 2 hours. 
In the detection step, 100 µL of anti-rabbit IgG conjugated Hemin NPs (Ab-Hemin NP) were 
added at a concentration of 40 µg hemin/mL in 7% BSA and incubated on a shaker for 1 hour. 
After each of these steps the plate was washed 5 times with PBST. Following the last wash, 50 
µL of 0.9 M pyridine in 10 mM borate buffer pH 8 was added and the plate shaken for an 
additional 5 minutes. Finally, 100 µL of TMB-One spiked with H2O2 to a final concentration of 8 
mM was added and the absorbance was read at 650 nm after 4 minutes. All incubations were 
performed at room temperature.  
For comparison, an identical assay was performed using HRPx conjugated anti-rabbit 
IgG as the detection element. To determine how much HRPx detection element to add to the 
assay, the number of Ab-Hemin NPs added per well was found based upon one Hemin NP 
containing 60,000 hemin molecules. The result was 6x1010 nanoparticles/well, so this number of 
HRPx anti-rabbit IgG molecules were added to each well. As a result, concentration of reagents 
used in this assay were: 4 µg/mL anti-rabbit IgG for capture, 1% BSA in PBST for blocking, 
Rab-IgG samples in 2% BSA, 0.16 µg/mL of HRPx anti-rabbit IgG in 7% BSA for detection. 
Absorbance at 650 nm was read after 4 minutes.  
Detection of Plasmodium Lactate Dehydrogenase  
Antibodies were coupled to Hemin NPs for detection of pLDH at the ratio of 32 µg anti-
pLDH antibody (1209) for every 100 µg of hemin. These anti-pLDH Hemin NPs (pLDH-Hemin 
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NPs) were then used in a plate assay for detection of pLDH. The assay was performed as the 
Rab-IgG assay but with the following modifications. Capture antibody (19g7) was added at a 
concentration of 1 µg/mL and the plate was blocked with 1% BSA in PBST. Samples were 
prepared in lysed whole blood (1:1 v/v whole blood:lysis buffer (100 mM PB pH=8, 300 mM 
NaCl, 2% Triton X-100)). The blood was then spiked with parasite culture to the specified 
concentration. In this culture, 1 parasite/µL was equal to approximately 5 pM pLDH. After 
incubation of these samples, pLDH-Hemin NPs were added at 40 µg hemin/mL in 12% BSA. 
Finally, pyridine and the TMB-One substrate were added for signal generation.   
 
Results and Discussion 
Hemin Nanoparticle Synthesis  
Nanoparticles made of the porphyrin, hemin (Fe(III) PPIX), were synthesized in the hope 
of developing an alternative detection strategy to the horseradish peroxidase enzyme (HRPx). 
HRPx is prevalently used in enzyme-linked immunosorbent assays (ELISA) for protein 
detection. These assays have great sensitivity as a result of the catalytic efficiency of HRPx in 
the turnover of colorimetric substrates producing signal amplification in the assay. As mentioned 
previously, HRPx is sensitive to heat, light, pH and other environmental conditions and as such 
is not practical for low-resource settings.97 Hemin, found in the active site of HRPx, can also 
turnover a colorimetric substrate, so nanoparticles made from this molecule could result in a 
detection strategy that employs signal amplification but is environmentally stable. In a Hemin 
NP detection strategy, signal amplification would occur in two ways. In the first, Hemin NPs 
would be broken apart into individual hemin molecules, producing tens of thousands of signal-
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generating, hemin molecules from one nanoparticle. Secondly, each of these hemin molecules 
would catalytically turnover a colorimetric substrate, amplifying the signal once again.  
To develop this detection strategy, a synthesis method was optimized for 100 nm Hemin 
NPs. This synthesis was based upon the mixed solvent method, which has been previously 
reported for the synthesis of other porphyrin nanoparticles.86 In this method, the porphyrin is 
dissolved in an organic solvent with a polyethylene glycol (PEG) stabilizer. The addition of a 
relatively large amount of water then forces the interaction of the porphyrin molecules with each 
other and these aggregates are stabilized by the PEG. Energy is then applied to the solution, in 
the form of mixing, resulting in a monodisperse solution of nanoparticles.87 To our knowledge, 
Hemin NPs have never been synthesized using this method, so a protocol was developed.  
 The first parameter that was optimized was the mixing method. It was necessary to find a 
mixing method that was reproducible and also sufficiently strong to produce particles in the 
desired 100 nm size range. A probe sonicator was chosen as it provided consistent and sufficient 
energy. In general, nanoparticles composed of metal porphyrins require higher energy mixing 
than free porphyrin nanoparticles, as a result of the additional interactions introduced by the 
metal ions.86 The optimum energy setting for the sonicator was found by varying the amplitude 
between 3% and 15%. It was found that with greater amplitude the particles size decreased but 
the polydispersity increased (Figure V.2A). Since previous experiments had shown low 
polydispersity to be the best indicator of nanoparticle stability, an amplitude of 3% was used for 
all further syntheses. The time of sonication was also examined but it was found to have no 
significant effect on particle size or polydispersity. Sonication for 2 minutes was found to be the 
most reproducible, so this parameter was used in the remaining syntheses (Figure V.2B).  
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 The concentration of hemin added to the reaction mixture was also optimized. Hemin 
concentrations between 1.9 mM and 3.0 mM were tested with 60 µL of HEGME. It was 
observed that adding higher concentrations of hemin resulted in larger particles (Figure V.2C). 
The larger particles quickly fell out of solution indicating greater concentrations of hemin did not 
necessarily produce bigger particles but instead unstable particles that quickly aggregated. 
Furthermore, the amount of HEGME added to the reaction mixture was explored. The volumes 
of HEGME tested were 60, 80 and 100 µL with 1.9 mM hemin. It was found that the particle 
size did not significantly change between these samples (Figure V.2D). Analysis of long term 
	  
Figure V.2. Hemin nanoparticle synthesis optimization. A) Energy of mixing for synthesis. 
Sonication amplitude of 3% was chosen. B) Mixing time. Sonication time of 2 minutes was 
selected. C) Concentration of hemin added to synthesis. 1.9 mM hemin was chosen. D) 
Volume of stabilizer added to synthesis. 80 µL of hexaethylene glycol monomethyl ether 
resulted in the most stable particles. 
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stability showed that the particles made with 60 µL or 100 µL of HEGME fell out of solution 
within 20 days, while the Hemin NPs made with 80 µL HEGME remained stable. Thus, 80 µL of 
HEGME per 100 µL of 1.9 mM hemin in DMF was selected for all future syntheses.  
Hexaethylene glycol, a stabilizer similar in structure to HEGME, was explored as a more 
cost-effective alternative for this synthesis. Unfortunately, use of this stabilizer resulted in large, 
polydisperse particles (Figure SI V.1). It has been previously observed that changing the type of 
stabilizer has a significant effect on nanoparticle synthesis when the porphyrin used has polar 
substituents. This is so because of greater interactions between the porphyrin, stabilizer and 
solvent. Since hemin contains polar substituents, it likely has significant interaction with the 
stabilizer which would explain the large effect the type of stabilizer had on the Hemin NP size 86.  
 It was also determined whether the temperature at which the synthesis was performed had 
an effect on Hemin NP size. The synthesis was performed at 0°C, 22°C and 50°C and no 
difference in nanoparticle size or polydispersity was observed (Figure SI V.2). Furthermore, 
scale up of the synthesis was tested. It was found that a 1.5x scale-up resulted in larger particles 
with greater polydispersity (Figure SI V.3). Thus, only 6 mL Hemin NPs batches were made in 
this study. 
 Using the optimized conditions of 100 µL of 1.9 mM hemin with 80 µL of HEGME and 
6 mL of water at 0°C, the resulting Hemin NPs had a diameter of 110 ± 10 nm and PdI = 0.20 ± 
0.03 (n = 10) (Figure V.3). The number of hemin molecules per nanoparticle was determined 
through finding the particle concentration in a sample with a known hemin concentration using a 
ZetaView particle analyzer. It was found that there were approximately 60,000 hemin 
molecules/nanoparticle. This number indicates that a large amplification should be achieved 
through dissolution of the nanoparticles. Optical analysis of the Hemin NPs showed an 
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absorbance spectrum with a broadened Soret band (l » 400 nm) compared to free hemin (Table 
SI V.1). This broadening is a result of the interactions of the hemin molecules with each other 
producing a wider range of absorbed wavelengths. Thus, a broadened Soret band is indicative 
and nanoparticles and a sharp Soret band of free hemin. 
 Lastly, it has been previously reported that the identity of the metal ion in the porphyrin 
affects nanoparticle formation.86 To explore this result in our system, nanoparticles were 
synthesized from the following PPIX derivatives: Mn(III) PPIX, Co(III) PPIX, Cu(II) PPIX and 
Zn(II) PPIX. The optical properties and size of the particles were then analyzed. Absorbance 
spectra showed broadened Soret bands for all particles. In the DLS analysis, a difference in 
particle size was seen corresponding to the oxidation state of the metal. Co(III) PPIX formed 
almost identical nanoparticles to hemin (Fe(III) PPIX). Mn(III) PPIX nanoparticles were larger 
than these particles but showed a similar size distribution. On the other hand, Zn(II) PPIX 
nanoparticles were much smaller with greater polydispersity. Cu(II) PPIX did not form stable 
	  
Figure V.3. Size distribution of Hemin NPs from the optimized synthesis procedure. These 
particles have a diameter of 110 ± 10 nm and polydispersity of 0.20 ± 0.03. 
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particles, as replicates varied greatly and the polydispersity was close to 1.0 (Table SI V.1). We 
hypothesize that the oxidation state affects the interplanar distance between the porphyrins upon 
pi-stacking. As a result, since interactions between the porphyrin molecules has change, re-
optimization of the method is required for synthesis of stable nanoparticles from porphyrins with 
metal centers in the lower (+2) oxidation state. 
Stability of Hemin Nanoparticles 
The size stability of Hemin NPs was examined through analysis of the particles by 
dynamic light scatter at different time points. The nanoparticles were stored in solution, at room 
temperature. It was found that Hemin NP size remained stable for 57 days. By day 70, the Hemin 
NPs had fallen out of solution. Thus, these particles show great stability as they remain 
suspended in aqueous solution, when stored at room temperature, for nearly 2 months (Figure SI 
V.4). 
 It has been previously reported that basic conditions can result in the dissolution of 
porphyrin nanoparticles.114 To determine the pH stability of Hemin NPs, the absorbance 
spectrum of the particles was recorded in solutions of different pH. It was seen that the sharpness 
of the Soret band increased as the pH increased, indicating a decrease in aggregation of the 
hemin molecules. This increase in absorbance occurred at three distinct points (Figure V.4). The 
first was at pH 3-4, where the Soret band was broadened and the intensity of the absorbance was 
very low. From pH = 5-9, the intensity of the absorbance increased, while the shape of the 
spectrum remained the same. Finally, at pH = 10-12, a sharp peak Soret band began to be visible. 
The Hemin NPs were then analyzed by DLS at pH = 3, 7 and 10, to see if there was a change in 
particle size that corresponded with the absorption spectrum. It was seen that the Hemin NPs 
form large aggregates (1 µm) at pH = 3, which would be expected as absorbance intensity is 
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known to decrease with aggregation. At pH = 7, the Hemin NP size was around 100 nm as 
previously observed. The reduced aggregation accounts for the observed increase in absorbance. 
Finally, at pH = 11, the DLS spectrum did not show a clear size distribution pointing to the 
dissolution of the Hemin NPs which corresponds to the sharp Soret band seen in the absorption 
spectrum. We conclude that the Hemin NPs are stable up to pH = 9, after which they fall apart. 
This would be expected as previous reports have shown hemin to be soluble in aqueous 
conditions around pH = 9.5.115 At this point, the carboxylic acid groups are deprotonated and the 
chloride ion on the iron center has been replaced by a hydroxyl group.116 This result 
demonstrates that Hemin NPs are more pH stable than the free base porphyrin NPs analyzed in 
Chapter IV.  
 The size stability of Hemin NPs at different temperatures was also explored. It was seen 
that when incubated for 20 minutes at various temperatures, the size of the nanoparticles 
remained constant, even at 80°C (Figure SI V.5). This result indicates the capacity of Hemin NPs 
to remain stable even in harsh environmental conditions.  
	  
Figure V.4. The pH stability of Hemin NPs. Hemin NPs were placed in solutions of different 
pH and absorption of the Soret band was measured. As pH increased the absorbance the Soret 
band also increased (left). The size of the Hemin NPs was analyzed in acidic, neutral and 
basic environments and dissolution of the nanoparticles was observed at pH = 11 (right). 
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Hemin-Pyridine Catalytic Complex 
The Hemin NP synthesis was developed in order to create a material which could mimic 
the signal amplification properties of HRPx but have increased stability. Once stable Hemin NPs 
were synthesized, their catalytic properties were explored. First, the ability of Hemin NPs to turn 
over a colorimetric substrate was determined. This property was tested by combining the Hemin 
NPs with a commercially available TMB substrate that contains hydrogen peroxide and 
measuring the absorbance over time. This turnover was tested without addition of a ligand and 
with addition of the following ligands: histidine, pyridine and imidazole. These specific ligands 
were tested because previous reports have demonstrated they increase the catalytic activity of 
hemin.108, 112, 117 This is so, because these ligands mimic the histidine residue found in the active 
site of HRPx (Figure V.5).118 In the active site, this histidine residue stabilizes the iron center of 
hemin for the formation of compound 1, the species responsible for oxidation of the colorimetric 
	  
	  
Figure V.5. Structure of the hemin molecule (left). The active site of the horseradish 
peroxidase enzyme. It can be seen that the iron center of the hemin molecule (in red) is 
stabilized by a histidine residue (right).118	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substrate (Figure SI V.6).119 Thus, introducing these ligands to a solution of Hemin NPs provides 
stabilization of the intermediate species required for substrate turnover.  
It was found that the turnover of the colorimetric substrate by Hemin NPs significantly 
increased with the addition of the ligands. Pyridine was found to have the largest impact on the 
turnover, and maximum turnover was observed with 2.4% (0.3 M) pyridine (Figure V.6). The 
addition of pyridine promotes dissolution of the Hemin NPs, the first type of signal amplification 
in this method (Figure SI V.7). Thus, this ligand break the Hemin NPs apart and assists in the 
catalytic turnover of the substrate. 
 The complex formed upon addition of pyridine to the Hemin NPs was further 
characterized to determine whether the iron center of hemin is mono or bis-ligated by pyridine. A 
bis-ligated species would be expected to have minimal catalytic turnover as the hydrogen 
peroxide binding site would be blocked by pyridine. Conversely the mono-ligated species would 
allow for hydrogen peroxide binding with a stabilized metal center. Since catalytic activity was 
observed, it was expected that the mono-ligated species was formed. Nonetheless, the amount of 
	  
Figure V.6. Turnover of a colorimetric substrate (3,3’,5,5’-tetramethylbenzidine) in the 
presence of various ligands (left). The greatest turnover was seen with pyridine. The 
concentration of pyridine that resulted in the best turnover was 2.4% (right). 
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pyridine added (2.4%) was in large molar excess to hemin, so the formation of the bis-ligated 
species was plausible. Therefore, the complex was analyzed further.  
 Literature reports have examined the hemin-pyridine complex in aqueous solutions by 
proton NMR. In these reports, the methyl resonances of the complex were monitored as 
increasing amounts of water were added to pyridine solutions containing hemin. It was found 
that in aqueous pyridine solutions containing 50% or less pyridine, the primary complex present 
in solution was mono-ligated with pyridine, and a water molecule was coordinated to the other 
side of iron center (aqua-pyridine complex). In solutions with more than 50% pyridine, a mixture 
of species were found, including the bis-ligated pyridine species and the aqua-pyridine 
complex.120, 121 These reports indicate that the catalytic complex observed in our system, at 2.4% 
pyridine, is mono-ligated. This hypothesis was further explored through analysis of the optical 
and electrochemical properties of the complex.  
The absorbance spectrum of Hemin NPs was measured in the presence of aqueous 
pyridine solutions. When hemin is in the nanoparticle, it is aggregated, producing a broad 
absorption band. Upon addition of the ligand, pi-pi interactions between porphyrin molecules are 
reduced resulting in deaggregation of the molecules and a corresponding sharp absorption 
band.89 Consequently, this band likely corresponds to breakdown of the Hemin NPs and binding 
of the pyridine to hemin. The sharp absorption band at 410 nm became visible at 1.0% pyridine 
and its maximum was reached at 7.2% pyridine (Figure V.7). We hypothesize that this range 
corresponds to mono-ligation of the hemin molecules with pyridine, forming the aqua-pyridine 
complex. Thus, the majority of hemin molecules are coordinated to one pyridine once a 
concentration of 7.2% pyridine is reached. Since the Hemin NP catalytic reaction is carried out at 
2.4% pyridine, it follows that the catalytic complex is mono-ligated. 
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 The hemin-pyridine complex was also analyzed by cyclic voltammetry, as ligand binding 
to the iron center affects its electrochemical properties. In these analyses, solutions of hemin in 
various concentrations of pyridine were evaluated. A large jump in oxidation and reduction 
potentials was observed between 0% and 4% pyridine, after which the potentials remained fairly 
consistent (Figure V.8). This positive shift in the reduction potential has been seen previously 
and it indicates that the reduction of the iron center occurs more easily upon binding of pyridine 
to hemin.121 This result would be expected as pyridine is less electron donating than the water/ 
hydroxide ligand it replaces, allowing for easier reduction of the iron center upon binding. This 
change in reduction potential corresponding to mono-ligation of hemin is observed in the 
pyridine concentration range where the catalytic complex is formed. Thus, this result also 
confirms that the species present at 2.4% pyridine is mono-ligated. Therefore, the hemin-
pyridine catalytic complex responsible for the turnover observed with the Hemin NP detection 
strategy has one pyridine coordinated to the iron center.  
	  
Figure V.7. The absorbance spectrum of Hemin NPs at various concentrations of pyridine. It 
can be seen there is an increasing sharpness of the Soret band with increasing pyridine 
concentration.  
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Kinetic Properties of Hemin NPs and Comparison to Horseradish Peroxidase  
Once it was confirmed that Hemin NPs could be used to produce a colorimetric signal, 
their kinetic properties were compared to HRPx. Michaelis–Menten kinetic behavior was 
observed and substrate versus velocity curves were plotted for HRPx, Hemin NPs with pyridine 
and Hemin NPs (Figure SI V.8). The concentration of active sites for each sample was known, so 
kcat values were calculated using Prism software. kcat is a measure of the number of substrate 
molecules converted to product per unit time by one active site. Thus, a higher kcat indicates a 
higher catalytic activity. As can be seen in Table V.1, Hemin NPs with pyridine have the greatest 
kcat. The kcat of the Hemin NPs with pyridine is 1,000x that of HRPx with respect to H2O2 and 
TMB. These kcat values were calculated based upon the assessment that there are 60,000 hemin 
molecules per nanoparticle. Thus, the kcat for a single hemin molecule within the nanoparticle is 
significantly lower (Table V.1, shown in parenthesis). Each horseradish peroxidase enzyme 
contains only one hemin molecule, so the fact that the kcat for HRPx is up to 100x that of a single 
	  
Figure V.8. The change in the oxidation and reduction potentials of the iron center of hemin 
with increasing concentrations of pyridine.  
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hemin molecule from the nanoparticles in the presence of pyridine demonstrates how the protein 
structure, which is removed in the Hemin NPs, significantly enhances substrate turnover by 
hemin. Consequently, the combination of signal amplification by dissolution of the nanoparticles 
with the catalytic turnover is essential for the Hemin NP method to have significant catalytic 
activity. 
Another interesting result of the kinetic characterization was the KM values. KM is 
defined as the concentration of substrate where half of the active sites are filled. As a result, KM 
is an indirect measure of the affinity of the substrate for the active site. The substrate has high 
affinity for the active site when the KM is small, indicating that a small amount of substrate is 
needed to reach this point. As can be seen in Table V.1, the KM values for the H2O2 substrate 
increase significantly between HRPx, Hemin NPs with pyridine, and just Hemin NPs. This result 
shows that the enzyme has a much greater affinity for H2O2 than does hemin. Nevertheless, the 
addition of pyridine greatly decreased the KM of Hemin NPs with respect to H2O2. This 
	  
 
Table V.1. A comparison of the catalytic properties of HRPx and Hemin NPs with and 
without pyridine.  
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observation suggests that the greater catalytic turnover observed upon addition of pyridine is a 
result of increased affinity for H2O2.  
 A more complete picture of the catalytic activity of the Hemin NPs can be seen when 
both kcat and KM are taken into account. These terms can be combined into a parameter called 
catalytic efficiency, which is defined as kcat/KM. Catalytic efficiency does not just look at the rate 
of turnover but also the amount of substrate required. As can be seen in Table V.1, the catalytic 
efficiency with respect to H2O2 of HRPx is 200x103, while that for Hemin NPs with pyridine is 
4,000x103. Thus, when considering the H2O2 substrate, the Hemin NP method is 20-fold more 
efficient than HRPx. The catalytic efficiencies with respect to TMB were 300x103 for HRPx and 
140,000x103 for Hemin NPs with pyridine. In this instance, the Hemin NP method is 500 times 
more efficient. Thus, the developed Hemin NP method has a higher catalytic efficiency than 
HRPx. The difference between the efficiencies based upon H2O2 and TMB substrates is expected 
as higher KM values were observed for H2O2 compared to TMB. The utility of these strategies to 
detect a protein biomarker is discussed in the next section and seen in Figure 10. 
 The stability of the catalytic activity of Hemin NPs was of great interest as one of the 
greatest downfalls of HRPx is that it quickly loses activity in non-ideal environmental 
conditions. To study this property, Hemin NPs were stored at room temperature and the 
absorbance generated by substrate turnover was measured at various time points. These values 
were compared to the initial signal. It was found that after 40 days, there was no statistical 
difference in the signal produced by the Hemin NPs compared to day 1 (Figure SI V.9). Thus, 
without refrigeration the Hemin NPs retain their catalytic activity, indicating the viability of this 
detection strategy in a low-resource setting. For comparison, a similar study was done with 
HRPx. By day 7, the signal produced had decreased by over 75%, and even within one day a 
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significant drop was seen (Figure V.9). The degradation of the protein structure is most likely the 
cause of this loss of signal. As there are no protein components in the Hemin NPs, a decrease in 
signal was not observed. Thus, the Hemin NP detection method has higher catalytic activity than 
HRPx and significantly greater environmental stability.  
Detection of Rabbit IgG 
Up to this point it has been shown that Hemin NPs are an efficient and stable signal-
generating material but the usefulness of this strategy for detection of biomolecules has not been 
demonstrated. To complete the Hemin NPs detection method, antibodies were coupled to Hemin 
NPs and these conjugates were used as the detection element in an ELISA-like assay for 
detection of the model biomarker, Rab-IgG. In this assay, a primary antibody was immobilized 
on a plate, followed by blocking and addition of the sample. The anti-rabbit IgG conjugated 
Hemin NPs (Ab-Hemin NPs) were then added as the detection element. 
	  
Figure V.9. The stability of the catalytic activity of Hemin NPs and HRPx. It can be seen 
that after seven days the ability of HRPx to turnover a substrate is lost. 
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The primary antibody concentration was optimized for this assay based upon signal-to-
noise, as too little primary antibody results in insufficient biomarker capture and too much can 
cause non-specific binding. It was found that 4 µg/mL resulted in the highest signal-to-noise with 
the least variability, so this concentration was chosen for the assay (Figure SI V.10A). The 
amount of BSA needed to block the plate to prevent non-specific binding was also explored. It 
was found that 1% BSA resulted in the best signal-to-noise (Figure SI V.10B). 
Optimal Ab-Hemin NP concentration and blocking were also determined. The 
concentration of Ab-Hemin NPs added to each well is important to ensure that the assay signal is 
dependent on the amount of biomarker present and not limited by the quantity of nanoparticles 
added. It was found the signal saturated at an Ab-Hemin NPs concentration of 40 µg/mL (Figure 
SI V.10C). The amount of BSA required for sufficient blocking of the Ab-Hemin NPs was also 
an essential optimization, as Ab-Hemin NPs displayed significant non-specific binding. This 
non-specific binding was mitigated with 7% BSA (Figure SI V.10D).  
 A Rab-IgG standard curve was performed using the optimized protocol and the result was 
an assay with a linear range from 15 to 250 pM Rab-IgG (Figure V.10). The limit of detection, 
calculated by 3sblank/slope, was 14.5 ± 0.8 pM Rab-IgG. An identical assay was then run with 
HRPx as the detection element allowing for comparison of the two strategies. The results showed 
a linear response over the concentration range of 10-100 pM Rab-IgG with a limit of detection of 
0.27 ± 0.01 pM Rab-IgG. The Hemin NP assay had greater sensitivity than the HRPx assay as 
the slope of the linear regression was greater (y = 0.0148x + 0.18 compared to y = 0.0064x + 
0.07). On the other hand, the HRPx assay had a lower background and was more precise, 
resulting in a lower calculated LOD (Figure V.10). This data shows that the combination of the 
two amplification strategies in the Hemin NP method produced a protein detection strategy with 
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greater sensitivity than HRPx, confirming the results of the kinetic analysis which showed the 
Hemin NP method had greater catalytic efficiency. Furthermore, it illustrates how signal 
amplification is profitable up to a point but then the corresponding amplification in error 
prevents a continued decrease in detection limits. Nonetheless, employing signal amplification 
with Hemin NP was shown to be both sensitive and stable. Furthermore, this method shows 
improvement over the fluorescent detection strategy developed in Chapter IV, as the absorbent 
signal easily read by the naked eye; an important characteristic for a low-resource diagnostic 
(Figure SI V.11).  
Detection of Plasmodium Lactate Dehydrogenase 
The Hemin NP strategy was then applied to the detection of a malarial biomarker in a 
whole blood matrix. As was discussed in Chapter II, there are two primary protein biomarkers 
used to detect malaria: (1) Plasmodium falciparum Histidine-Rich Protein II (pfHRPII) and (2) 
plasmodium lactate dehydrogenase (pLDH). It was found that there are downfalls associated 
	  
Figure V.10. A comparison of the standard curves generated when Rab-IgG was detected in a 
plate assay with Hemin NPs and HRPx. 
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with using pfHRPII as a biomarker, including its persistence in the blood, which can result in 
false positive test results. Therefore, pLDH was selected as the target for this assay as it clears 
quickly from the bloodstream and is found in all species of malaria. The Hemin NP detection 
strategy was optimized for detection of pLDH in lysed whole blood samples spiked with parasite 
culture. The parameters that resulted in the best assay signal-to-noise were found to be 1 µg/mL 
anti-pLDH antibody (19g7) for capture, 1% BSA for blocking of the plate, and 40 µg/mL of 
pLDH-Hemin NPs blocked of 12% BSA (Figure SI V.12A-C).  
 The optimized pLDH assay had a linear range from 100-1750 parasites/µL and a 
calculated limit of detection of 18.6 ± 0.6 parasites/µL (~90 pM pLDH) (Figure V.11). This limit 
of detection is well within the submicroscopic range of malaria infections and is of the same 
order of magnitude as commercially available ELISA kits for detection of pLDH.36 This assay 
was also reproducible, as the inter-assay variability was found to be 5% and the intra-assay 
	  
Figure V.11. Detection of pLDH from parasite-spiked lysed blood using pLDH-Hemin NPs. 
Linear concentration dependent response observed from 100-1750 parasites/µL. 
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variability between 250 and 1750 parasites/µL was 18% (n=3). Thus, the Hemin NP detection 
strategy is stable, sensitive and reproducible and can be used to detect a malarial biomarker at 
clinically relevant concentrations from a complex matrix.   
 
Conclusion 
A novel, nanoparticle-based detection strategy using hemin nanoparticles has been 
reported. This method, which takes inspiration from the horseradish peroxidase enzyme, employs 
two-types of signal amplification. The first is dissolution of the Hemin NPs into tens of 
thousands of constituent hemin molecules and the second is catalytic turnover of a colorimetric 
substrate by each hemin molecule. A synthesis for Hemin NPs was developed and the catalytic 
properties of the resulting nanoparticles were optimized and characterized. The result was a 
detection element that showed great stability compared to HRPx, maintaining catalytic activity 
even after storage at room temperature for 40 days. Furthermore, biomolecule detection by the 
Hemin NP strategy was found to have greater sensitivity than HRPx and it detected picomolar 
levels of both the model biomarker, Rab-IgG and malarial biomarker, pLDH. This method could 
also easily be used for detection of protein biomarkers indicative of other diseases by changing 
the conjugated antibody. The easily observable signal, sensitivity, stability and versatility of the 
Hemin NP detection method makes it a very promising option for future incorporation into 
paper-based, low-resource diagnostics. 
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CHAPTER VI 
 
CELLULOSE MEMBRANES MODIFIED WITH METAL AFFINITY LIGAND FOR 
CAPTURE AND DETECTION OF MALARIAL BIOMARKERS 
 
Introduction 
 One of the most effectively implemented low-resource diagnostics is the rapid diagnostic 
test (RDT).72, 122 These tests are easy to use, requiring minimal user steps and reducing the need 
for highly trained personnel. RDTs are also stable, allowing to shipment and storage in ambient 
conditions.72, 123 Thus, RDTs can withstand many of the rigors of low-resource environments. 
The low cost of RDTs has enabled their procurement on a mass scale and the lack of 
instrumentation allows their use at all levels of health facilities in low-resource settings.74, 124 As 
a result, RDTs have been extensively used in malaria elimination campaigns around the world. In 
certain areas of Sub-Saharan Africa, diagnosis by RDT with subsequent treatment has resulted in 
a significant decline in the prevalence of the malaria.20, 125  
Unfortunately, as discussed in Chapter III, RDTs still have limitations, namely a lack of 
sensitivity. This lack of sensitivity prevents RDTs from detecting submicroscopic malaria 
infections, many of which are asymptomatic, resulting in a sustained disease reservoir and 
preventing disease elimination.27, 70 In order to enhance the sensitivity of these tests, a simple 
sample processing step was introduced in Chapter III, which purifies and concentrates the 
malarial biomarker Plasmodium falciparum histidine-rich protein II (pfHRPII) using Ni-NTA 
magnetic beads which bind to the histidines in pfHRPII. Using this technique, the limit of 
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detection of a several RDT brands was decreased to single digit parasitemias, which is well 
within the submicroscopic infection range.27 
 While this sample preparation procedure was very successful, it added several steps to the 
process of performing an RDT and required extract diagnostic components, a less than ideal 
characteristic in low-resource settings where trained personnel are limited. The efficacy of this 
sample preparation step was a result of the fact that it overcame the sample volume limitation of 
RDTs, a primary contributor to their lack of sensitivity. RDTs are sample volume limited in that 
the addition of large sample volumes, which present more biomarker to the test, is not feasible 
since blood volumes above those recommended by the manufacturer do not clear from the test.28 
In the sample processing step, the biomarker from a large sample volume is concentrated into a 
small volume that can be added to the RDT. Thus, more biomarker is presented to the test, 
allowing smaller infection levels to be detected.  
In this chapter, we present an alternative method for concentration of pfHRPII that does 
not require the extra components and steps used in the previous method. This new design utilizes 
cellulose that is functionalized with metal affinity ligands to capture the biomarker. Similar 
materials have been synthesized previously with several different metal affinity ligands including 
iminodiacetic acid, nitrilotriacetic acid and N, N, N,-tris(carboxymethyl)ethylenediamine.126, 127 
Application of these membranes included metal capture out of solution and protein 
purification.128-131 In the following work, cellulose membranes were modified with the 
iminodiacetic acid (IDA) and zinc was subsequently coordinated to this ligand. These Zn-IDA 
cellulose membranes were used to capture pfHRPII, as the intrinsic histidines will bind to zinc.29, 
132 A diagnostic which utilizes the Zn-IDA membrane will have a large sample volume capacity, 
as the sample can simply flow through the membrane which will capture the pfHRPII, 
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concentrating it for subsequent detection. A strength of this approach is that paper is the only 
material required for concentration of the biomarker, making this an inexpensive and simple 
option for low-resource settings.  
 Furthermore, the use of paper allows the sample preparation step and the diagnostic to be 
combined into one complete test. For example, the simple addition of a detection element, which 
binds to the biomarker captured on the cellulose membrane, would allow for biomarker detection 
on the membrane. Assays have been previously developed for detection of malaria, p24, and 
prostate-specific antigen, that utilize this flow-through diagnostic technique. These assays 
utilized aptamers or antibodies for capture of the biomarker and assay signals were produced by 
either gold nanoparticles or enzymes. Clinically relevant concentrations were detected by these 
methods and increased sensitivity was observed with greater sample volumes.31, 33, 133 In the 
following, we demonstrate how Zn-IDA membranes can be used for the effective capture of the 
malarial biomarker (pfHRPII). For detection, the hemin nanoparticle method developed in 
Chapter V was implemented because of its sensitivity and stability. Up to this point the Hemin 
NP method had only been implemented in a plate assay format, which is not feasible in low-
resource settings. But through combination of this method with the Zn-IDA membranes, it will 
be utilized in a low-resource format. Thus, this work combines sample preparation and 
biomarker detection in one diagnostic device. The capture of pfHRPII is by the Zn-IDA 
membranes is characterized. Furthermore, the hemin nanoparticle detection strategy is optimized 
for this paper-based method and the limit of detection for pfHRPII, using this flow-through 
diagnostic, is reported. 
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Experimental 
Materials 
Sharkskin (catalog no. 09800965), Whatman 2589A (catalog no. 09924374), Whatman 
91 (catalog no. 09927547), and Whatman 3 (catalog no. 09-820H) cellulose membranes were 
purchased from Fisher Scientific. Regenerated cellulose membranes were acquired from 
Sartorius (catalog no. 18406--47------N). (±)-Epichlorohydrin (catalog no. 45340) and 
ethylenediaminetetraacetic acid tripotassium salt dihydrate (catalog no. 03664) were purchased 
from Sigma Aldrich. Zinc sulfate heptahydrate (catalog no. Z68), nitric acid (TraceMetalä 
Grade) (catalog no. A509P500) and 33 mm (pore size 0.45 µm) PVDF syringe filters (catalog no. 
09-719-002) for preparation of ICP-OES samples were acquired from Fisher Scientific. 
PlasmaCAL multi-element standard (catalog no. 600-698-201) for ICP-OES analysis was 
purchased from SCP Science. For flow-through assays Norm-Jectä 3 mL syringes were used. 
Plasmodium falciparum D6 strain (1 parasite/µL » 2.9 pM pfHRPII) was cultured in house and 
Human Whole Blood (CPD) was purchased from Bioreclamation IVT (catalog no. 
HMWBCPD). pfHRPII ELISA capture and detection antibodies were acquired from Abcam Inc. 
(catalog nos. ab9206 and ab30384, respectively). Immulon 2HB ELISA plates (catalog no. 14-
245-61) and Promega 3,3’,5,5’-tetramethylbenzidine (TMB) One ELISA substrate (catalog no. 
PR-G7431) were purchased from Fisher Scientific. Hemin for nanoparticle synthesis was 
acquired from MP Biomedicals (catalog no. 198820). Pierce™ Sulfo-NHS-LC diazirine 
photoreactive crosslinker (catalog no. PI-26174), 10 kDa SnakeSkin™ dialysis tubing, and 0.5 
mL Zeba™ Spin Desalting Columns (7K MWCO) were purchased from Fisher Scientific. 1000 
kDa Spectra/Por® Float-A-Lyzer® G2 dialysis devices (catalog no. G235062) and Spectra/Gel® 
absorbent (catalog no. 292600) were acquired from Spectrum Laboratories Inc. Goat anti-rabbit 
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IgG antibody (pAb) (catalog no. A00131), goat anti-rabbit IgG antibody [HRP] (catalog no. 
A00098) and rabbit IgG control (whole molecule) (catalog no. A01008) were purchased from 
Genscript Inc. The anti-Plasmodium falciparum antibodies for conjugation to hemin 
nanoparticles and capture in the plate assay were acquired from Abcam (catalog nos. ab9203 and 
ab9206, respectively). All other reagents were obtained from either Sigma-Aldrich or Fisher 
Scientific.  
Instrumentation 
Zinc was quantified using an Optima 7000 DV inductively coupled plasma optical 
emission spectrometer (ICP-OES). Sonication during nanoparticle synthesis was carried out with 
an Ace Glass GEX 600-5 Ultrasonic Processor. A Spectroline handheld UV light (Model ENF-
260C) with irradiation at 365 nm was used to initiate the photoreactive crosslinker. Absorbance 
measurements were collected on a Biotek Synergy™ H4 microplate reader. Membranes were 
imaged using a HP Color Laser Jet Pro MFP M476dw scanner. 
Membrane Synthesis 
Zn-IDA functionalized membranes were synthesized with slight modification to a 
previously reported procedure.130 Briefly, a 25 mL solution containing 80% 1.6 M sodium 
hydroxide and 20% (±)-Epichlorohydrin (EPI) was added to a glass vessel with the cellulose 
membrane of choice. After 8 hours, the membrane was removed from the solution and washed 
three times with DI water. It was then added to a 25 mL solution of 1 M iminodiacetic acid 
(IDA) in 1 M sodium carbonate. This reaction was allowed to proceed overnight. Next, the 
membrane was washed with DI water three more times. Finally, the membrane was added to 25 
mL of 25 mM zinc sulfate for 1 hour, washed again with DI water and then allowed to dry. IDA 
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control membranes were synthesized in the same way except the synthesis was terminated after 
reaction with IDA in sodium carbonate, so zinc was not coordinated to the membrane. 
Zinc Quantification with ICP-OES 
The amount of zinc bound to IDA on the membrane was quantified by ICP-OES. A piece 
of membrane with a known size was placed in a 1.5 mL microcentrifuge tube with 13.3% trace 
metal free nitric acid. This tube was placed on a shaker for 15 minutes before the solution was 
passed through a PVDP syringe filter to remove remaining cellulose. The solution was then 
diluted to a concentration of 2% nitric acid. If further dilution was required for the sample to be 
within the linear range of the instrument, this was done with 2% nitric acid. These samples were 
then analyzed against standards and zinc was measured at a wavelength of 206.2 nm. 
Capture Efficiency 
For determination of the amount of pfHRPII that could be captured by the Zn-IDA 
membrane, a d = 1 cm section of membrane was placed in the bottom of a 3 mL plastic syringe. 
A 500 µL sample at 200 parasites/µL was then added to the syringe. Samples in buffer (50 mM 
phosphate buffer pH = 8, 300 mM NaCl, and 0.1% BSA), whole blood and lysed whole blood 
(1:1 v/v whole blood:lysis buffer (100 mM PB pH=8, 300 mM NaCl, 2% Triton X-100)) were 
analyzed. The samples were allowed to gravity flow through the membrane for 1 minute before 
the remaining sample was pushed through by the plunger. This sample was collected for analysis 
by pfHRPII ELISA to determine the amount of pfHRPII remaining in the solution after flow 
through the membrane. A positive and negative control were also analyzed. The amount of 
pfHRPII bound to the membrane was determined by subtracting the amount of pfHRPII in the 
sample that passed through the membrane from the amount of pfHRPII in the original sample 
(the positive control).  
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pfHRPII ELISA Protocol 
The protocol for the ELISA used to quantify pfHRPII bound by the Zn-IDA membranes 
has been reported previously.26 Briefly, 1 µg/mL of anti-HRPII IgM (ab9206) in PBS was 
immobilized in a 96-well plate, which was then blocked with 5% BSA in PBST (1X PBS, 0.1% 
Tween-20). Samples were diluted in sample buffer (PBST, 0.1% BSA) and added to the plate. 
Finally, horseradish peroxidase conjugated detection antibody (ab30384) was added at 0.5 
µg/mL in PBST with 0.5% BSA. Signal was visualized with TMB-One and stopped with 2M 
sulfuric acid. Absorbance was read at 450 nm.  
Membrane Selection Study 
Sharkskin, Whatman 2589A, Whatman 91, and Whatman 3 cellulose membranes and a 
regenerated cellulose membrane from Sartorius were functionalized with Zn-IDA as described 
earlier in this section. After synthesis, each membrane was analyzed by ICP-OES to determine 
zinc binding. Additionally, the pfHRPII capture efficiency of each membrane was quantified by 
pfHRPII ELISA. 
Antibody Conjugation to Hemin Nanoparticles 
Hemin NPs were synthesized as described in Chapter V. For lyophilization studies, anti-
rabbit IgG antibodies were conjugated to the nanoparticles (Ab-Hemin NPs) through a 
photoreactive linker. This procedure is also reported in Chapter V. In a similar manner, Hemin 
NPs for detection of pfHRPII in the flow-through assay were conjugated to anti-Plasmodium 
falciparum antibodies through a photoreactive linker. In this reaction, the ratio of antibody to 
hemin was 32 µg antibody per 100 µg hemin (pfAb-Hemin NPs). These particles were tested in a 
plate assay to confirm their ability to detect pfHRPII before they were used for on-membrane 
detection. The plate assay was performed by adding 100 µL of 2 µg/mL of capture antibody 
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(ab9206) to a plate for 1 hour, followed by the addition of 300 µL of 2% BSA in PBST for 2 
hours. Next, 100 µL samples of D6 parasite culture spiked into 2% BSA were added. The final 
step included the addition of 100 µL of pfAb-Hemin NP at 40 µg hemin/mL in 10% BSA. The 
plate was washed with PBST after each step. The signal was then visualized through the addition 
of 50 µL of 0.9 M pyridine and 100 µL TMB-One. 
Hemin Nanoparticle Lyophilization 
The stability of the Hemin NP detection strategy upon lyophilization was explored 
through analysis of the size distribution of the particles by DLS before and after lyophilization. 
The Hemin NPs were lyophilized in solutions of 0, 2, 5, 10 and 15% trehalose with 10 mM PB 
pH = 5.7. Before lyophilization, the nanoparticles were frozen at -80°C for 6 hours. The samples 
were then lyophilized for at least 24 hours. For size analysis after lyophilization, Hemin NPs 
were resuspended in DI water. 
 To test if Ab-Hemin NPs could still bind to their target and produce signal post-
lyophilization, they were lyophilized in 15% trehalose with 10 mM PB pH=5.7 and stored in 
Ziploc bags with desiccant packs at room temperature. At various time points these Ab-Hemin 
NPs were resuspended and used as the detection element in the Rab-IgG detection assay 
described in Chapter V. The signal from the Ab-Hemin NPs was normalized to an HRPx 
conjugated anti-rabbit IgG detection antibody control. For the detection step in the control wells, 
0.5 µg/mL of anti-rabbit IgG HRPx in 1% BSA was added. 
On-Membrane Detection of pfHRPII 
For detection of pfHRPII on Zn-IDA membranes, a piece of membrane (d = 1 cm) was 
placed in the bottom of a 3 mL, plastic syringe. A 500 µL sample of parasite culture spiked in 
10% BSA was added to the syringe. After 1 minute, any sample remaining in the syringe was 
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expelled. Next, 250 µL of pfAb-Hemin NPs in 10% BSA were added at a concentration of 0.4 
µg/mL. Again, after 1 minute the remaining solution was pushed through the membrane. The 
membrane was then washed wish a 500 µL of 1X PBS (10 mM phosphate buffered saline, 150 
mM NaCl). Finally, 100 µL of detection solution (2:1 v/v TMB-One:0.9 M pyridine in 10 mM 
borate buffer pH = 8) was added. Color was allowed to develop for 10 minutes before the 
membranes were scanned and the images analyzed by ImageJ. 
Image Analysis 
The signal on the membrane was quantified by scanning the membranes and analyzing 
these images with ImageJ software available on the National Institute of Health’s website. When 
images were opened in this software, they were converted to the HSB (hue, saturation, 
brightness) color scheme. In this color scheme, saturation takes into account the intensity of the 
color. As a more intense blue color is indicative of higher biomarker concentrations, saturation of 
the images was measured. This analysis gave a quantitative result for the intensity of the signal 
on the membrane.  
 
Results and Discussion 
Membrane Selection Study 
Zn-IDA cellulose membranes were made through modification of the membrane with the 
metal affinity ligand, iminodiacetic acid, and subsequent coordination of zinc to this ligand 
(Figure VI.1). Functionalization with Zn-IDA allowed the cellulose membranes to bind pfHRPII, 
a histidine-rich protein biomarker of malaria, as the histidines in pfHRPII have a high affinity for 
zinc.132 Biomarker capture on this membrane is essential for the development of a flow-through 
diagnostics. To determine the best membrane for pfHRPII capture, several different cellulose 
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membranes, with varying pore sizes and thicknesses, were tested. The specifications of the five 
membrane types that were modified with Zn-IDA are shown in Table VI.1.  
The modified membranes were analyzed for zinc content by ICP-OES. Zinc content was 
observed for all membranes indicating successful functionalization with Zn-IDA (Table VI.1). It 
can be seen that the amount of zinc loading corresponded to the surface area available on the 
membrane. Sharkskin and Whatman 91 had the lowest amount of zinc loading and were 
relatively thin with large pores. Whatman 3 and 2589A were much thicker membranes and high 
zinc loading was observed. The Sartorius regenerated cellulose (Sartorius RC) membranes had 
high zinc loading even though they were relatively thin, which must be the result of larger 
surface area for Zn-IDA functionalization from the smaller pore size and greater porosity of 
these membranes. The ability of these membranes to bind pfHRPII, in a flow-through format, 
was also analyzed. It was found that the three membrane types with the highest zinc loading 
were the ones that resulted in greatest capture of pfHRPII (Table VI.1). 
As essentially complete capture of pfHRPII was observed for both Sartorius RC and 
Whatman 3 cellulose membranes, other characteristics were taken into account in selection of the 
	  
	  
Figure VI.1. Synthesis scheme used for the functionalization of cellulose membranes with 
iminodiacetic acid coordinated to zinc (Zn-IDA). These membranes were used to capture and 
concentrate pfHRPII. 
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membrane type for the flow-through assay. The Sartorius RC membrane is made of regenerated 
cellulose which has a greater wet strength and solvent compatibility compared to cellulose, the 
material from which Whatman 3 is made. While this is a positive characteristic considering the 
harsh reaction conditions required for functionalization, upon drying, these membranes became 
very brittle and making handling difficult. Thus, for ease of use and compatibility with the flow-
through assay format, Whatman 3 membranes were selected for this study. A more complete 
characterization of the Whatman 3 Zn-IDA membranes (W3-Zn-IDA) showed specific binding 
of zinc to IDA. The zinc content of non-functionalized Whatman 3 membranes, which were 
mixed in a zinc sulfate solution for 1 hour, was 0.031 ± 0.009 µmol/cm2. After functionalization 
with IDA, zinc content was found to be 4.1 ± 0.4 µmol/cm2.  
pfHRPII Capture by Zn-IDA Membranes 
As it has been shown that W3-Zn-IDA binds essentially all of the pfHRPII out of 
solution, it was then necessary to determine the specificity of this binding. This analysis was 
	  
	  
Table VI.1 Characteristics of the cellulose membranes that were modified with Zn-IDA. Zinc 
loading and pfHRPII capture are also listed. 
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done by quantitating pfHRPII binding to a membrane solely functionalized with IDA, thus the 
zinc atoms to which the pfHRPII should specifically bind were eliminated. The result showed no 
binding (0 ± 2 % pfHRPII) to the IDA control membrane indicating that the 95 ± 1 % pfHRPII 
was specifically bound by W3-Zn-IDA (Figure VI.2). The ability of the W3-Zn-IDA to bind 
pfHRPII from various matrices was also explored. It was seen that essentially complete capture 
was observed from buffer, whole blood and lysed whole blood (Figure VI.2). This result was 
excellent, as it demonstrated that pfHRPII could be directly captured from a patient sample 
without any additional preparation steps.  
Additionally, in development of a diagnostic, the sensitivity is very important as it allows 
for the detection of low infections levels. In the case of malaria, these low, asymptomatic 
infections often go undiagnosed and untreated which is detrimental to patient health and leaves a 
reservoir of the disease.18, 22, 45 One of the strengths of a flow-through assay is the concentration 
of the biomarker that occurs on the membrane surface. This property can be used to detect lower 
	  
Figure VI.2. pfHRPII specifically binds to zinc on W3-Zn-IDA, as binding was only 
observed with the membrane to which zinc was coordinated. Binding occurs between the 
intrinsic histidines in pfHRPII and zinc (left). W3-Zn-IDA membranes show complete capture 
of pfHRPII out of various sample matrices (right). 
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infection levels by simply increasing the sample volume that is analyzed. This is so because there 
is a greater total amount of biomarker in a large sample volume compared to a small sample 
volume, so more biomarker is captured as sample volume increases. To test whether or not this 
increased biomarker capture was observed in our system, samples with a constant concentration 
of pfHRPII but of varying volumes were analyzed. It was found that with an increase in sample 
volume there was a corresponding increase in pfHRPII captured (Figure VI.3). This indicates 
larger samples volumes could be incorporated into our system for detection of low level 
infections.  
The complete capture of pfHRPII from large sample volumes is possible because of the 
excess of zinc binding sites compared to the number of pfHRPII molecules within a sample. 
According to ICP-OES results, there are 2x1018 zinc atoms in a d = 1 cm section of membrane. 
In a 500 µL sample with a parasite concentration of 200 parasites/µL, there are 2x1014 pfHRPII 
molecules. Thus, there is a 10,000-fold excess of binding sites on the membrane, meaning the 4-
	  
Figure VI.3. Increasing sample volume results in greater biomarker capture on the Zn-IDA 
functionalized Whatman 3 membrane.  
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fold increase in sample volume did not come close to saturating the number of available binding 
sites. As a result, all of the pfHRPII was bound. Additionally, the large excess of binding sites 
increases the rate of pfHRPII capture allowing all of the pfHRPII to be bound within one minute. 
This is very amenable to a low-resource setting, considering fast assay time is often a necessity.  
Optimization of Hemin Nanoparticle Lyophilization 
After it was determined that pfHRPII could be effectively captured by W3-Zn-IDA, a 
method for detection of the biomarker, on the membrane, was developed. The nanoparticle-based 
detection strategy developed in Chapter V was both sensitive and stable and as such it seemed 
ideal for incorporation into the Zn-IDA flow-through assay. One important characteristic to 
determine for the selected detection strategy was whether the detection element could be 
lyophilized, resuspended and still successfully detect a biomarker. Since effective paper-based 
	  
Figure VI.4. The size of Hemin NPs after lyophilization and resuspension. It can be seen that 
nanoparticle structure was retained (compared to the original sample), when lyophilization 
was performed in 15% trehalose. 
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diagnostic strategies require storage for long periods of time, this stability of the detection 
element is essential.  
To test whether the Hemin NP detection element could be lyophilized and remain 
effective, several lyophilization conditions were tested. Initially, it was determined which 
conditions resulting in Hemin NPs of the original size after resuspension. To perform this 
experiment, Hemin NPs were placed in solutions of varying concentrations of trehalose. 
Trehalose was chosen as it is a sugar that has been shown to greatly stabilize materials and 
antibodies upon lyophilization. The crystalline sugar structure that forms around the 
nanoparticles prevents collapse of the particle during the lyophilization procedure.134 Thus, 
Hemin NPs were lyophilized in these solution, resuspended in DI water and their size measured 
by DLS. It was found that at a concentration of 15% trehalose there was no difference in the 
Hemin NP size seen before and after lyophilization, indicating that the nanoparticles remained 
stable through the process (Figure VI.4). 
As a result, 15% trehalose was used for lyophilization of Ab-Hemin NPs. These 
antibody-conjugated particles were tested to see if the detection capabilities of Hemin NPs 
remained stable in addition to Hemin NPs size. The lyophilized Ab-Hemin NPs were stored at 
room temperature and then resuspended for use in a sandwich assay for detection of Rab-IgG. It 
was found that after 1 month these nanoparticles were able to produce signal and specifically 
detect IgG.  
On-Membrane Detection of pfHRPII 
 As the Hemin NP detection strategy was evidenced to be ideal for on-membrane 
detection of pfHRPII because of its sensitivity and stability, it was implemented into the flow-
through diagnostic assay. To develop this assay for detection of pfHRPII, anti-Plasmodium 
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falciparum antibodies had to be conjugated to the Hemin NPs. The pfAb-Hemin NPs were first 
tested in a plate assay and the resulting standard curve had a LOD of 12.2 ± 0.7 parasites/µL 
(~35 pM pfHRPII) (Figure VI.5). These particles were then implemented into the flow-through 
assay, where pfHRPII was captured on the membrane and then subsequently detected by the 
pfAb-Hemin NPs through addition of the colorimetric substrate.  
Initially, pfAb-Hemin NPs were added at similar concentration to that required by the 
plate assay, but the result was a high background signal. It was found that as the concentration of 
pfAb-Hemin NPs was decreased, the assay signal-to-noise increased (Figure VI.6). As a result, a 
particle concentration of 0.4 µg hemin/mL was chosen for the assay, as it gave large positive 
signal with minimal background. The fact that the flow-through assay required much less 
detection element is likely a result of the flow of the pfAb-Hemin NPs through the membrane. 
This process concentrates the detection element at the membrane surface as well as forces 
interaction with the bound biomarker. This result is another great advantage of the flow-through 
	  
Figure VI.5. Detection of pfHRPII using pfAb-Hemin NPs in a plate assay. 
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diagnostic strategy, as the cost of the assay is significantly decreased by reduction in the amount 
of pfAb-Hemin NPs required.  
Detection Limit of the pfHRPII Flow-Through Assay 
 Once signal was successfully achieved on-membrane for detection of pfHRPII, samples 
of various pfHRPII concentrations were analyzed to determine the limit of detection of the assay. 
As can be seen in Figure VI.7, samples between 0 and 200 parasites/µL were analyzed and a 
visual signal was observed even at 12.5 parasites/µL. Images of the membranes were analyzed 
by ImageJ for color saturation and a standard curve was produced (Figure VI.7). The limit of 
detection of the assay was determined from the linear portion of this curve (3sblank/slope). The 
result was a LOD of 2.2 ± 0.2 parasites/µL (6.5 ± 0.5 pM pfHRPII). Thus, this method allows for 
detection of low infection levels within the range corresponding to asymptomatic patients. This 
outcome demonstrates that biomarker capture and concentration on the Zn-IDA membrane 
	  
Figure VI.6. Optimization of the amount of pfAb-Hemin NPs required for the flow-through 
assay. The concentration of pfAb-Hemin NPs was significantly reduced compared to that used 
in the plate assay in order to minimize non-specific background signal. 
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combined with the Hemin NP detection strategy, resulted in a sensitive diagnostic using a format 
that is both stable and cost effective. Future work will look to design a user-friendly diagnostic 
housing.  
 
 
 
 
	  
Figure VI.7. Detection of pfHRPII in the flow-through assay format using Zn-IDA 
functionalized Whatman 3 membranes for capture and pfAb-Hemin NPs for detection. A 
visual signal was observed as low as 12.5 parasites/µL and the calculated LOD after image 
analysis was 2.2 parasites/µL. 
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Conclusion 
 In this work, cellulose membranes were effectively modified with Zn-IDA ligands for the 
specific capture of a histidine-rich malarial biomarker, pfHRPII. Capture of this biomarker was 
achieved through interaction between the histidine moieties and the zinc atoms. It was found that 
these membranes could essentially capture all of the pfHRPII out sample volumes from 250-
2000 µL and in buffer and whole blood matrices. The Hemin NP detection strategy reported in 
Chapter V was used to detect the captured pfHRPII and produced a visual signal. The result was 
a flow-through diagnostic that was able to detect single digit parasitemias. Thus, the individual 
assay components developed throughout this work were combined to produce a simple, sensitive 
and stable low-resource diagnostic for malaria. 
 
Future Directions 
 Zn-IDA cellulose membranes are very intriguing components in the design of diagnostics 
for low-resource settings. The fact that these membranes are cheap, disposable and have 
essentially complete biomarker capture ability, is very unique. It has been shown how this 
effective capture can be used to detect low-levels of biomarker on membrane and one could 
imagine there are other diagnostic strategies which could be greatly enhanced by use of these 
membranes.  
 As has been mentioned throughout this document, rapid diagnostic tests (RDT) are the 
most effectively implemented low-resource diagnostic throughout the world.72 These tests are 
cost-effective and stable, not to mention simple to perform and analyze. RDTs are widely 
distributed, so healthcare workers around the world are familiar with running and reading these 
tests. Thus, while a flow-through assay has many advantages, as was highlighted in the 
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beginning of this chapter, the necessity to re-train individuals in order to implement this strategy 
is not ideal. Furthermore, implementation of controls and multiplex detection into a flow-through 
test can be challenging. As a result, a lateral flow diagnostic similar to an RDT would be ideal 
	  
	  
Figure VI.8. Workflow for the origami RDT, which combines a Zn-IDA functionalized 
membrane with a lateral flow assay, for sensitive detection of malaria. Malarial biomarker 
pfHRPII is captured directly on the membrane and pLDH is captured through a unique 
capture and release (C&R) reagent. Through a simple fold these biomarkers are presented to 
the lateral flow assay and released by imidazole. Figure graciously provided by Westley 
Bauer. 
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for low-resources settings. But, as has been fully discussed in this document, RDTs lack 
sensitivity. In Chapter III, a sample preparation method was presented that effectively used Ni-
NTA magnetic beads to increase the sensitivity of commercially available RDTs. Unfortunately, 
the procedure was somewhat complex and required separate assay components. Thus, it was 
considered whether the Zn-IDA membranes could be incorporated into a lateral flow assay to 
provide the same enhancement as the magnetic beads but in a more simple format.  
This thought led to the design of the origami RDT, which combines Zn-IDA membranes 
with a lateral flow assay. In this design, sample is flowed through a Zn-IDA membrane where 
the biomarker is captured and concentrated. A simple fold of the test then presents all of the 
captured biomarker to the lateral flow assay where a release buffer is added, freeing the 
biomarker for capture at the test line (Figure VI.8). The incorporation of the Zn-IDA membrane 
eliminates the sample volume limitation of RDTs, the major cause of their lack of sensitivity. 
Sample volume is no longer limited as large sample volumes can be added to the Zn-IDA 
membrane for biomarker capture and then through folding of the test, the biomarker from the 
large volume is presented to the test without the sample matrix. Thus, sample processing and the 
RDT are combined into one test, so no additional assay components are needed.  
An obvious requirement of this diagnostic strategy is the ability to release the biomarker 
from the membrane in order for it to flow down the lateral flow assay for detection. Release of 
pfHRPII was attempted by addition of imidazole, which at high concentrations out competes 
pfHRPII for binding to the zinc atoms. Preliminary experiments showed that a 4 M imidazole 
solution (pH = 8) was able to release 85% of the pfHRPII when the sample matrix was buffer and 
50% when the sample matrix was whole blood (Figure VI.9). The reduced recovery observed 
from whole blood samples is likely due to the fact that it is a complex matrix and interactions 
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with the components of the blood reduce the interaction of imidazole with the bound pfHRPII. 
Nonetheless, these results show great promise for the origami RDT as it was demonstrated that 
the biomarker can simply be released from the membrane through incorporation of imidazole 
into the release buffer. It is expected that amount of imidazole required for release could be 
lowered by decreasing the amount of zinc coordinated to the membrane, thus reducing the 
number of pfHRPII re-binding events.  
 Furthermore, this origami RDT design can be used for enhanced detection of biomarkers 
other than pfHRPII through the use of a unique capture and release reagent (C&R) developed in 
our lab.135 This reagent is an antibody modified with a histidine peptide. The result is essentially 
a His-tagged antibody that can specifically bind to the Zn-IDA membrane. This process 
functionalizes the membrane with an antibody. As a result, whatever biomarker the antibody is 
against can also be captured on the Zn-IDA membrane (Figure VI.8). Since this binding is based 
upon interaction between histidine and zinc, just as with pfHRPII, this biomarker-antibody 
	  
Figure VI.9. The amount pfHRPII captured, from buffer and whole blood sample matrices, 
by Zn-IDA membranes and subsequently released upon addition of imidazole.  
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complex can also be released by imidazole for subsequent detection on the lateral flow strip 
(Figure VI.10).  
While this catch and release agent can be designed for a variety of biomarkers, it is 
specifically being developed for pLDH. This biomarker was mentioned in Chapter II as a good 
alternative to pfHRPII, as it is found in all species of malaria and also clears in the same time 
frame as the parasite. In the proposed origami RDT, the Zn-IDA membrane will be used to 
capture both pfHRPII and pLDH for subsequent release onto a dual RDT that can detect both 
biomarkers. The ability to detect these biomarkers produces a much more effective malaria RDT 
as detection of pLDH informs whether or not there is an active malaria infection, while the 
simultaneous presence of pfHRPII confirms a falciparum infection (Figure VI.11). The 
determination of species is important, as the treatment plan changes for falciparum vs. non-
falciparum infections.136 
Thus, the development of the origami RDT from combination of a Zn-IDA flow-through 
membrane for capture of histidine-rich biomarkers or capture agents and a lateral flow assay for 
subsequent detection will produce an enhanced RDT for malaria. The incorporation of the Zn-
	  
	  
Figure VI.10. The catch and release reagent bound to a Zn-IDA functionalized membrane. 
This reagent allows for capture of pLDH on the membrane and subsequent elution results 
from addition of imidazole.  
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IDA membrane produces a large volume RDT, which allows more biomarker to be presented to 
the test, increasing the ability of the test to detect low-infection level. It is expected that a sample 
volume of 500 µL will result in a 2-log enhancement in the limit of detection relative to 
commercially available RDTs. Furthermore, only a simple fold is required to achieve this result. 
This test has the potential to have a large impact on low-resource malaria diagnosis, as it will not 
only allow for the detection of low level infections but also provide information on the type of 
malaria infection. Thus, a new diagnostic will be developed that takes on the format of currently 
used RDTs, producing a more sensitive and accurate test with a workflow that will be familiar to 
healthcare workers.  
In this work, many promising methods and designs for effective low-resource diagnostics 
have been presented. As these diagnostic strategies have been shown to effectually detect 
infectious diseases, the final challenge in diagnostic development arises: the translation of a 
diagnostic from the academic setting into a product that can be distributed throughout the world. 
This transition is a challenge that requires the collaboration of scholars in science, engineering 
and business, as well as academia and industry. It is only through such collaborations that these 
	  
 
Figure V.11. Possible test outcomes for the origami RDT. Detection of both pfHRPII and 
pLDH allows for the user to distinguish between falciparum and non-falciparum infections. 
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diagnostic tools can actually be implemented. As I leave Vanderbilt, I am confident in the ability 
of the scientists that remain to carry on the development of the origami RDT. I also see an 
infrastructure forming that will bring together experts from a variety of backgrounds for the 
translation of these technologies into useful products. This outlook gives me great hope that the 
academic work presented here will move forward to impact the world. 
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APPENDIX A 
 
SUPPORTING INFORMATION: CHAPTER II 
 
 
Figure SI II.1. The effect of vortex mixing time on pfHRPII recovery. No difference was 
observed between time points. 
 
Figure SI II.2. The effect of the volume of extraction buffer on pfHRPII recovery. No 
difference was observed with different volumes.   
	   134 
 
 
Figure SI II.3. A dried blood spot (DBS) ELISA standard curve was performed with one 
and two DBS samples in 300 µL of extraction buffer. As was expected, when two DBS 
were used the assay had twice the sensitivity. One DBS y = 0.0023x, two DBS y = 0.0043x. 
 
Figure SI II.4. pfHRPII ELISA standard curves performed at Macha Research Trust. 
Standards were made from parasite spiked diluted whole blood. These fourteen curves had an 
intra-assay variability of 6% and an inter-assay variability of 18% with a calculated LOD of 
0.165 ± 0.003 pM pfHRPII. 
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Table SI II.1. pfHRPII levels found by pfHRPII DBS ELISA for patient samples from several of 
the first and last points in the time study. Values were not corrected for the inherent dilution that 
occurs upon DBS extraction. Microscopy results are also shown in parasites/µL (par/µL). 
 
! 9 
Table S-2. pfHRPII levels f  y pfHRPII DBS ELISA for patient samples analyzed at first 
and last time points. Values were not corrected for inherent dilution that occurs upon DBS 
extraction. 
 
Patient 
Sample 
ID 
Time 
Point 
(days) 
Microscopy 
(par/µL) 
pfHRPII DBS 
ELISA (pM) 
Standard 
deviation (pM) 
Patient 
Sample 
ID 
Time 
Point 
(days) 
Microscopy 
(par/µL) 
pfHRPII DBS 
ELISA (pM) 
Standard 
deviation (pM) 
Patient1 0.1 242000 1410 90 
Patient 
19 0.1 43440 230 70 
 0.25 8000 570 40  0.25 21880 48 6 
 0.5 840 227 5  0.5 10160 158 9 
 0.75 0 52 3  0.75 3720 89 4 
 37 0 0.12 0.03  35 0 1.04 0.06 
Patient 2 0.1 145600 2490 80 
Patient 
20 0.1 3280 25 2 
 0.25 24360 1400 200  0.25 50858 35 2 
 0.5 22720 400 200  0.5 51556 64 4 
 0.75 10080 300 100  0.75 66551 114 7 
 38 0 -0.03 0.03  41 0 0.01 0.04 
Patient 3 0.1 1440 670 40 
Patient 
21 0.1 17040 8 1 
 0.25 3520 470 30  0.5 89875 145 7 
 0.5 3680 170 10  0.75 40157 8.0 0.6 
 0.75 1080 720 50  38 0 0.07 0.06 
 31 0 -0.02 0.02      
 38 0 180 10      
Patient 4 0.1 1800 14 1 
Patient 
23 0.1 159600 600 30 
 0.25 15280 29 2  0.25 12600 110 7 
 0.5 14720 43 3  0.5 3640 36 2 
 0.75 2120 37 4  0.75 840 25 2 
 31 0 1.0 0.2  44 0 0.03 0.05 
 38 0 1.1 0.1      
Patient 5 0.1 61680 670 30 
Patient 
24 0.1 92960 9.1 0.6 
 0.25 29440 280 10  0.25 55136 66 3 
 0.5 22469 300 100  0.75 3160 23 4 
 0.75 1600 190 10  38 0 0.09 0.04 
 35 0 0.48 0.08      
Patient 6 0.1 36400 200 10 
Patient 
26 0.1 3640 4600 400 
 0.25 51239 45 2  0.25 4080 3400 200 
 0.5 71016 31 2  0.5 1480 1400 100 
 0.75 1560 71 4  0.75 128 1200 200 
 40 0 0.66 0.03  28 0 0.13 0.07 
      35 0 0.46 0.07 
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! 10 
Patient 7 0.1 23720 380 17 
Patient 
28 0.1 26980 11300 500 
 0.25 14960 160 17  0.25 18760 10900 400 
 0.5 560 72 3  0.5 1400 1700 200 
 0.75 400 62 3  0.75 48 1829.514 700 
 35 0 0.049 0.008  37 0 0.17 0.04 
Patient 8 0.1 66400 350 40 
Patient 
31 0.1 10160 7500 600 
 0.25 124160 1120 50  0.25 4800 500 200 
 0.5 52045 249 6  0.5 2440 77 8 
 0.75 1280 530 20  0.75 1360 110 6 
 36 0 0.8 0.2  35 0 0.03 0.02 
Patient 9 0.1 90080 240 10 
Patient 
32 0.1 4800 1200 50 
 0.25 3640 250 10  0.25 1200 800 40 
 0.5 3120 94 4  0.5 720 560 30 
 0.75 272 38 3  0.75 0 880 40 
 38 0 0.56 0.05  41 0 0.15 0.01 
      48 0 0.18 0.02 
Patient 
10 0.1 29000 720 50 
Patient 
33 0.1 17040 3900 200 
 0.25 37246 550 20  0.25 560 760 50 
 0.5 39500 300 10  0.5 640 40 2 
 0.75 480 51 2  0.75 520 40 10 
 39 0 0.08 0.04  38 0 0.15 0.01 
Patient 
11 0.1 1120 6.7 0.8 
Patient 
34 0.1 3760 1200 100 
 0.25 176 7 2  0.25 100652 100 20 
 0.5 0 5.4 0.6  0.5 70788 54 3 
 0.75 0 2 2  0.75 62725 72 4 
 33 0 -0.06 0.008  44 0 0.05 0.01 
 40 0 -0.049 0.008      
Patient 
12 0.1 49960 630 90 
Patient 
35 0.1 6440 1800 500 
 0.25 32836 930 40  0.25 4080 2100 400 
 0.5 8240 240 10  0.5 1480 740 50 
 0.75 1040 280 10  0.75 600 130 10 
 42 0 -0.01 0.01  39 0 1.2 0.1 
      46 0 0.07 0.01 
Patient 
13 0.1 13760 370 30 
Patient 
36 0.1 18440 1330 60 
 0.25 6240 86 7  0.25 1160 2000 100 
 0.5 64 19.0 0.8  0.5 480 3600 200 
 0.75 0 8 2  0.75 176 3100 200 
 41 0 -0.04 0.01  41 0 0  
	   137 
 
 
 
 
 
 
 
 
 ! 11 
Patient 
14 0.1 5160 82 4 
Patient 
37 0.1 13120 1520 60 
 0.25 173667 33 3  0.25 5080 115 2 
 0.5 170667 200 20  0.5 1960 73 1 
 0.75 28629 50 20  0.75 680 117 2 
 38 0 -0.06 0.04  35 0 117 8 
Patient 
15 0.1 460200 540 30 
Patient 
38 0.1 82320 2900 100 
 0.25 304000 330 10  0.25 7840 420 50 
 0.5 152000 700 70  35 0 2.6 0.1 
 0.75 4120 230 10      
 40 0 0.4 0.1      
Patient 
16 0.1 81000 480 50 
Patient 
39 0.1 10560 520 40 
 0.25 9240 64 7  0.25 21788 261 7 
 0.5 17240 9.3 0.3  0.5 11240 90 10 
 0.75 256 49 3  0.75 5720 78 3 
 39 0 0.60 0.06  35 0 2.0 0.1 
Patient 
17 0.1 7200 10 20 
Patient 
40 0.1 22120 560 20 
 0.25 117819 30 3  0.25 12640 104 4 
 0.5 1280 140 10  0.5 11480 129 6 
 0.75 5400 13 1  0.75 960 63 3 
 39 0 0.3 0.2  35 0 2.2 0.1 
Patient 
18 0.1 6640 86 8      
 0.25 440 40 2      
 0.5 352 28 1      
 0.75 112 18 3      
 31 0 0.06 0.04      
 39 0 0.2 0.2      
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APPENDIX B 
 
SUPPORTING INFORMATION: CHAPTER V 
 
Table SI V.1. Size and optical characterization of the nanoparticles synthesized from various 
metal protoporphyrin IX derivatives. 
 
	  
	  
	   140 
 
	  
 
Figure SI V.1. The size and polydispersity of hemin nanoparticles synthesized with either 
hexaethylene glycol monomethyl ether (HEGME) or hexaethylene glycol (HEG) as the 
stabilizer. A stable nanoparticle sample was not produced when HEG was used as the 
stabilizer. 
	  
 
Figure SI V.2. Hemin nanoparticles were synthesized at different temperatures and no 
difference in nanoparticle size or polydispersity were seen. 
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Figure SI V.3. The scale of the hemin nanoparticles synthesis was increased by 1.5X and an 
increase in particle size and polydispersity was observed. 
	  
	  
Figure SI V.4. The size stability of hemin nanoparticles, in solution, over time. The diameter 
of the particles remained around 100 nm for almost 2 months. 
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Figure SI V.5. The size of hemin nanoparticles remained constant even when exposed to 
temperatures of up to 80 °C for 20 minutes. 
	  
Figure SI V.6. The catalytic cycle of horseradish peroxidase. S = substrate, Ex. TMB 
(3,3’,5,5’-tetramethylbenzidine). L = Ligand, Ex. histidine residue. Modified from Velde, F.; 
Rantwijk, F.; Sheldon, R. Trends Biotechnol. 2001, 19 (2), 73-80. 
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Figure SI V.7. The size distribution of hemin nanoparticles in 7.2% (0.9 M) pyridine. This is 
the concentration of pyridine added for hemin nanoparticle dissolution before addition of the 
colorimetric substrate (3,3’,5,5’-tetramethylbenzidine). Nanoparticles are no longer observed 
after addition of pyridine. 
	   144 
 
	  
	  
Figure SI V.8. Substrate vs. velocity curves for horseradish peroxidase and hemin 
nanoparticles with and without pyridine.  
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Figure SI V.9. The stability of the catalytic activity of hemin nanoparticles over time. No 
significant difference in signal was observed between Day 1 and Day 40. 
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Figure SI V.10. Optimization experiments for the rabbit IgG detection assay using the hemin 
nanoparticle detection strategy (Ab-Hemin NPs). A) Capture antibody concentration of 4 
µg/mL was chosen. B) Plate blocking with 1% BSA was selected. C) Ab-Hemin NP 
concentration of 40 µg/mL resulted in maximum assay signal. D) Ab-Hemin NPs were 
blocked with 7% BSA.  
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Figure SI V.11. The visual signal produced by the hemin nanoparticle detection strategy. 
Negative = 0 pM Rab-IgG, Positive = 100 pM Rab-IgG. 
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Figure SI V.12. Optimization experiments for the pLDH assay using the hemin nanoparticle 
detection strategy (pLDH Hemin NP). A) Capture antibody concentration of 1 µg/mL was 
chosen. B) pLDH-Hemin NP concentration of 40 µg/mL resulted in maximum assay signal. 
C) pLDH-Hemin NPs were blocked with 12% BSA. 
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APPENDIX C 
 
DETECTION OF MALARIAL DNA WITH HEMIN NANOPARTICLES 
 
Introduction 
 The hemin nanoparticle (Hemin NP) detection strategy described in detail in Chapter V 
shows great promise for application in low-resource settings. This method has great stability but 
also employs multiple modes of signal amplification, resulting in a sensitive assay with a simple 
signal readout. In Chapters V and VI, this method was successfully used for the detection of 
protein biomarkers with limits of detection well within clinically relevant ranges. While protein 
detection is essential, there are also many nucleic acid biomarkers which are of interest for 
disease diagnosis. Particularly, in the diagnosis of malaria, not only is the extent of the infection 
important to diagnosis but also the species of plasmodium infecting the individual. This species 
differentiation is most effectively done through the use of nucleic acid biomarkers.137, 138 Taking 
this into consideration, a natural extension of the Hemin NP detection strategy is detection of 
nucleic acid biomarkers. In the following, we show a strategy for nucleic acid detection with 
Hemin NPs through biotin-streptavidin linkages. These particles are then used in a plate assay 
for the specific detection of malaria target DNA. 
 
Experimental 
Materials 
Malaria target DNA and capture and detection DNA sequences were purchased from 
Integrated DNA Technologies (IDT). Specific sequences are detailed in Table 1. The capture and 
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detection sequences are thiolated, allowing for biotinylation through a maleimide-PEG2-biotin 
linker (catalog no. 21901BID). Manufacturer instructions were followed for this reaction. All 
other reagents are specified in Chapter V or were purchased from Sigma Aldrich or Fisher 
Scientific. 
Streptavidin-Conjugated Hemin Nanoparticles 
Hemin NPs were synthesized as described in Chapter V and streptavidin was conjugated 
to the nanoparticles through the same diazirine-based photoreactive linker (Strep-Hemin NP). In 
the coupling reaction, 16 µg of streptavidin was added for every 100 µg of hemin. Successful 
conjugation was determined by using these Strep-Hemin NPs to detect biotinylated rabbit IgG 
(biotin-Rab-IgG). This assay was carried out by laying down various concentrations biotin-Rab-
IgG in buffer (1X PBS) and incubating for two hours. The plate was then blocked with 1% BSA 
in PBST (1X PBS with 0.1% Tween-20) for two hours. Following this step, Strep-Hemin NPs 
were blocked with 10% BSA and added to the assay at a concentration of 25 µg/mL for one 
hour. The plate was washed between each step with PBST. After the last wash, 50 µL of 0.9 M 
	  
 
Table 1. Specific sequences of the target, capture and detection DNA used in the nucleic acid 
Hemin NP detection strategy. 
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pyridine in borate buffer pH = 8 was added to each well, followed by 100 µL of TMB-One 
substrate. Absorbance was read at 650 nm. 
Detection of Malaria Target DNA 
To detect malaria target DNA in a plate assay format, 100 µL of 30 µg/mL streptavidin 
was immobilized on a plate with a 1 hour incubation. Next, 100 µL of 1 µM capture DNA was 
added in DNA binding buffer (5 mM Tris-HCl, 0.5 mM EDTA, 1 M NaCl, 0.05% Tween-20) 
and incubated for 1 hour. The plate was then blocked for two hours with 2% BSA in PBST with 
10 µM biotin. The samples containing malaria target DNA and 500 nM detection DNA, were 
then added in 1X PBS and incubated for 1 hour. Finally, Strep-Hemin NPs were added at a 
concentration of 25 µg hemin/mL, in 10% BSA, for 1 hour. This step was followed by the 
addition of pyridine and TMB-One for signal generation and absorbance was read at 650 nm. 
Molecular biology grade water was used in this assay to prevent DNA degradation. The plate 
was washed with PBST between each step. 
	  
Figure 1. Size distribution of Hemin NP is various conditions. Hemin NPs: d = 132 ± 2 nm 
(blue), Strep-Hemin NPs: d = 132 ± 1 nm (red) and Strep-Hemin NPs in 150 mM NaCl: d = 
144 ± 2 nm (green). Hemin NP size remained consistent in between these conditions. 
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Results and Discussion 
Characterization of Streptavidin-Conjugated Hemin Nanoparticles 
Hemin NPs were characterized by dynamic light scattering (DLS) to determine their size 
and the stability of this size in different conditions. It was found that the conjugation of 
streptavidin did not significantly affect nanoparticle size, which would be expected since it is a 
relatively small protein (Figure 1). This observation also indicates that the Hemin NPs did not 
aggregate after conjugation, which shows the stability of the particles after conjugation. 
Additionally, the Hemin NPs were analyzed after the addition of 150 mM NaCl. This 
concentration of salt is necessary to facilitate DNA binding. It was thought that this amount of 
salt might interfere with the non-covalent interactions which hold the Hemin NPs together but 
DLS analysis showed that the Hemin NPs remained stable in these conditions (Figure 1).  
Detection of Biotinylated Protein 
 The strategy chosen for modification of Hemin NPs for nucleic acid detection was 
conjugation of biotinylated detection DNA to streptavidin-conjugated Hemin NPs. The 
	  
Figure 2. Detection of biotin-Rab IgG with Strep-Hemin NPs. This data proves effective 
conjugation of streptavidin to the nanoparticles. 
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conjugation of streptavidin to the particles was achieved through a photoreactive linker. To test 
whether this conjugation was successful and if the Hemin NPs would specifically bind to biotin, 
an assay for detection of biotinylated Rab-IgG was performed. In this assay, specific detection of 
the biotin-Rab-IgG was seen at nanomolar concentrations (Figure 2). Additionally, it was 
determined that a concentration of 25 µg hemin/mL of Strep-Hemin NPs was required to saturate 
the assay signal. This data was used to ensure sufficient Strep-Hemin NPs were added to this and 
future assays (Figure 3).  
Detection of Malaria Target DNA 
 The goal of this project was to specifically detect a nucleic acid biomarker of malaria, as 
detection of these biomarkers allows for development of species-specific assays. To prove that 
specific detection could be achieved, a biotinylated capture DNA strand was immobilized on a 
streptavidin coated plate. Samples of target DNA, that had been pre-mixed with the biotinylated 
detection DNA, were then added followed by the Strep-Hemin NPs, which bind to the detection 
DNA (Figure 4).  
	  
Figure 3. Concentration optimization of Strep-Hemin NPs for maximum assay signal in the 
detection of biotin-Rab IgG. 
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 The assay was optimized through determination of the amount of streptavidin required 
for immobilization of sufficient capture DNA on the plate. Also, the necessary blocking of the 
Strep-Hemin NPs with BSA was found. Using the optimized parameters, specific detection of 
the malaria target DNA was achieved with a signal-to-noise of 8 ± 3 (Figure 5). This result 
	  
 
Figure 4. The detection scheme for malaria target DNA. Streptavidin is immobilized on the 
plate to anchor the capture DNA, which binds the malaria target DNA. Biotinylated detection 
DNA also binds the target sequence followed by binding of the Strep-Hemin NPs for signal 
generation. 
	  
Figure 5. Specific detection of malaria target DNA with the Hemin NP detection strategy. 
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shows the versatility of the Hemin NP detection strategy in that it can be used to detect nucleic 
acids and proteins, as was described in Chapters V and VI. Additionally, this plate assay can be 
easily translated to a paper diagnostic, as it is known that streptavidin sticks to nitrocellulose 
allowing for immobilization on paper instead of the plate. 
 
Conclusion 
The Hemin NP detection strategy has been shown to specifically detect a malaria target 
DNA sequence. Detection was achieved through conjugation of streptavidin to the Hemin NPs 
for further conjugation to biotinylated DNA. This work shows the adaptability of the Hemin NP 
detection method to a wide range of biomarkers, making it a very flexible strategy. Future work 
will look to lower the limit of detection of the assay through additional optimization of the 
conjugation between the detection DNA and the Hemin NPs. Applications include low-resource, 
nucleic acid-based diagnostics for species differentiation and diagnosis of disease.  
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APPENDIX D 
 
SELECTION OF X-APTAMERS AGAINST INFECTION DISEASE BIOMARKERS 
 
Introduction 
 In the development of a diagnostic, the selection of the molecular recognition element is 
one of the most integral steps. The molecular recognition element is the diagnostic component 
responsible for binding the biomarker and the specificity and affinity with which it binds greatly 
impacts the sensitivity and specificity of the resulting diagnostic. Antibodies are extensively 
employed as molecular recognition elements and are used in diagnostics from enzyme-linked 
immunosorbent assays to rapid diagnostics tests. Antibodies have many advantages including 
high affinity and specificity for the target and the ability to be generated for a wide variety of 
disease markers. Despite these advantages, antibodies lack stability and if denaturation occurs, it 
is irreversible. Furthermore, antibodies are produced in vivo, which can be difficult and 
expensive.139 These downfalls are especially detrimental in low-resource settings where extreme 
environmental conditions often result in antibody degradation and diagnostic failure and high 
cost can prohibit diagnostic implementation.  
As a result, additional molecular recognition elements of increased stability are of great 
interest. Aptamers are one such class of molecules. Aptamers are short, single stranded 
oligonucleotides that bind with high affinity to protein targets based upon 3-D confirmation.140 
Aptamers are much more stable that antibodies, allowing for easier and more reliable storage. 
Additionally, they are produced in vitro which is simple and cost effective.139 Unfortunately, 
aptamers are not stable in vivo because they are susceptible to nucleases. To address this 
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problem, X-aptamers were developed. These aptamers are synthesized with a 
phosphorodithiolate backbone, preventing recognition of the aptamers by nucleases. 
Additionally, chemical modifications are introduced into the nucleotide bases of X-aptamers to 
produce a greater variety of structures resulting in more specific binding.141, 142  
 In the following, a kit produced by AM Biotechnologies for selection of X-aptamers is 
tested. The X-aptamer library is bead-based. It is synthesized by a split-and-pool synthesis 
method and there is one aptamer sequence per bead. While the traditional method for aptamer 
selection, systematic evolution of ligands by exponential enrichment (SELEX), require 10-15 
selection rounds, the bead-based method requires only two rounds. Furthermore, the bead-based 
selection method allows for incorporation of modifications into X-aptamers that are not 
compatible with SELEX.142 In this work, the X-aptamer kit was used to select aptamers against 
three infectious disease biomarkers: Plasmodium falciparum histidine-rich protein II (malarial 
biomarker), p24 capsid protein (human immunodeficiency virus (HIV) biomarker), and CD4 
(biomarker for extent of HIV infection). After selection of the X-aptamers, resulting hits were 
analyzed by bio-layer interferometry (BLI) to determine the affinity of the X-aptamers for their 
targets. Discovery of X-aptamers against these targets could result in the development of more 
stable low-resource diagnostics where X-aptamers are used as the molecular recognition element 
in the place of antibodies. 
 
Experimental 
Materials 
Recombinant HIV-1 p24, biotin labeled was acquired from ProSpec (catalog no. hiv-
106). Recombinant Plasmodium falciparum histidine-rich protein II (rc-pfHRPII) was purchased 
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from CTK Biotech Inc. (catalog no. A3000). sCD4-183 (2-domain) was acquired from NIH 
AIDS Reagent Program (catalog no. 7356).143 AM Biotechnologies, LLC X-Aptamer selection 
kit was obtained from AM Biotechnologies. EZ-Link Micro NHS-PEG4-Biotinylation Kit was 
purchased from ThermoFisher Scientific (catalog no. 21955). Dynabeads M-280 Streptavidin 
(catalog no. 11205D), Dynabeads His-Tag Isolation (catalog no. 10103D) and 8% TBE gel 
(catalog no. EC62155BOX) were acquired from ThermoFisher Scientific. PCR reagents were 
purchased from Roche. Octet biosensors were acquired from Pall ForteBio.  
X-Aptamer Selection Protocol 
The X-aptamer selection was performed according to the manufacturer provided 
procedure. The following is a brief summary of this process (Figure 1). In the first step, a 
negative selection was performed which ensured any X-aptamers that non-specifically bound to 
other components in the selection process (such as magnetic beads) were eliminated. In this 
particular selection, both Dynabeads M-280 Streptavidin and Dynabeads His-Tag Isolation were 
used as p24 and CD4 were biotinylated and rc-pfHRPII has many intrinsic histidines. Thus, a 
negative selection was performed using both of these bead types (300 µL of each at the original 
concentration), where the beads were added to the aptamer library (typically 108 members), 
allowed to incubate, and then magnetically separated along with any other X-aptamers that were 
non-specifically bound to the magnetic beads.  
Following this, the target proteins were bound to their respective magnetic beads and a 
positive primary selection was completed. This was done by combining all protein coupled 
magnetic beads with the X-aptamer library that remained after the negative selection. After 
incubation, the magnetic particles were again separated out along with any X-aptamers that were 
specifically bound to the target proteins. At this point, these aptamers were cleaved off the beads 
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through heat and basic conditions. Following this, the solution of cleaved oligonucleotides was 
neutralized for the secondary pull down selection. In this pull down, the cleaved X-aptamers 
were divided into five tubes and each target protein added to a different tube. The additional 
tubes were controls. Thus, each target was incubated individually with the library. After this 
incubation, the respective magnetic particles were added to magnetically separate the proteins 
and any bound X-aptamers. 
At this point the selection was completed and the resulting X-aptamers were amplified by 
polymerase chain reaction (PCR) with slight modification to the manufacturer’s protocol. For a 
100 µL PCR reaction, the following final concentrations of reagents were used: 1X PCR Buffer, 
2.5 mM MgCl2, 0.2 mM dNTP, 0.5 µM forward primer, 0.5 µM specified reverse primer, and 
1.5 units Taq polymerase. Primers were provided by AM Biotechnologies. Thermal cycler 
	  
	  
Figure 1. X-aptamer selection process with the AM Biotechnologies kit. 
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conditions were 94 °C for 1 minute, cycles of 94 °C for 30 seconds, 50 °C for 30 seconds, 72 °C 
for one minute and a final extension of 72 °C for 3 minutes. A PCR of 25 cycles was found to be 
sufficient. It was also found that SYBR green inhibited this PCR reaction. 
After amplification with PCR, the resulting products were visualized on an 8% Tris-
Borate-EDTA (TBE) gel with TBE running buffer. Sample (5 µL) was added to 2 µL of 5x non-
reducing TBE sample buffer and 3 µL molecular biology grade water for analysis. The gel was 
run for 35-40 minutes at 200 V. SYBR green was used to stain the gel for 15 minutes before the 
gel was imaged on a UV-transilluminator. GeneRulerä Ultra Low Range DNA Ladder was used 
and, as expected, the aptamer band was present around 75 base pairs. At this point, the amplified 
product was returned to AM Biotechnologies for next generation sequencing. 
Bio-Layer Interferometry Protocol  
 All solutions were made in the PBSTM (1X PBS, 1 mM MgCl2, 0.05% Tween-20). 
Analysis of the binding of CD4 and rc-pfHRPII X-aptamers was done by loading 100 nM 
biotinylated X-aptamer on streptavidin biosensors. These sensors were then blocked with 10 
µg/mL of biocytin before the association step with the respective protein at the specified 
concentration. The experimental setup for the Octet instrument included a 300 second 
equilibration step, followed by 600 second aptamer load, 60 second biocytin quench, 300 second 
wash, 60-180 second baseline, 600 second protein association and 600 second dissociation steps. 
Parallel reference sensors were run in an identical manner but without aptamer loading. These 
tips were used for background subtraction, eliminating any non-specific signal. Since the p24 
protein was purchased biotinylated it was loaded onto the tips instead of the X-aptamers. 
Originally, very little binding to the tips was observed so p24 was biotinylated further with the 
EZ-link biotin reagent. p24 was loaded at a concentration of 50 µg/mL. X-aptamers were 
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associated to p24 at a concentration of 5 µM. All other steps of the assay performed as specified 
above. 
 
Results and Discussion 
The X-aptamer selection produced 60 sequences that were synthesized by AM 
Biotechnologies for further analysis. Twenty-five of these sequences were against rc-pfHRPII 
(Table 1), twenty against CD4 (Table 2), and fifteen against p24 (Table 3). The affinity of these 
X-aptamers for their target proteins was then assessed using an Octet RED96. This instrument 
uses bio-layer interferometry (BLI) to measure binding and dissociation in real time. BLI is an 
optical technique where white light is passed down a fiber optic biosensor. This light is reflected 
back from two surfaces. One is a reflective reference surface and the other is a biocompatible 
layer at the end of the sensor. These two beams of light interfere with each other and this 
interference pattern changes upon binding. There is a change because when a molecule binds, the 
	  
	  
Figure 2. Bio-layer interferometry theory. This technique is used by the Octet RED96 to 
monitor binding events in real time.144  
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distance between the two reflective surfaces changes causing the shift in the interference pattern, 
this is represented as a nm shift and is related to how many molecules bind to the biosensor 
(Figure 2). This data can then be used to determine the equilibrium dissociation constant, KD, 
which is the ratio of off-rate to on-rate, producing a metric for how tightly two molecules bind. If 
two molecules have a very high affinity for each other, then the resulting KD is low.144 
 To discover the best X-aptamers that resulted from the selection, a screen was performed 
where each aptamer was tested for binding with 5 µM of protein target. This concentration was 
chosen because if binding was not observed with this amount of protein then the affinity of the 
aptamer and protein pair is not sufficient for implementation into a diagnostic. The screen for rc-
pfHRPII was done by immobilization of the biotinylated X-aptamers on a streptavidin biosensor 
and association of the protein. Only X-aptamer 2.19 showed any indication of binding and the 
amount of binding observed was not sufficient for a KD below the micromolar range. A screen 
against CD4 resulted in five X-aptamers (3.05, 3.15, 3.16, 3.17, and 3.18b) that displayed 
	  
Figure 3. Association and dissociation curves for X-aptamers 3.15 and 3.17, two of the five 
selected aptamers that showed significant binding with low micromolar amounts CD4 target 
protein. 
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significant binding at 5 µM target protein. These aptamers were further analyzed at lower 
concentrations and were all found to have high nanomolar equilibrium dissociation constants 
(Figure 3). The aptamer with the best affinity was X-aptamer 3.05. Binding of this aptamer was 
analyzed at six CD4 concentrations and after fitting the data to a 1:1 kinetics model it was found 
to have a KD = 436 ± 7 nM with a kon = 10,100 ± 100 (M×sec)-1 and a koff = 4.42x10-3 ± 2x10-5 
(sec)-1 (Figure 4). Finally, the p24 screen was completed by loading the biotinylated protein onto 
the biosensor tips and then associating 5 µM of the aptamers. No binding was observed in this 
screen.  
There are several explanations for why binding was only observed for the X-aptamers 
selected against CD4. First, CD4 was the only target protein that was not tagged. The rc-pfHRPII 
	  
Figure 4. The association and dissociation curves for X-Aptamer 3.05 with CD4 target 
protein measured on the Octet RED96. The equilibrium dissociation constant (KD) for this 
aptamer was found to be 436 nM.  
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protein was tagged with Glutathione S-transferase (GST) and p24 was fused to beta-
galactosidase. It could be that most of the aptamers selected for these proteins were against the 
tag instead of the protein and then these sequences were eliminated by the algorithm used by AM 
Biotechnologies for selection of the most promising aptamer sequences for synthesis. As a result, 
there could have been high-affinity X-aptamers selected against these specific target proteins. 
Furthermore, the complete lack of binding observed for any of the p24 X-aptamers could be a 
result of the change in the arrangement of the protein and aptamer when analysis was performed 
on the Octet. As was mentioned previously, the thickness of the layer on the end of the biosensor 
produces the nanometer shift measured by the instrument. As a result, large molecules cause a 
much greater shift than small ones. Aptamers are much smaller than proteins, so in the rc-
pfHRPII and CD4 assay, we were looking for the association of the protein which should be easy 
to see. In the p24 assay, the protein was loaded, giving a big shift, followed by the aptamer, 
which would give a small shift. So, it is possible the shift caused by binding of the aptamers was 
not observed. As a result, for any future analyses the aptamer will be loaded on the tips first, 
followed by association of the protein.  
 
Conclusion 
 The X-aptamer selection kit produced by AM Biotechnologies was found to be user-
friendly with minimal time required for aptamer selection. This kit was used for the selection of 
X-aptamers against three infectious disease protein biomarkers: CD4, rc-pfHRPII and p24. The 
affinity of the resulting X-aptamers for their protein target was analyzed by BLI and the best 
aptamers were found to bind CD4 with high nanomolar affinity. A second, more targeted 
selection based upon the CD4 X-aptamers that were found in this work could result in the 
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discovery of an X-aptamer with a high affinity for CD4. This X-aptamer could then be 
incorporated into a diagnostic producing a more stable test for low-resource settings. 
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Table 1. The sequences for the X-aptamers that were selected for pfHRPII. Only aptamer 2.19 
showed binding with micromolar protein concentrations. 
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Table 2. The sequences for the X-aptamers that were selected for CD4. X-aptamers 3.05, 
3.15, 3.16, 3.17 and 3.18b showed high nanomolar binding affinities (KD). 
	  
	  
Table 3. The sequences for the X-aptamers that were selected for p24. No binding was 
observed. 
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APPENDIX E 
 
SURFACE TENSION VALVES AS SEPARATION BARRIERS FOR A SERUM 
CREATININE ASSAY 
 
Introduction 
 Low-resource areas around the world suffer from a lack of sensitive medical diagnostics, 
which is a result of limited monetary resources, environmental conditions that leave many assays 
ineffective, and a lack of trained personnel. In Chapter III, a simple sample processing step was 
introduced that increased the sensitivity of the commercially available low-resource diagnostics. 
The effectiveness of this technique led the Gates Foundation to provide further funding to 
develop this process into an automated, all-in-one diagnostic to minimize user error and required 
training. To achieved this goal, an instrument was designed by the Haselton laboratory that could 
automatically mix samples in the tube, eliminating the need for a handheld magnet. Additionally, 
a spectrophotometer was incorporated into the instrument to read the assay signal. Assays for 
measurement of proteins using an ELISA strategy and nucleic acids with PCR were developed 
for this instrument. In the following, this work was extended through the development of an 
assay for the analysis of a clinical chemistry marker. This assay for serum creatinine, an 
indicator of renal health, was developed using air valves as separation barriers within the tube. 
The combination of all of these analyses into one, cost-effective instrument, with minimal user 
steps, brings a diversity of sensitive diagnostic assays into a format that shows great potential for 
implementation at major health facilities in low-resource areas. 
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Experimental 
Materials 
Picric acid (catalog no. 197378) and creatinine (catalog no. C4255) were purchased from 
Sigma Aldrich. Square FEP Tubing (0.093" ID, 1/8" OD, 0.016" Wall Thickness) was acquired 
from Zeus (catalog no. 0000174799). Cha-seal tube sealant was used to seal the ends of the tube. 
Hardened 440C Stainless Steel Balls, 1.5 mm diameter were purchased from McMaster-Carr 
(catalog no. 1598K17). Steel sandblasting beads were also used to mix samples. Human serum 
was purchased from Bioreclamation IVT (catalog no. HMSRM).  
Jaffe Reaction 
The Jaffe reaction has been extensively used in clinical chemistry for the determination 
of creatinine for many years.145, 146 This reaction takes advantage of the fact that an alkaline 
picric acid solution turns from yellow to red in the presence of creatinine. The Jaffe reagent was 
made with 4 parts, 0.2 M sodium hydroxide (NaOH) and 1 part, 30 mM picric acid. This was 
mixed in a 10:1 ratio with the sample. As a result, the final concentrations after sample addition 
were 0.145 M NaOH and 5.45 mM picric acid. Samples were either creatinine standards 
(creatinine in 1X PBS) or human serum. Unless otherwise specified, the reaction was allowed to 
proceed for 12 minutes before absorbance was read at 500 nm. 
Preparation of Clinical Chemistry Assay Tube 
The assay tube for the Jaffe reaction was prepared by first cutting a 5 cm section of 
square FEP tubing. Next, 100 µL of Jaffe reagent was added by pipette forming the reaction 
chamber. The end of the tube closest to this chamber was sealed and then 3 stainless steel balls 
were added to this chamber. Next, a 20 µL sample was added at the unsealed end of the tube, 
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making sure it was separated from the reaction chamber by an air valve. Finally, this end of the 
tube was also sealed.  
Magnetic Bead Selection 
Magnetic beads were used in this assay to break the surface tension of the air valve 
within the tube and mix the reagents and sample. Two types of beads were tested, sandblasting 
beads and stainless steel beads. To test whether these magnetic particles would interfere with the 
reaction, the integrity of the beads in aqueous solution was tested over time. After 1 hour, the 
beads were visualized with a macro lens on cell phone camera. Additionally, the stainless steel 
beads were added to the Jaffe reagent and monitored over time to see if an increase in 
absorbance at 500 nm was observed. This observation would indicate non-specific turnover of 
the reagent by the beads. 
Mixing Optimization 
The time required for breaking the air valve and mixing the two chambers with stainless 
steel beads was also tested. The time required was determined on the instrument by rotating the 
cartridge in relation to a stationary magnet, causing the movement of the magnetic particles, for 
different lengths of time. The absorbance of the reaction product was measured after 15 minutes.  
Automated Serum Creatinine Assay  
 The clinical chemistry assay tube was made as previously specified and then placed in the 
instrument cartridge, between the grooves, and over the area backed with copper tape. The 
cartridge was aligned such that the magnetic beads were directly next to the stationary magnet. 
Before mixing, an absorbance reading was taken in the reaction chamber as a reference value. 
The cartridge was then rotated sufficiently so that the magnetic beads traversed through the 
entire tube. A back and forth rotation was continued for 4 minutes and then the solution was 
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allowed to sit for 8 minutes before the final absorbance reading was taken. These absorbance 
values were compared to those measured on a plate reader by removing reagents from the tube 
and adding to a plate for analysis. 
 
Results and Discussion 
Plate Assay for Determination of Creatinine 
 Creatinine is an important clinical chemistry biomarker used to determine renal health. It 
is a small molecule formed irreversibly from creatine, which is a required for generation of 
adenosine triphosphate (ATP). Creatinine, a waste product of this reaction, is found in many 
biological fluids and is cleared through glomerular filtration. Thus, the rate of creatinine 
elimination is related to renal health. In serum, creatinine remains stable day-to-day but 
accumulates in the case of renal failure. So serum was chosen as the biological matrix for 
analysis.147  
	  
	  
Figure 1. A) The standard curve for the detection of creatinine, using the Jaffe reaction, in a 
plate assay format. The linear regression was y = 0.66x and the limit of detection was 7.4 ± 
0.2 µM creatinine. B) The time required for the Jaffe reaction to go to completion. It was 
found that with 1 mM creatinine the signal saturated around 12 minutes (right).  
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The Jaffe reaction was first reported over 100 years ago and has since been used 
extensively by clinical chemistry laboratories for the measurement of creatinine levels.145, 146 In 
this reaction, picric acid forms a red complex with creatinine in an alkaline solution.148 This 
assay is sensitive and simple, so it was employed in this work. First, the Jaffe reaction was run in 
a plate assay with creatinine standards to determine the LOD of the assay (Figure 1A). The LOD 
was found to be 7.4 ± 0.2 µM creatinine. The normal range of serum creatinine is 50 – 105 µM 
in adults and can be as low as 20 µM in young children.149, 150 Additionally, the concentration of 
creatinine increases with a decline in renal health. Thus, the LOD found for the Jaffe reaction is 
satisfactory for clinical analyses. In addition to determination of the LOD, the time required to 
reach the maximum signal was found. Thus, the progress of the reaction was monitored over 
time and it was found that the signal saturated after 12 minutes (Figure 1B).  
 
	  
	  
Figure 2. The major components of the automated, all-in-one instrument used for 
determination of serum creatinine. 
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Optimization of Automated Creatinine Assay 
The goal of this project was to incorporate a clinical chemistry test into an all-in-one 
instrument that also performs PCR and ELISA assays in a relatively inexpensive, low-resource 
format. The goal was to create “one-touch” assays where an assay tube could simply be placed in 
the instrument cartridge, a button pushed and the test run automatically. This instrument was 
designed by our collaborators in the Haselton laboratory at Vanderbilt University (the specifics 
of this instrumentation will not be discussed in this dissertation). Briefly, the instrument 
consisted of circular cartridge that rotates relative to a stationary magnet. The rotation was 
programed so that the magnet moved magnetic beads between specific chambers. A 
spectrophotometer is present on the other side of the cartridge for measurement of the absorbent 
signal produced by the assay (Figure 2). The expected commercial cost of the instrument is 
$15,000, which is much cheaper than purchasing individual instrumentation for each of the 
assays. To incorporate the serum creatinine assay into a format that could be used with this 
instrumentation, the reagents and sample were loaded into a section of tubing, separated by an air 
	  
	  
Figure 3. The clinical chemistry assay tube for analysis of serum creatinine. The reaction 
chamber contains the Jaffe reagent, which is separated from the sample chamber containing a 
creatinine sample by an air valve. The magnetic beads used to break the air valve and mix the 
two chambers are at the end of the tube and both ends of the tube are sealed. This tube is place 
on the cartridge in the instrument. 
	   174 
(surface tension) valve. Magnetic beads were also added to the tube and the magnet was used to 
move these beads back and forth, breaking the surface tension valve and mixing the Jaffe reagent 
and sample. As a result, the reaction for analysis of serum creatinine began when mixing was 
initiated (Figure 3).  
The first step for incorporation of this assay into the tube was to determine the best bead 
type. It was discovered that beads with a diameter around 1 mm were sufficiently large to break 
the surface tension of the air valve. First, sandblasting beads were tested but they were found to 
corrode in aqueous solution after one hour. Thus, stainless steel beads where tested and after one 
hour, no corrosion was observed (Figure 4). This result would be expected because the 
sandblasting beads were made of steel, which is known to corrode much easier than stainless 
steel. Once the stainless steel beads were chosen, it was determined whether they caused the 
Jaffe reagent to turnover. To test this parameter, the stainless steel beads were incubated in this 
	  
	  
Figure 4. Magnetic beads were placed in aqueous solutions for 1 hour to determine their 
stability. The sandblasting beads (left) were found to corrode, while the stainless steel beads 
(right) retained their integrity. 
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reagent and the absorbance was monitored at 500 nm. No color change was observed (Figure 
5A). Thus, the stainless steel beads were chosen for this assay.  
An essential step in this assay is mixing, as no assay signal will be observed unless the air 
valve between the sample and reagent is broken. As a result, the mixing time required to 
consistently break this valve was determined. It was seen that similar assay signal was observed 
for all mixing times but the smallest error was observed after 4 minutes (Figure 5B). This aligned 
with visual observation which showed that the air valve was not consistently removed until the 4 
minute time point (Figure 5C). It was also found that it was much easier to break the air valve 
when square tubing was used as opposed to round tubing. This observation is a result of lower 
surface tension with this geometry. Furthermore, the flat surface provided by the square tubing 
resulted in more reproducible optical measurements. 
	  
 
Figure 5. A) The absorbance of the Jaffe reagent without stainless steel beads and in the 
presences of the beads after one hour. No difference was observed. B) Optimization of the time 
required to break the air valve and mix the Jaffe reagent and sample. After two minutes, no 
significant difference in assay signal was observed. C) Visual observation of the mixing time 
showed that 4 minutes was required to fully eliminate the air valve. 
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Automated Detection of Creatinine in Serum Samples 
Once these assay parameters were optimized, the creatinine assay was run in the tube 
with automated mixing and absorbance readings on the instrument. First, creatinine standards in 
buffer were run. The resulting standard curve is shown in Figure 6A. The LOD (3sblank/slope) 
was 20.2 ± 0.6 µM creatinine. After this, three human serum samples from individual donors 
were analyzed and all creatinine values were found to be within the normal clinical range (Figure 
6B). Furthermore, these samples were also analyzed with a plate reader to confirm that the 
absorbance read by the automated instrument was correct. It was found that there was no 
difference between the measured values. Thus, the Jaffe method for determination of serum 
creatinine was effectively and reliably implemented in the tube assay design with a LOD 
comparable to that achieved in a plate assay. 
 
 
	  
Figure 6. A) The creatinine standard curve acquired from analysis of standards on the 
automated instrument. The linear regression was y = 0.61x + 0.005 and the limit of detection 
20.2 ± 0.6 µM creatinine. B) Human serum samples from individual donors were analyzed for 
creatinine content. The same samples were also analyzed on the plate reader and the results 
were not statistically different. 
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Conclusion 
 In this work, it was shown that a serum creatinine assay could be effectively implemented 
in a tube-based format that employed air valves as separation barriers. To initiate the reaction 
these air valves were broken by magnetic beads, allowing the sample and Jaffe reagent to mix. 
An automated system designed for low-resource settings was used to both mix the reagents and 
read the resulting absorbent signal. This automated assay was found to detect clinically relevant 
concentrations of creatinine, from normal levels to levels observed in patients with renal failure. 
Finally, this assay was found to effectively detect creatinine in human serum samples. This 
instrument shows great versatility as it is able to perform the serum creatinine clinical chemistry 
assay in addition to ELISA and PCR. As a result, it shows great promise for implementation at 
major city or district level health clinics in low-resource areas of the world. 
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